Homogeneously . . O O
staining . . O O
chromosomal . . O O
regions . . O O
contain . . O O
amplified . . O O
copies . . O O
of . . O O
an . . O O
abundantly . . O O
expressed . . O O
cellular . . O O
oncogene . . O O
( . . O O
c . . O O
- . . O O
myc . . O O
) . . O O
in . . O O
malignant . . O O
neuroendocrine . . O O
cells . . O O
from . . O O
a . . O O
human . . O O
colon . . O O
carcinoma . . O O
. . . O O

Two . . O O
human . . O O
neuroendocrine . . O O
tumor . . O O
cell . . O O
lines . . O O
derived . . O O
from . . O O
a . . O O
colon . . O O
carcinoma . . O O
contain . . O O
either . . O O
numerous . . O O
double . . O O
minute . . O O
chromosomes . . O O
( . . O O
COLO . . O O
320 . . O O
DM . . O O
) . . O O
or . . O O
a . . O O
homogeneously . . O O
staining . . O O
marker . . O O
chromosome . . O O
( . . O O
COLO . . O O
320 . . O O
HSR . . O O
) . . O O
. . . O O

We . . O O
found . . O O
amplification . . O O
and . . O O
enhanced . . O O
expression . . O O
of . . O O
the . . O O
cellular . . O O
oncogene . . O O
c . . O O
- . . O O
myc . . O O
in . . O O
both . . O O
COLO . . O O
320 . . O O
DM . . O O
and . . O O
HSR . . O O
cells . . O O
, . . O O
and . . O O
we . . O O
were . . O O
able . . O O
to . . O O
show . . O O
that . . O O
the . . O O
homogeneously . . O O
staining . . O O
regions . . O O
of . . O O
the . . O O
COLO . . O O
320 . . O O
HSR . . O O
marker . . O O
chromosome . . O O
contain . . O O
amplified . . O O
c . . O O
- . . O O
myc . . O O
. . . O O

From . . O O
previous . . O O
and . . O O
present . . O O
karyotypes . . O O
, . . O O
it . . O O
appears . . O O
that . . O O
the . . O O
homogeneously . . O O
staining . . O O
regions . . O O
reside . . O O
on . . O O
a . . O O
distorted . . O O
X . . O O
chromosome . . O O
. . . O O

Therefore . . O O
, . . O O
amplification . . O B-Mutation
of . . O O
c . . O O
- . . O O
myc . . O O
has . . O O
been . . O O
accompanied . . O O
by . . O O
translocation . . B-Mutation O
of . . O O
the . . O O
gene . . O O
from . . O O
its . . O O
normal . . O O
position . . O O
on . . O O
chromosome . . O O
8 . . O O
( . . O O
8q24 . . O O
) . . O O
. . . O O

Because . . O O
double . . O O
minute . . O O
chromosomes . . O O
were . . O O
features . . O O
of . . O O
primary . . O O
cultures . . O O
from . . O O
the . . O O
original . . O O
tumor . . O O
, . . O O
it . . O O
seems . . O O
reasonable . . O O
to . . O O
suspect . . O O
that . . O O
amplification . . O O
of . . O O
c . . O O
- . . O O
myc . . O O
may . . O O
have . . O O
contributed . . O O
to . . O O
tumorigenesis . . O O
. . . O O

Distinct . . O O
high . . O O
resolution . . O O
genome . . O O
profiles . . O O
of . . O O
early . . O O
onset . . O O
and . . O O
late . . O O
onset . . O O
colorectal . . O O
cancer . . O O
integrated . . O O
with . . O O
gene . . O O
expression . . O O
data . . O O
identify . . O O
candidate . . O O
susceptibility . . O O
loci . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Estimates . . O O
suggest . . O O
that . . O O
up . . O O
to . . O O
30 . . O O
% . . O O
of . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRC . . O O
) . . O O
may . . O O
develop . . O O
due . . O O
to . . O O
an . . O O
increased . . O O
genetic . . O O
risk . . O O
. . . O O

The . . O O
mean . . O O
age . . O O
at . . O O
diagnosis . . O O
for . . O O
CRC . . O O
is . . O O
about . . O O
70 . . O O
years . . O O
. . . O O

Time . . O O
of . . O O
disease . . O O
onset . . O O
20 . . O O
years . . O O
younger . . O O
than . . O O
the . . O O
mean . . O O
age . . O O
is . . O O
assumed . . O O
to . . O O
be . . O O
indicative . . O O
of . . O O
genetic . . O O
susceptibility . . O O
. . . O O

We . . O O
have . . O O
compared . . O O
high . . O O
resolution . . O O
tumor . . O O
genome . . O O
copy . . B-Mutation B-Mutation
number . . I-Mutation I-Mutation
variation . . I-Mutation I-Mutation
( . . O O
CNV . . B-Mutation O
) . . O O
( . . O O
Roche . . O O
NimbleGen . . O O
, . . O O
385 . . O O
000 . . O O
oligo . . O O
CGH . . O O
array . . O O
) . . O O
in . . O O
microsatellite . . O O
stable . . O O
( . . O O
MSS . . O O
) . . O O
tumors . . O O
from . . O O
two . . O O
age . . O O
groups . . O O
, . . O O
including . . O O
23 . . O O
young . . O O
at . . O O
onset . . O O
patients . . O O
without . . O O
known . . O O
hereditary . . O O
syndromes . . O O
and . . O O
with . . O O
a . . O O
median . . O O
age . . O O
of . . O O
44 . . O O
years . . O O
( . . O O
range . . O O
: . . O O
28 . . O O
- . . O O
53 . . O O
) . . O O
and . . O O
17 . . O O
elderly . . O O
patients . . O O
with . . O O
median . . O O
age . . O O
79 . . O O
years . . O O
( . . O O
range . . O O
: . . O O
69 . . O O
- . . O O
87 . . O O
) . . O O
. . . O O

Our . . O O
aim . . O O
was . . O O
to . . O O
identify . . O O
differences . . O O
in . . O O
the . . O O
tumor . . O O
genomes . . O O
between . . O O
these . . O O
groups . . O O
and . . O O
pinpoint . . O O
potential . . O O
susceptibility . . O O
loci . . O O
. . . O O

Integration . . O O
analysis . . O O
of . . O O
CNV . . B-Mutation O
and . . O O
genome . . O O
wide . . O O
mRNA . . O O
expression . . O O
data . . O O
, . . O O
available . . O O
for . . O O
the . . O O
same . . O O
tumors . . O O
, . . O O
was . . O O
performed . . O O
to . . O O
identify . . O O
a . . O O
restricted . . O O
candidate . . O O
gene . . O O
list . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
total . . O O
fraction . . O O
of . . O O
the . . O O
genome . . O O
with . . O O
aberrant . . B-Mutation O
copy . . I-Mutation O
number . . I-Mutation O
, . . O O
the . . O O
overall . . O O
genomic . . O O
profile . . O O
and . . O O
the . . O O
TP53 . . O O
mutation . . B-Mutation B-Mutation
spectrum . . O O
were . . O O
similar . . O O
between . . O O
the . . O O
two . . O O
age . . O O
groups . . O O
. . . O O

However . . O O
, . . O O
both . . O O
the . . O O
number . . O O
of . . O O
chromosomal . . B-Mutation O
aberrations . . I-Mutation B-Mutation
and . . O O
the . . O O
number . . O O
of . . O O
breakpoints . . O O
differed . . O O
significantly . . O O
between . . O O
the . . O O
groups . . O O
. . . O O

Gains . . B-Mutation O
of . . O O
2q35 . . O O
, . . O O
10q21 . . O O
. . . O O
3 . . O O
- . . O O
22 . . O O
. . . O O
1 . . O O
, . . O O
10q22 . . O O
. . . O O
3 . . O O
and . . O O
19q13 . . O O
. . . O O
2 . . O O
- . . O O
13 . . O O
. . . O O
31 . . O O
and . . O O
losses . . B-Mutation O
from . . O O
1p31 . . O O
. . . O O
3 . . O O
, . . O O
1q21 . . O O
. . . O O
1 . . O O
, . . O O
2q21 . . O O
. . . O O
2 . . O O
, . . O O
4p16 . . O O
. . . O O
1 . . O O
- . . O O
q28 . . O O
. . . O O
3 . . O O
, . . O O
10p11 . . O O
. . . O O
1 . . O O
and . . O O
19p12 . . O O
, . . O O
positions . . O O
that . . O O
in . . O O
total . . O O
contain . . O O
more . . O O
than . . O O
500 . . O O
genes . . O O
, . . O O
were . . O O
found . . O O
significantly . . O O
more . . O O
often . . O O
in . . O O
the . . O O
early . . O O
onset . . O O
group . . O O
as . . O O
compared . . O O
to . . O O
the . . O O
late . . O O
onset . . O O
group . . O O
. . . O O

Integration . . O O
analysis . . O O
revealed . . O O
a . . O O
covariation . . O O
of . . O O
DNA . . O O
copy . . O O
number . . O O
at . . O O
these . . O O
sites . . O O
and . . O O
mRNA . . O O
expression . . O O
for . . O O
107 . . O O
of . . O O
the . . O O
genes . . O O
. . . O O

Seven . . O O
of . . O O
these . . O O
genes . . O O
, . . O O
CLC . . O O
, . . O O
EIF4E . . O O
, . . O O
LTBP4 . . O O
, . . O O
PLA2G12A . . O O
, . . O O
PPAT . . O O
, . . O O
RG9MTD2 . . O O
, . . O O
and . . O O
ZNF574 . . O O
, . . O O
had . . O O
significantly . . O O
different . . O O
mRNA . . O O
expression . . O O
comparing . . O O
median . . O O
expression . . O O
levels . . O O
across . . O O
the . . O O
transcriptome . . O O
between . . O O
the . . O O
two . . O O
groups . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Ten . . O O
genomic . . O O
loci . . O O
, . . O O
containing . . O O
more . . O O
than . . O O
500 . . O O
protein . . O O
coding . . O O
genes . . O O
, . . O O
are . . O O
identified . . O O
as . . O O
more . . O O
often . . O O
altered . . O O
in . . O O
tumors . . O O
from . . O O
early . . O O
onset . . O O
versus . . O O
late . . O O
onset . . O O
CRC . . O O
. . . O O

Integration . . O O
of . . O O
genome . . O O
and . . O O
transcriptome . . O O
data . . O O
identifies . . O O
seven . . O O
novel . . O O
candidate . . O O
genes . . O O
with . . O O
the . . O O
potential . . O O
to . . O O
identify . . O O
an . . O O
increased . . O O
risk . . O O
for . . O O
CRC . . O O
. . . O O

Hypermutability . . B-Mutation O
and . . O O
mismatch . . O O
repair . . O O
deficiency . . O O
in . . O O
RER . . O O
+ . . O O
tumor . . O O
cells . . O O
. . . O O

A . . O O
subset . . O O
of . . O O
sporadic . . O O
colorectal . . O O
tumors . . O O
and . . O O
most . . O O
tumors . . O O
developing . . O O
in . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
patients . . O O
display . . O O
frequent . . O O
alterations . . B-Mutation O
in . . O O
microsatellite . . O O
sequences . . O O
. . . O O

Such . . O O
tumors . . O O
have . . O O
been . . O O
thought . . O O
to . . O O
manifest . . O O
replication . . O O
errors . . O O
( . . O O
RER . . O O
+ . . O O
) . . O O
, . . O O
but . . O O
the . . O O
basis . . O O
for . . O O
the . . O O
alterations . . O O
has . . O O
remained . . O O
conjectural . . O O
. . . O O

We . . O O
demonstrate . . O O
that . . O O
the . . O O
mutation . . B-Mutation B-Mutation
rate . . O O
of . . O O
( . . O O
CA . . O O
) . . O O
n . . O O
repeats . . O O
in . . O O
RER . . O O
+ . . O O
tumor . . O O
cells . . O O
is . . O O
at . . O O
least . . O O
100 . . O O
- . . O O
fold . . O O
that . . O O
in . . O O
RER . . O O
- . . O O
tumor . . O O
cells . . O O
and . . O O
show . . O O
by . . O O
in . . O O
vitro . . O O
assay . . O O
that . . O O
increased . . O O
mutability . . O B-Mutation
of . . O O
RER . . O O
+ . . O O
cells . . O O
is . . O O
associated . . O O
with . . O O
a . . O O
profound . . O O
defect . . O O
in . . O O
strand . . O O
- . . O O
specific . . O O
mismatch . . O O
repair . . O O
. . . O O

This . . O O
deficiency . . O O
was . . O O
observed . . O O
with . . O O
microsatellite . . B-Mutation O
heteroduplexes . . I-Mutation O
as . . O O
well . . O O
as . . O O
with . . O O
heteroduplexes . . B-Mutation O
containing . . O O
single . . B-Mutation O
base . . I-Mutation O
- . . I-Mutation O
base . . I-Mutation O
mismatches . . I-Mutation B-Mutation
and . . O O
affected . . O O
an . . O O
early . . O O
step . . O O
in . . O O
the . . O O
repair . . O O
pathway . . O O
. . . O O

Thus . . O O
, . . O O
a . . O O
true . . O O
mutator . . O B-Mutation
phenotype . . O O
exists . . O O
in . . O O
a . . O O
subset . . O O
of . . O O
tumor . . O O
cells . . O O
, . . O O
the . . O O
responsible . . O O
defect . . O O
is . . O O
likely . . O O
to . . O O
cause . . O O
transitions . . B-Mutation O
and . . O O
transversions . . B-Mutation B-Mutation
in . . O O
addition . . O O
to . . O O
microsatellite . . O B-Mutation
alterations . . B-Mutation I-Mutation
, . . O O
and . . O O
a . . O O
biochemical . . O O
basis . . O O
for . . O O
this . . O O
phenotype . . O O
has . . O O
been . . O O
identified . . O O
. . . O O

Numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
: . . O O
Incidence . . O O
and . . O O
correlation . . O O
with . . O O
clinical . . O O
and . . O O
biological . . O O
findings . . O O
and . . O O
the . . O O
prognosis . . O O
of . . O O
the . . O O
disease . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

In . . O O
recent . . O O
years . . O O
important . . O O
information . . O O
has . . O O
accumulated . . O O
on . . O O
the . . O O
genetic . . B-Mutation B-Mutation
alterations . . I-Mutation I-Mutation
present . . O O
in . . O O
colorectal . . O O
tumors . . O O
. . . O O

However . . O O
, . . O O
thus . . O O
far . . O O
few . . O O
studies . . O O
have . . O O
analyzed . . O O
the . . O O
impact . . O O
of . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
, . . O O
which . . O O
carry . . O O
the . . O O
p53 . . O O
and . . O O
DCC . . O O
plus . . O O
SHAD4 . . O O
/ . . O O
DPC4 . . O O
genes . . O O
involved . . O O
in . . O O
colorectal . . O O
cancer . . O O
, . . O O
on . . O O
the . . O O
clinical . . O O
and . . O O
biological . . O O
behaviors . . O O
of . . O O
the . . O O
disease . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

With . . O O
the . . O O
use . . O O
of . . O O
interphase . . O O
fluorescence . . O O
in . . O O
situ . . O O
hybridization . . O O
( . . O O
FISH . . O O
) . . O O
, . . O O
we . . O O
analyzed . . O O
the . . O O
incidence . . O O
of . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
in . . O O
a . . O O
series . . O O
of . . O O
malignant . . O O
colorectal . . O O
tumors . . O O
and . . O O
explored . . O O
its . . O O
potential . . O O
association . . O O
with . . O O
clinicobiological . . O O
behavior . . O O
and . . O O
the . . O O
prognosis . . O O
of . . O O
the . . O O
disease . . O O
. . . O O

For . . O O
this . . O O
purpose . . O O
, . . O O
94 . . O O
consecutive . . O O
patients . . O O
newly . . O O
diagnosed . . O O
with . . O O
colorectal . . O O
cancer . . O O
were . . O O
analyzed . . O O
. . . O O

In . . O O
all . . O O
cases . . O O
, . . O O
FISH . . O O
analyses . . O O
of . . O O
the . . O O
number . . O O
of . . O O
copies . . O O
and . . O O
nuclei . . O O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
were . . O O
performed . . O O
in . . O O
interphase . . O O
nuclei . . O O
with . . O O
the . . O O
use . . O O
of . . O O
double . . O O
stainings . . O O
. . . O O

For . . O O
all . . O O
patients . . O O
, . . O O
information . . O O
on . . O O
age . . O O
, . . O O
sex . . O O
, . . O O
tumor . . O O
size . . O O
, . . O O
Dukes . . O O
' . . O O
stage . . O O
, . . O O
tumor . . O O
localization . . O O
, . . O O
DNA . . O O
ploidy . . O O
status . . O O
, . . O O
and . . O O
the . . O O
proportion . . O O
of . . O O
S . . O O
- . . O O
phase . . O O
tumor . . O O
cells . . O O
was . . O O
recorded . . O O
. . . O O

Median . . O O
follow . . O O
- . . O O
up . . O O
was . . O O
38 . . O O
months . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
were . . O O
present . . O O
in . . O O
most . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
( . . O O
57 . . O O
% . . O O
and . . O O
52 . . O O
% . . O O
, . . O O
respectively . . O O
) . . O O
. . . O O

Gains . . B-Mutation O
of . . O O
chromosome . . O O
17 . . O O
and . . O O
monosomy . . B-Mutation O
18 . . I-Mutation O
were . . O O
found . . O O
in . . O O
51 . . O O
% . . O O
and . . O O
29 . . O O
% . . O O
of . . O O
cases . . O O
, . . O O
respectively . . O O
, . . O O
and . . O O
they . . O O
were . . O O
the . . O O
most . . O O
frequent . . O O
individual . . O O
abnormalities . . B-Mutation O
for . . O O
each . . O O
chromosome . . O O
. . . O O

The . . O O
simultaneous . . O O
analysis . . O O
of . . O O
the . . O O
number . . O O
of . . O O
copies . . O O
of . . O O
both . . O O
chromosomes . . O O
in . . O O
the . . O O
same . . O O
cell . . O O
showed . . O O
that . . O O
, . . O O
in . . O O
most . . O O
cases . . O O
displaying . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
for . . O O
these . . O O
chromosomes . . O O
, . . O O
two . . O O
or . . O O
more . . O O
different . . O O
tumor . . O O
cell . . O O
clones . . O O
were . . O O
present . . O O
. . . O O

From . . O O
a . . O O
clinical . . O O
point . . O O
of . . O O
view . . O O
, . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosome . . O O
17 . . O O
, . . O O
especially . . O O
monosomy . . B-Mutation O
17 . . I-Mutation O
, . . O O
were . . O O
associated . . O O
with . . O O
a . . O O
significantly . . O O
higher . . O O
incidence . . O O
of . . O O
rectal . . O O
tumors . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
and . . O O
Dukes . . O O
' . . O O
stage . . O O
D . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
02 . . O O
) . . O O
and . . O O
a . . O O
lower . . O O
median . . O O
of . . O O
disease . . O O
- . . O O
free . . O O
survival . . O O
among . . O O
patients . . O O
who . . O O
underwent . . O O
curative . . O O
surgery . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
05 . . O O
) . . O O
, . . O O
as . . O O
compared . . O O
with . . O O
diploid . . O O
cases . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
cases . . O O
with . . O O
an . . O O
altered . . B-Mutation O
number . . I-Mutation O
of . . I-Mutation O
copies . . I-Mutation O
of . . O O
chromosome . . O O
17 . . O O
showed . . O O
a . . O O
higher . . O O
incidence . . O O
of . . O O
DNA . . O O
aneuploidy . . B-Mutation B-Mutation
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
0001 . . O O
) . . O O
and . . O O
a . . O O
greater . . O O
proportion . . O O
of . . O O
S . . O O
- . . O O
phase . . O O
cells . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
by . . O O
flow . . O O
cytometry . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
no . . O O
clear . . O O
association . . O O
was . . O O
found . . O O
between . . O O
the . . O O
presence . . O O
of . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosome . . O O
18 . . O O
and . . O O
clinicobiological . . O O
disease . . O O
characteristics . . O O
, . . O O
except . . O O
for . . O O
a . . O O
higher . . O O
incidence . . O O
of . . O O
DNA . . O O
aneuploidy . . B-Mutation B-Mutation
by . . O O
flow . . O O
cytometry . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
001 . . O O
) . . O O
and . . O O
a . . O O
lower . . O O
median . . O O
of . . O O
disease . . O O
- . . O O
free . . O O
survival . . O O
( . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
06 . . O O
) . . O O
. . . O O

Multivariate . . O O
analysis . . O O
showed . . O O
that . . O O
numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosome . . O O
17 . . O O
, . . O O
but . . O O
not . . O O
of . . O O
chromosome . . O O
18 . . O O
, . . O O
are . . O O
an . . O O
independent . . O O
prognostic . . O O
factor . . O O
for . . O O
predicting . . O O
disease . . O O
- . . O O
free . . O O
survival . . O O
in . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Numerical . . B-Mutation O
abnormalities . . I-Mutation O
of . . O O
chromosomes . . O O
17 . . O O
and . . O O
18 . . O O
were . . O O
relatively . . O O
common . . O O
findings . . O O
in . . O O
patients . . O O
with . . O O
colorectal . . O O
cancer . . O O
, . . O O
with . . O O
chromosome . . O O
17 . . O O
being . . O O
associated . . O O
with . . O O
a . . O O
higher . . O O
incidence . . O O
of . . O O
tumors . . O O
localized . . O O
to . . O O
the . . O O
rectum . . O O
and . . O O
a . . O O
worse . . O O
clinical . . O O
outcome . . O O
. . . O O

Cytometry . . O O
Part . . O O
B . . O O
( . . O O
Clin . . O O
. . . O O
Cytometry . . O O
) . . O O
51B . . O O
: . . O O
14 . . O O
- . . O O
20 . . O O
, . . O O
2003 . . O O
. . . O O

Associations . . O O
of . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
in . . O O
miR . . O O
- . . O O
146a . . O O
, . . O O
miR . . O O
- . . O O
196a . . O O
, . . O O
miR . . O O
- . . O O
149 . . O O
and . . O O
miR . . O O
- . . O O
499 . . O O
with . . O O
colorectal . . O O
cancer . . O O
susceptibility . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

MicroRNAs . . O O
( . . O O
miRNAs . . O O
) . . O O
are . . O O
an . . O O
abundant . . O O
class . . O O
of . . O O
endogenous . . O O
small . . O O
non . . O O
- . . O O
coding . . O O
RNAs . . O O
of . . O O
20 . . O O
- . . O O
25 . . O O
nucleotides . . O O
in . . O O
length . . O O
that . . O O
function . . O O
as . . O O
negative . . O O
gene . . O O
regulators . . O O
. . . O O

MiRNAs . . O O
play . . O O
roles . . O O
in . . O O
most . . O O
biological . . O O
processes . . O O
, . . O O
as . . O O
well . . O O
as . . O O
diverse . . O O
human . . O O
diseases . . O O
including . . O O
cancer . . O O
. . . O O

Recently . . O O
, . . O O
many . . O O
studies . . O O
investigated . . O O
the . . O O
association . . O O
between . . O O
SNPs . . B-Mutation B-Mutation
in . . O O
miR . . O O
- . . O O
146a . . O O
rs2910164 . . B-Mutation B-Mutation
, . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
, . . O O
miR . . O O
- . . O O
149 . . O O
rs229283 . . B-Mutation B-Mutation
, . . O O
miR . . O O
- . . O O
499 . . O O
rs3746444 . . B-Mutation B-Mutation
and . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
, . . O O
which . . O O
results . . O O
have . . O O
been . . O O
inconclusive . . O O
. . . O O

# . . O O
# . . O O
METHODOLOGY . . O O
/ . . O O
PRINCIPAL . . O O
FINDINGS . . O O

PubMed . . O O
, . . O O
EMBASE . . O O
, . . O O
CNKI . . O O
databases . . O O
were . . O O
searched . . O O
with . . O O
the . . O O
last . . O O
search . . O O
updated . . O O
on . . O O
November . . O O
5 . . O O
, . . O O
2013 . . O O
. . . O O

For . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
, . . O O
a . . O O
significantly . . O O
decreased . . O O
risk . . O O
of . . O O
CRC . . O O
development . . O O
was . . O O
observed . . O O
under . . O O
three . . O O
genetic . . O O
models . . O O
( . . O O
dominant . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
848 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
735 . . O O
- . . O O
0 . . O O
. . . O O
979 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
025 . . O O
; . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
838 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
721 . . O O
- . . O O
0 . . O O
. . . O O
974 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
; . . O O
homozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
754 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
627 . . O O
- . . O O
0 . . O O
. . . O O
907 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
003 . . O O
) . . O O
. . . O O

In . . O O
the . . O O
subgroup . . O O
analyses . . O O
, . . O O
miR . . O O
- . . O B-Mutation
196a2 . . O I-Mutation
* . . O I-Mutation
T . . B-Mutation I-Mutation
variant . . I-Mutation I-Mutation
was . . O O
associated . . O O
with . . O O
a . . O O
significantly . . O O
decreased . . O O
susceptibility . . O O
of . . O O
CRC . . O O
( . . O O
allele . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
839 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
749 . . O O
- . . O O
0 . . O O
. . . O O
940 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
000 . . O O
; . . O O
dominant . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
770 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
653 . . O O
- . . O O
0 . . O O
. . . O O
980 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
; . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
802 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
685 . . O O
- . . O O
0 . . O O
. . . O O
939 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
006 . . O O
; . . O O
homozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
695 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
: . . O O
0 . . O O
. . . O O
570 . . O O
- . . O O
0 . . O O
. . . O O
847 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
000 . . O O
) . . O O
. . . O O

As . . O O
for . . O O
miR . . O O
- . . O O
149 . . O O
rs2292832 . . B-Mutation B-Mutation
, . . O O
the . . O O
two . . O O
genetic . . O O
models . . O O
( . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
199 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
028 . . O O
- . . O O
1 . . O O
. . . O O
398 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
021 . . O O
; . . O O
heterozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
226 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
039 . . O O
- . . O O
1 . . O O
. . . O O
447 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
013 . . O O
) . . O O
demonstrated . . O O
increased . . O O
susceptibility . . O O
to . . O O
CRC . . O O
. . . O O

On . . O O
subgroup . . O O
analysis . . O O
, . . O O
significantly . . O O
increased . . O O
susceptibility . . O O
of . . O O
CRC . . O O
was . . O O
found . . O O
in . . O O
the . . O O
genetic . . O O
models . . O O
( . . O O
recessive . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
180 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
008 . . O O
- . . O O
1 . . O O
. . . O O
382 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
040 . . O O
; . . O O
heterozygous . . O O
model . . O O
: . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
202 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
013 . . O O
- . . O O
1 . . O O
. . . O O
425 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
013 . . O O
) . . O O
in . . O O
the . . O O
Asian . . O O
group . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

These . . O O
findings . . O O
supported . . O O
that . . O O
the . . O O
miR . . O O
- . . O O
196a2 . . O O
rs11614913 . . B-Mutation B-Mutation
and . . O O
miR . . O O
- . . O O
149 . . O O
rs2292832 . . B-Mutation B-Mutation
polymorphisms . . B-Mutation I-Mutation
may . . O O
contribute . . O O
to . . O O
susceptibility . . O O
to . . O O
CRC . . O O
. . . O O

Linkage . . O O
disequilibrium . . O O
and . . O O
haplotype . . O O
analysis . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
development . . O O
. . . O O

Single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
( . . O O
SNPs . . B-Mutation B-Mutation
) . . O O
in . . O O
the . . O O
promoter . . O O
and . . O O
untranslated . . O O
region . . O O
of . . O O
cyclooxygenase . . O O
( . . O O
COX . . O O
) . . O O
- . . O O
2 . . O O
, . . O O
an . . O O
inducible . . O O
enzyme . . O O
responsible . . O O
for . . O O
the . . O O
synthesis . . O O
of . . O O
prostaglandins . . O O
, . . O O
have . . O O
been . . O O
reported . . O O
to . . O O
modulate . . O O
the . . O O
risk . . O O
for . . O O
many . . O O
human . . O O
cancers . . O O
. . . O O

We . . O O
performed . . O O
comprehensive . . O O
linkage . . O O
disequilibrium . . O O
( . . O O
LD . . O O
) . . O O
and . . O O
haplotype . . O O
analyses . . O O
of . . O O
13 . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
of . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
gene . . O O
and . . O O
examined . . O O
its . . O O
susceptibility . . O O
to . . O O
adenoma . . O O
development . . O O
in . . O O
72 . . O O
African . . O O
American . . O O
cases . . O O
and . . O O
142 . . O O
controls . . O O
. . . O O

Results . . O O
revealed . . O O
significant . . O O
variation . . O B-Mutation
in . . O O
LD . . O O
patterns . . O O
with . . O O
consequence . . O O
for . . O O
adenoma . . O O
development . . O O
. . . O O

Two . . O O
distinct . . O O
haplotype . . O O
blocks . . O O
were . . O O
identified . . O O
; . . O O
one . . O O
block . . O O
covered . . O O
the . . O O
coding . . O O
regions . . O O
of . . O O
exon . . O O
1 . . O O
, . . O O
introns . . O O
and . . O O
a . . O O
section . . O O
of . . O O
the . . O O
3 . . O O
' . . O O
- . . O O
unstranslated . . O O
region . . O O
( . . O O
3 . . O O
' . . O O
- . . O O
UTR . . O O
) . . O O
, . . O O
whereas . . O O
the . . O O
second . . O O
block . . O O
resided . . O O
solely . . O O
in . . O O
the . . O O
3 . . O O
' . . O O
- . . O O
UTR . . O O
region . . O O
. . . O O

A . . O O
haplotype . . O O
in . . O O
block . . O O
1 . . O O
increased . . O O
the . . O O
risk . . O O
of . . O O
adenoma . . O O
development . . O O
by . . O O
threefold . . O O
( . . O O
odds . . O O
ratio . . O O
[ . . O O
OR . . O O
] . . O O
= . . O O
2 . . O O
. . . O O
9 . . O O
, . . O O
confidence . . O O
interval . . O O
[ . . O O
CI . . O O
] . . O O
= . . O O
1 . . O O
. . . O O
8 . . O O
- . . O O
3 . . O O
. . . O O
7 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
002 . . O O
) . . O O
. . . O O

Regression . . O O
analysis . . O O
showed . . O O
, . . O O
increase . . O O
in . . O O
copies . . O O
of . . O O
minor . . O O
alleles . . O O
of . . O O
6 . . O O
, . . O O
064 . . O B-Mutation
( . . O I-Mutation
T . . B-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
) . . O O
polymorphism . . B-Mutation B-Mutation
associated . . O O
with . . O O
increased . . O O
odds . . O O
of . . O O
adenoma . . O O
development . . O O
by . . O O
80 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
80 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
09 . . O O
- . . O O
3 . . O O
. . . O O
21 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
034 . . O O
) . . O O
, . . O O
10 . . O O
, . . O O
848 . . O O
( . . O O
G . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
) . . O O
by . . O O
84 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
84 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
05 . . O O
- . . O O
3 . . O O
. . . O O
23 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
034 . . O O
) . . O O
and . . O O
10 . . O O
, . . O O
935 . . O O
( . . O O
A . . B-Mutation B-Mutation
> . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
) . . O O
by . . O O
32 . . O O
% . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
32 . . O O
, . . O O
CI . . O O
= . . O O
1 . . O O
. . . O O
12 . . O O
- . . O O
3 . . O O
. . . O O
69 . . O O
, . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
036 . . O O
) . . O O
. . . O O

These . . O O
results . . O O
support . . O O
the . . O O
hypothesis . . O O
that . . O O
COX . . O O
- . . O O
2 . . O O
gene . . O O
might . . O O
play . . O O
a . . O O
role . . O O
in . . O O
the . . O O
etiology . . O O
of . . O O
colon . . O O
cancer . . O O
and . . O O
warrant . . O O
further . . O O
investigation . . O O
in . . O O
other . . O O
cancers . . O O
. . . O O

Besides . . O O
, . . O O
these . . O O
variations . . B-Mutation B-Mutation
should . . O O
be . . O O
taken . . O O
into . . O O
account . . O O
for . . O O
disease . . O O
- . . O O
based . . O O
association . . O O
studies . . O O
in . . O O
which . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
polymorphism . . B-Mutation B-Mutation
is . . O O
considered . . O O
as . . O O
a . . O O
candidate . . O O
gene . . O O
. . . O O

Clin . . O O
Trans . . O O
Sci . . O O
2012 . . O O
; . . O O
Volume . . O O
5 . . O O
: . . O O
60 . . O O
- . . O O
64 . . O O
. . . O O

Mutations . . B-Mutation B-Mutation
in . . O O
two . . O O
short . . O O
noncoding . . O O
mononucleotide . . O O
repeats . . O O
in . . O O
most . . O O
microsatellite . . B-Mutation B-Mutation
- . . I-Mutation I-Mutation
unstable . . I-Mutation I-Mutation
colorectal . . O O
cancers . . O O
. . . O O

DNA . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
- . . O O
deficient . . O O
cells . . O O
typically . . O O
accumulate . . O O
mutations . . B-Mutation B-Mutation
in . . O O
short . . O O
repetitive . . O O
DNA . . O O
tracts . . O O
. . . O O

This . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
facilitates . . O O
malignant . . O O
transformation . . O O
when . . O O
affecting . . O O
genes . . O O
with . . O O
growth . . O O
- . . O O
related . . O O
and . . O O
caretaker . . O O
functions . . O O
. . . O O

To . . O O
date . . O O
, . . O O
several . . O O
putative . . O O
MSI . . B-Mutation B-Mutation
target . . O O
genes . . O O
have . . O O
been . . O O
proposed . . O O
mainly . . O O
based . . O O
on . . O O
high . . O O
mutation . . B-Mutation B-Mutation
frequency . . O O
within . . O O
their . . O O
coding . . O O
regions . . O O
. . . O O

However . . O O
, . . O O
some . . O O
intronic . . O O
repeat . . O O
mutations . . B-Mutation B-Mutation
have . . O O
also . . O O
been . . O O
suggested . . O O
to . . O O
associate . . O O
with . . O O
MSI . . B-Mutation B-Mutation
tumorigenesis . . O O
, . . O O
indicating . . O O
the . . O O
need . . O O
for . . O O
additional . . O O
analyses . . O O
on . . O O
noncoding . . O O
repeats . . O O
. . . O O

Here . . O O
we . . O O
have . . O O
analyzed . . O O
an . . O O
intronic . . O O
T9 . . O O
repeat . . O O
of . . O O
semenogelin . . O O
I . . O O
( . . O O
SEMG1 . . O O
) . . O O
and . . O O
report . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
of . . O O
51 . . O O
% . . O O
( . . O O
75 . . O O
of . . O O
146 . . O O
) . . O O
and . . O O
62 . . O O
% . . O O
( . . O O
8 . . O O
of . . O O
13 . . O O
) . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
primary . . O O
colorectal . . O O
cancers . . O O
and . . O O
cell . . O O
lines . . O O
, . . O O
respectively . . O O
. . . O O

The . . O O
putative . . O O
effect . . O O
of . . O O
the . . O O
SEMG1 . . O O
mutations . . B-Mutation B-Mutation
was . . O O
assessed . . O O
by . . O O
RNA . . O O
and . . O O
protein . . O O
level . . O O
analyses . . O O
, . . O O
but . . O O
no . . O O
differences . . O O
were . . O O
detected . . O O
between . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
with . . O O
different . . O O
SEMG1 . . O O
status . . O O
. . . O O

Subsequently . . O O
, . . O O
the . . O O
general . . O O
background . . O O
mutation . . B-Mutation B-Mutation
frequency . . O O
of . . O O
MSI . . B-Mutation B-Mutation
colorectal . . O O
cancers . . O O
was . . O O
assessed . . O O
by . . O O
screening . . O O
for . . O O
intergenic . . O O
T9 . . O O
repeat . . O O
alterations . . B-Mutation O
. . . O O

One . . O O
of . . O O
10 . . O O
examined . . O O
repeats . . O O
was . . O O
mutated . . B-Mutation B-Mutation
in . . O O
70 . . O O
% . . O O
( . . O O
102 . . O O
of . . O O
145 . . O O
) . . O O
of . . O O
the . . O O
colorectal . . O O
cancers . . O O
evaluated . . O O
. . . O O

The . . O O
frequencies . . O O
observed . . O O
here . . O O
are . . O O
notably . . O O
higher . . O O
than . . O O
previously . . O O
published . . O O
in . . O O
noncoding . . O O
repeats . . O O
shorter . . O O
than . . O O
10 . . O O
bp . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
primary . . O O
tumors . . O O
. . . O O

Our . . O O
results . . O O
indicate . . O O
that . . O O
high . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
, . . O O
similar . . O O
or . . O O
higher . . O O
than . . O O
those . . O O
observed . . O O
in . . O O
proposed . . O O
and . . O O
approved . . O O
target . . O O
genes . . O O
, . . O O
can . . O O
be . . O O
detected . . O O
in . . O O
repeat . . O O
tracts . . O O
of . . O O
MSI . . B-Mutation B-Mutation
tumors . . O O
without . . O O
any . . O O
apparent . . O O
selection . . O O
pressure . . O O
. . . O O

These . . O O
data . . O O
call . . O O
for . . O O
urgent . . O O
and . . O O
thorough . . O O
large . . O O
- . . O O
scale . . O O
evaluation . . O O
of . . O O
mutation . . B-Mutation B-Mutation
frequencies . . O O
in . . O O
neutral . . O O
short . . O O
repetitive . . O O
sequences . . O O
in . . O O
MMR . . O O
- . . O O
deficient . . O O
tumors . . O O
. . . O O

Coprocytobiology . . O O
: . . O O
on . . O O
the . . O O
nature . . O O
of . . O O
cellular . . O O
elements . . O O
from . . O O
stools . . O O
in . . O O
the . . O O
pathophysiology . . O O
of . . O O
colonic . . O O
disease . . O O
. . . O O

The . . O O
gastrointestinal . . O O
epithelium . . O O
is . . O O
known . . O O
to . . O O
undergo . . O O
constant . . O O
and . . O O
rapid . . O O
renewal . . O O
resulting . . O O
in . . O O
millions . . O O
of . . O O
cells . . O O
being . . O O
shed . . O O
into . . O O
the . . O O
fecal . . O O
stream . . O O
every . . O O
day . . O O
. . . O O

The . . O O
conventional . . O O
wisdom . . O O
was . . O O
that . . O O
these . . O O
cells . . O O
disintegrate . . O O
upon . . O O
exfoliation . . O O
and . . O O
will . . O O
not . . O O
survive . . O O
the . . O O
transit . . O O
through . . O O
the . . O O
intestinal . . O O
tract . . O O
. . . O O

In . . O O
1990 . . O O
, . . O O
we . . O O
( . . O O
P . . O O
. . . O O
N . . O O
. . . O O
) . . O O
made . . O O
the . . O O
discovery . . O O
that . . O O
a . . O O
significant . . O O
number . . O O
of . . O O
these . . O O
cells . . O O
remain . . O O
intact . . O O
and . . O O
viable . . O O
and . . O O
that . . O O
they . . O O
can . . O O
be . . O O
isolated . . O O
. . . O O

The . . O O
implications . . O O
of . . O O
this . . O O
important . . O O
discovery . . O O
became . . O O
apparent . . O O
when . . O O
we . . O O
demonstrated . . O O
that . . O O
these . . O O
cells . . O O
are . . O O
exclusively . . O O
of . . O O
colonic . . O O
origin . . O O
, . . O O
are . . O O
anatomically . . O O
representative . . O O
of . . O O
the . . O O
entire . . O O
colon . . O O
, . . O O
and . . O O
can . . O O
be . . O O
used . . O O
for . . O O
clinical . . O O
investigations . . O O
of . . O O
disease . . O O
processes . . O O
. . . O O

The . . O O
term . . O O
coprocytobiology . . O O
( . . O O
CCB . . O O
) . . O O
was . . O O
coined . . O O
to . . O O
encompass . . O O
the . . O O
broad . . O O
range . . O O
of . . O O
applications . . O O
of . . O O
this . . O O
new . . O O
technology . . O O
. . . O O

The . . O O
somatic . . O O
cell . . O O
sampling . . O O
and . . O O
recovery . . O O
( . . O O
SCSR . . O O
) . . O O
process . . O O
involves . . O O
the . . O O
isolation . . O O
of . . O O
exfoliated . . O O
colonocytes . . O O
from . . O O
a . . O O
small . . O O
sample . . O O
of . . O O
stool . . O O
( . . O O
approximately . . O O
1 . . O O
g . . O O
) . . O O
collected . . O O
and . . O O
transported . . O O
in . . O O
a . . O O
unique . . O O
medium . . O O
at . . O O
ambient . . O O
temperature . . O O
, . . O O
providing . . O O
cells . . O O
for . . O O
the . . O O
detection . . O O
of . . O O
a . . O O
number . . O O
of . . O O
biomarkers . . O O
of . . O O
disease . . O O
propensity . . O O
. . . O O

These . . O O
exfoliated . . O O
colonocytes . . O O
express . . O O
cytokeratins . . O O
indicating . . O O
epithelial . . O O
lineage . . O O
as . . O O
well . . O O
as . . O O
colon . . O O
- . . O O
specific . . O O
antigen . . O O
. . . O O

Over . . O O
the . . O O
years . . O O
, . . O O
the . . O O
study . . O O
of . . O O
exfoliated . . O O
colonocytes . . O O
has . . O O
provided . . O O
striking . . O O
new . . O O
insights . . O O
into . . O O
the . . O O
biology . . O O
of . . O O
colon . . O O
cancer . . O O
and . . O O
inflammatory . . O O
bowel . . O O
disease . . O O
, . . O O
including . . O O
detection . . O O
of . . O O
p53 . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
, . . O O
reverse . . O O
transcriptase . . O O
polymerase . . O O
chain . . O O
reaction . . O O
amplification . . O O
, . . O O
and . . O O
identification . . O O
of . . O O
CD44 . . O O
splice . . B-Mutation O
variants . . I-Mutation B-Mutation
, . . O O
neoplasia . . O O
- . . O O
associated . . O O
specific . . O O
binding . . O O
of . . O O
plant . . O O
lectins . . O O
, . . O O
and . . O O
expression . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
, . . O O
the . . O O
inducible . . O O
form . . O O
of . . O O
cyclooxygenase . . O O
. . . O O

The . . O O
functional . . O O
diversity . . O O
of . . O O
cells . . O O
isolated . . O O
by . . O O
SCSR . . O O
is . . O O
revealed . . O O
by . . O O
the . . O O
demonstration . . O O
of . . O O
cell . . O O
surface . . O O
markers . . O O
such . . O O
as . . O O
secretory . . O O
component . . O O
, . . O O
IgA . . O O
, . . O O
and . . O O
IgG . . O O
on . . O O
the . . O O
one . . O O
hand . . O O
and . . O O
the . . O O
amplification . . O O
and . . O O
cloning . . O O
of . . O O
the . . O O
human . . O O
insulin . . O O
receptor . . O O
and . . O O
the . . O O
expression . . O O
of . . O O
the . . O O
multidrug . . O O
resistance . . O O
gene . . O O
mdr . . O O
- . . O O
1 . . O O
on . . O O
the . . O O
other . . O O
hand . . O O
. . . O O

This . . O O
review . . O O
portrays . . O O
the . . O O
immense . . O O
potential . . O O
of . . O O
CCB . . O O
as . . O O
a . . O O
powerful . . O O
tool . . O O
for . . O O
investigating . . O O
the . . O O
pathophysiology . . O O
of . . O O
disease . . O O
, . . O O
identifying . . O O
genetic . . O O
variants . . B-Mutation B-Mutation
in . . O O
pharmacogenetics . . O O
, . . O O
assessment . . O O
of . . O O
mucosal . . O O
immunity . . O O
, . . O O
and . . O O
several . . O O
other . . O O
applications . . O O
that . . O O
use . . O O
somatic . . O O
cells . . O O
. . . O O

Attenuated . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
associated . . O O
with . . O O
advanced . . O O
rectal . . O O
cancer . . O O
in . . O O
a . . O O
16 . . O O
- . . O O
year . . O O
- . . O O
old . . O O
boy . . O O
: . . O O
report . . O O
of . . O O
a . . O O
case . . O O
. . . O O

We . . O O
herein . . O O
present . . O O
a . . O O
case . . O O
of . . O O
attenuated . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
AFAP . . O O
) . . O O
with . . O O
advanced . . O O
rectal . . O O
cancer . . O O
in . . O O
a . . O O
16 . . O O
- . . O O
year . . O O
- . . O O
old . . O O
boy . . O O
. . . O O

His . . O O
mother . . O O
and . . O O
younger . . O O
brother . . O O
both . . O O
had . . O O
subcutaneous . . O O
soft . . O O
tissue . . O O
tumors . . O O
in . . O O
the . . O O
back . . O O
and . . O O
sparse . . O O
- . . O O
type . . O O
colorectal . . O O
polyposis . . O O
. . . O O

His . . O O
mother . . O O
also . . O O
had . . O O
dental . . O O
anomalies . . O O
and . . O O
gastric . . O O
fundic . . O O
gland . . O O
polyposis . . O O
. . . O O

The . . O O
patient . . O O
was . . O O
admitted . . O O
to . . O O
our . . O O
hospital . . O O
for . . O O
investigation . . O O
of . . O O
bloody . . O O
stools . . O O
. . . O O

Barium . . O O
enema . . O O
and . . O O
colonofiberscopy . . O O
revealed . . O O
advanced . . O O
rectal . . O O
cancer . . O O
and . . O O
sparse . . O O
( . . O O
< . . O O
50 . . O O
) . . O O
colorectal . . O O
polyps . . O O
. . . O O

He . . O O
also . . O O
had . . O O
dental . . O O
anomalies . . O O
, . . O O
a . . O O
subcutaneous . . O O
soft . . O O
tissue . . O O
tumor . . O O
in . . O O
the . . O O
back . . O O
, . . O O
and . . O O
gastric . . O O
fundic . . O O
gland . . O O
polyposis . . O O
as . . O O
extracolonic . . O O
manifestations . . O O
. . . O O

A . . O O
total . . O O
proctocolectomy . . O O
and . . O O
ileoanal . . O O
anastomosis . . O O
were . . O O
performed . . O O
, . . O O
and . . O O
histological . . O O
examination . . O O
of . . O O
the . . O O
resected . . O O
specimens . . O O
confirmed . . O O
moderately . . O O
differentiated . . O O
adenocarcinomas . . O O
of . . O O
the . . O O
rectum . . O O
with . . O O
metastases . . O O
to . . O O
the . . O O
regional . . O O
lymph . . O O
nodes . . O O
. . . O O

The . . O O
other . . O O
colorectal . . O O
polyps . . O O
were . . O O
tubular . . O O
adenomas . . O O
with . . O O
no . . O O
evidence . . O O
of . . O O
malignancy . . O O
. . . O O

Germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
APC . . O O
gene . . O O
were . . O O
observed . . O O
in . . O O
codons . . O O
486 . . O O
, . . O O
545 . . O O
, . . O O
1493 . . O O
, . . O O
and . . O O
1556 . . O O
. . . O O

This . . O O
case . . O O
serves . . O O
to . . O O
demonstrate . . O O
that . . O O
a . . O O
total . . O O
proctocolectomy . . O O
with . . O O
ileoanal . . O O
anastomosis . . O O
should . . O O
be . . O O
the . . O O
procedure . . O O
of . . O O
choice . . O O
for . . O O
young . . O O
patients . . O O
found . . O O
to . . O O
have . . O O
advanced . . O O
rectal . . O O
cancer . . O O
associated . . O O
with . . O O
FAP . . O O
. . . O O

Expression . . O O
of . . O O
p53 . . O O
in . . O O
colorectal . . O O
cancer . . O O
and . . O O
dysplasia . . O O
complicating . . O O
ulcerative . . O O
colitis . . O O
. . . O O

An . . O O
immunohistochemical . . O O
method . . O O
using . . O O
Pab1801 . . O O
, . . O O
a . . O O
monoclonal . . O O
antibody . . O O
specific . . O O
to . . O O
the . . O O
human . . O O
p53 . . O O
protein . . O O
, . . O O
was . . O O
applied . . O O
to . . O O
detect . . O O
p53 . . O O
expression . . O O
in . . O O
colorectal . . O O
cancer . . O O
and . . O O
dysplasia . . O O
complicating . . O O
ulcerative . . O O
colitis . . O O
. . . O O

Of . . O O
20 . . O O
tissue . . O O
samples . . O O
with . . O O
dysplasia . . O O
, . . O O
six . . O O
showed . . O O
positive . . O O
immunoreactivity . . O O
. . . O O

Archival . . O O
paraffin . . O O
- . . O O
embedded . . O O
tissue . . O O
blocks . . O O
from . . O O
21 . . O O
colitic . . O O
cancers . . O O
were . . O O
analysed . . O O
; . . O O
11 . . O O
showed . . O O
positive . . O O
immunoreactivity . . O O
, . . O O
compared . . O O
with . . O O
ten . . O O
of . . O O
21 . . O O
samples . . O O
from . . O O
matched . . O O
sporadic . . O O
colorectal . . O O
cancers . . O O
( . . O O
P . . O O
not . . O O
significant . . O O
) . . O O
. . . O O

Previous . . O O
data . . O O
suggesting . . O O
that . . O O
colorectal . . O O
carcinoma . . O O
complicating . . O O
ulcerative . . O O
colitis . . O O
has . . O O
a . . O O
reduced . . O O
frequency . . O O
of . . O O
c . . O O
- . . O O
Ki . . O O
- . . O O
ras . . O O
mutation . . B-Mutation B-Mutation
compared . . O O
with . . O O
sporadic . . O O
cancer . . O O
have . . O O
led . . O O
to . . O O
the . . O O
hypothesis . . O O
that . . O O
different . . O O
genetic . . O O
lesions . . O O
underlie . . O O
colitic . . O O
and . . O O
sporadic . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

The . . O O
present . . O O
results . . O O
suggest . . O O
that . . O O
this . . O O
is . . O O
not . . O O
the . . O O
case . . O O
with . . O O
regard . . O O
to . . O O
p53 . . O O
gene . . O O
alterations . . B-Mutation B-Mutation
. . . O O

Leiden . . O O
Open . . O O
Variation . . O B-Mutation
Database . . O O
of . . O O
the . . O O
MUTYH . . O O
gene . . O O
. . . O O

The . . O O
MUTYH . . O O
gene . . O O
encodes . . O O
a . . O O
DNA . . O O
glycosylase . . O O
involved . . O O
in . . O O
base . . O O
excision . . O O
repair . . O O
( . . O O
BER . . O O
) . . O O
. . . O O

Biallelic . . O O
pathogenic . . O O
MUTYH . . O O
variants . . B-Mutation B-Mutation
have . . O O
been . . O O
associated . . O O
with . . O O
colorectal . . O O
polyposis . . O O
and . . O O
cancer . . O O
. . . O O

The . . O O
pathogenicity . . O O
of . . O O
a . . O O
few . . O O
variants . . B-Mutation B-Mutation
is . . O O
beyond . . O O
doubt . . O O
, . . O O
including . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
536A4G . . I-Mutation I-Mutation
/ . . O I-Mutation
p . . B-Mutation I-Mutation
. . . I-Mutation I-Mutation
Tyr179Cys . . I-Mutation I-Mutation
and . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
1187G4A . . I-Mutation I-Mutation
/ . . O I-Mutation
p . . B-Mutation I-Mutation
. . . I-Mutation I-Mutation
Gly396Asp . . I-Mutation I-Mutation
( . . O O
previously . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
494A4G . . I-Mutation I-Mutation
/ . . O I-Mutation
p . . B-Mutation I-Mutation
. . . I-Mutation I-Mutation
Tyr165Cys . . I-Mutation I-Mutation
and . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
1145G4A . . I-Mutation I-Mutation
/ . . O I-Mutation
p . . B-Mutation I-Mutation
. . . I-Mutation I-Mutation
Gly382Asp . . I-Mutation I-Mutation
) . . O O
. . . O O
However . . O O
, . . O O
for . . O O
a . . O O
substantial . . O O
fraction . . O O
of . . O O
the . . O O
detected . . O O
variants . . B-Mutation B-Mutation
, . . O O
the . . O O
clinical . . O O
significance . . O O
remains . . O O
uncertain . . O O
, . . O O
compromising . . O O
molecular . . O O
diagnostics . . O O
and . . O O
thereby . . O O
genetic . . O O
counseling . . O O
. . . O O

We . . O O
have . . O O
established . . O O
an . . O O
interactive . . O O
MUTYH . . O O
gene . . O O
sequence . . O O
variant . . O B-Mutation
database . . O O
( . . O O
www . . O O
. . . O O
lovd . . O O
. . . O O
nl . . O O
/ . . O O
MUTYH . . O O
) . . O O
with . . O O
the . . O O
aim . . O O
of . . O O
collecting . . O O
and . . O O
sharing . . O O
MUTYH . . O O
genotype . . O O
and . . O O
phenotype . . O O
data . . O O
worldwide . . O O
. . . O O

To . . O O
support . . O O
standard . . O O
variant . . B-Mutation O
description . . O O
, . . O O
we . . O O
chose . . O O
NM . . O O
_ . . O O
001128425 . . O O
. . . O O
1 . . O O
as . . O O
the . . O O
reference . . O O
sequence . . O O
. . . O O

The . . O O
database . . O O
includes . . O O
records . . O O
with . . O O
variants . . O B-Mutation
per . . O O
individual . . O O
, . . O O
linked . . O O
to . . O O
available . . O O
phenotype . . O O
and . . O O
geographic . . O O
origin . . O O
data . . O O
as . . O O
well . . O O
as . . O O
records . . O O
with . . O O
in . . O O
vitro . . O O
functional . . O O
and . . O O
in . . O O
silico . . O O
test . . O O
data . . O O
. . . O O

As . . O O
of . . O O
April . . O O
2010 . . O O
, . . O O
the . . O O
database . . O O
contains . . O O
1968 . . O O
published . . O O
and . . O O
423 . . O O
unpublished . . O O
submitted . . O O
entries . . O O
, . . O O
and . . O O
230 . . O O
and . . O O
61 . . O O
unique . . O O
variants . . B-Mutation B-Mutation
, . . O O
respectively . . O O
. . . O O

This . . O O
open . . O O
- . . O O
access . . O O
repository . . O O
allows . . O O
all . . O O
involved . . O O
to . . O O
quickly . . O O
share . . O O
all . . O O
variants . . B-Mutation B-Mutation
encountered . . O O
and . . O O
communicate . . O O
potential . . O O
consequences . . O O
, . . O O
which . . O O
will . . O O
be . . O O
especially . . O O
useful . . O O
to . . O O
classify . . O O
variants . . B-Mutation B-Mutation
of . . O O
uncertain . . O O
significance . . O O
. . . O O

BRCA1 . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
. . . O O

Breast . . O O
cancer . . O O
susceptibility . . O O
gene . . O O
BRCA1 . . O O
has . . O O
been . . O O
implicated . . O O
in . . O O
the . . O O
control . . O O
of . . O O
gene . . O O
regulation . . O O
and . . O O
such . . O O
regulated . . O O
genes . . O O
are . . O O
thought . . O O
to . . O O
mediate . . O O
the . . O O
biological . . O O
role . . O O
of . . O O
BRCA1 . . O O
. . . O O

Overexpression . . O O
of . . O O
BRCA1 . . O O
induces . . O O
GADD45 . . O O
, . . O O
a . . O O
p53 . . O O
- . . O O
regulated . . O O
and . . O O
stress . . O O
- . . O O
inducible . . O O
gene . . O O
. . . O O

However . . O O
, . . O O
the . . O O
molecular . . O O
mechanism . . O O
by . . O O
which . . O O
BRCA1 . . O O
induces . . O O
the . . O O
expression . . O O
GADD45 . . O O
remains . . O O
unclear . . O O
. . . O O

In . . O O
this . . O O
report . . O O
, . . O O
we . . O O
have . . O O
shown . . O O
that . . O O
the . . O O
GADD45 . . O O
promoter . . O O
is . . O O
strongly . . O O
activated . . O O
following . . O O
expression . . O O
of . . O O
wild . . O O
- . . O O
type . . O O
BRCA1 . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
both . . O O
the . . O O
tumor . . O O
- . . O O
derived . . O O
BRCA1 . . O O
mutants . . B-Mutation B-Mutation
( . . O O
p1749R . . B-Mutation O
and . . O O
Y1853insA . . B-Mutation O
) . . O O
and . . O O
truncated . . O O
BRCA1 . . O O
mutant . . B-Mutation B-Mutation
protein . . O O
( . . O O
Delta500 . . B-Mutation O
- . . I-Mutation O
1863 . . I-Mutation O
BRCA1 . . O O
) . . O O
, . . O O
which . . O O
lack . . O O
transactivation . . O O
activity . . O O
, . . O O
were . . O O
unable . . O O
to . . O O
activate . . O O
the . . O O
GADD45 . . O O
promoter . . O O
, . . O O
indicating . . O O
that . . O O
the . . O O
BRCA1 . . O O
- . . O O
mediated . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
requires . . O O
normal . . O O
transcriptional . . O O
properties . . O O
of . . O O
BRCA1 . . O O
. . . O O

BRCA1 . . O O
did . . O O
not . . O O
induce . . O O
the . . O O
c . . O O
- . . O O
Jun . . O O
and . . O O
c . . O O
- . . O O
fos . . O O
promoters . . O O
, . . O O
which . . O O
rules . . O O
out . . O O
a . . O O
general . . O O
effect . . O O
of . . O O
BRCA1 . . O O
on . . O O
other . . O O
immediate . . O O
- . . O O
responsive . . O O
genes . . O O
. . . O O

Expression . . O O
of . . O O
the . . O O
human . . O O
papillomavirus . . O O
E6 . . O O
and . . O O
the . . O O
dominant . . O O
- . . O O
negative . . O O
mutant . . B-Mutation B-Mutation
p53 . . O O
proteins . . O O
had . . O O
no . . O O
effect . . O O
on . . O O
the . . O O
induction . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
by . . O O
BRCA1 . . O O
, . . O O
suggesting . . O O
that . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
by . . O O
BRCA1 . . O O
is . . O O
independent . . O O
of . . O O
cellular . . O O
p53 . . O O
function . . O O
. . . O O

With . . O O
the . . O O
5 . . O O
' . . O O
- . . O O
deletion . . O B-Mutation
analysis . . O O
, . . O O
the . . O O
BRCA1 . . O O
- . . O O
responsive . . O O
element . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
was . . O O
mapped . . O O
at . . O O
the . . O O
region . . O O
from . . O O
- . . O O
121 . . O O
to . . O O
- . . O O
75 . . O O
. . . O O

Disruption . . O O
of . . O O
this . . O O
region . . O O
resulted . . O O
in . . O O
the . . O O
abrogation . . O O
of . . O O
BRCA1 . . O O
activation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
. . . O O

Taken . . O O
together . . O O
, . . O O
these . . O O
results . . O O
demonstrate . . O O
that . . O O
the . . O O
mechanism . . O O
by . . O O
which . . O O
BRCA1 . . O O
induces . . O O
GADD45 . . O O
is . . O O
mainly . . O O
through . . O O
the . . O O
transactivation . . O O
of . . O O
the . . O O
GADD45 . . O O
promoter . . O O
, . . O O
further . . O O
demonstrating . . O O
the . . O O
evidence . . O O
that . . O O
GADD45 . . O O
acts . . O O
as . . O O
one . . O O
of . . O O
the . . O O
BRCA1 . . O O
- . . O O
regulated . . O O
genes . . O O
. . . O O

Oncogene . . O O
( . . O O
2000 . . O O
) . . O O
19 . . O O
, . . O O
4050 . . O O
- . . O O
4057 . . O O
. . . O O

Mutation . . B-Mutation B-Mutation
spectrum . . O O
in . . O O
human . . O O
colorectal . . O O
cancers . . O O
and . . O O
potential . . O O
functional . . O O
relevance . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Somatic . . O O
variants . . B-Mutation B-Mutation
, . . O O
which . . O O
occur . . O O
in . . O O
the . . O O
genome . . O O
of . . O O
all . . O O
cells . . O O
, . . O O
are . . O O
well . . O O
accepted . . O O
to . . O O
play . . O O
a . . O O
critical . . O O
role . . O O
in . . O O
cancer . . O O
development . . O O
, . . O O
as . . O O
their . . O O
accumulation . . O O
in . . O O
genes . . O O
could . . O O
affect . . O O
cell . . O O
proliferations . . O O
and . . O O
cell . . O O
cycle . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

In . . O O
order . . O O
to . . O O
understand . . O O
the . . O O
role . . O O
of . . O O
somatic . . O O
mutations . . B-Mutation B-Mutation
in . . O O
human . . O O
colorectal . . O O
cancers . . O O
, . . O O
we . . O O
characterized . . O O
the . . O O
mutation . . B-Mutation B-Mutation
spectrum . . O O
in . . O O
two . . O O
colorectal . . O O
tumor . . O O
tissues . . O O
and . . O O
their . . O O
matched . . O O
normal . . O O
tissues . . O O
, . . O O
by . . O O
analyzing . . O O
deep . . O O
- . . O O
sequenced . . O O
transcriptome . . O O
data . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

We . . O O
found . . O O
a . . O O
higher . . O O
mutation . . B-Mutation B-Mutation
rate . . O O
of . . O O
somatic . . O O
variants . . B-Mutation B-Mutation
in . . O O
tumor . . O O
tissues . . O O
in . . O O
comparison . . O O
with . . O O
normal . . O O
tissues . . O O
, . . O O
but . . O O
no . . O O
trend . . O O
was . . O O
observed . . O O
for . . O O
mutation . . B-Mutation B-Mutation
properties . . O O
. . . O O

By . . O O
applying . . O O
a . . O O
series . . O O
of . . O O
stringent . . O O
filters . . O O
, . . O O
we . . O O
identified . . O O
418 . . O O
genes . . O O
with . . O O
tumor . . O O
specific . . O O
disruptive . . O O
somatic . . O O
variants . . B-Mutation B-Mutation
. . . O O

Of . . O O
these . . O O
genes . . O O
, . . O O
three . . O O
genes . . O O
in . . O O
mucin . . O O
protein . . O O
family . . O O
( . . O O
MUC2 . . O O
, . . O O
MUC4 . . O O
, . . O O
and . . O O
MU12 . . O O
) . . O O
are . . O O
of . . O O
particular . . O O
interests . . O O
. . . O O

It . . O O
has . . O O
been . . O O
reported . . O O
that . . O O
the . . O O
expression . . O O
of . . O O
mucin . . O O
proteins . . O O
was . . O O
correlated . . O O
with . . O O
the . . O O
progression . . O O
of . . O O
colorectal . . O O
cancer . . O O
therefore . . O O
somatic . . O O
variants . . B-Mutation B-Mutation
within . . O O
those . . O O
genes . . O O
can . . O O
interrupt . . O O
their . . O O
normal . . O O
expression . . O O
and . . O O
thus . . O O
contribute . . O O
to . . O O
the . . O O
tumorigenesis . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Our . . O O
findings . . O O
provide . . O O
evidence . . O O
of . . O O
the . . O O
utility . . O O
of . . O O
RNA . . O O
- . . O O
Seq . . O O
in . . O O
mutation . . B-Mutation B-Mutation
screening . . O O
in . . O O
cancer . . O O
studies . . O O
, . . O O
and . . O O
suggest . . O O
a . . O O
list . . O O
of . . O O
candidate . . O O
genes . . O O
for . . O O
future . . O O
colorectal . . O O
cancer . . O O
diagnosis . . O O
and . . O O
treatment . . O O
. . . O O

MLH3 . . O O
mutation . . B-Mutation B-Mutation
in . . O O
endometrial . . O O
cancer . . O O
. . . O O

MLH3 . . O O
is . . O O
a . . O O
recently . . O O
described . . O O
member . . O O
of . . O O
the . . O O
DNA . . O O
mismatch . . O O
repair . . O O
gene . . O O
family . . O O
. . . O O

Based . . O O
on . . O O
its . . O O
interaction . . O O
with . . O O
the . . O O
MutL . . O O
homologue . . O O
MLH1 . . O O
, . . O O
it . . O O
was . . O O
postulated . . O O
that . . O O
MLH3 . . O O
might . . O O
play . . O O
a . . O O
role . . O O
in . . O O
tumorigenesis . . O O
. . . O O

Germ . . O O
line . . O O
and . . O O
somatic . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MLH3 . . O O
have . . O O
been . . O O
identified . . O O
in . . O O
a . . O O
small . . O O
fraction . . O O
of . . O O
colorectal . . O O
cancers . . O O
, . . O O
but . . O O
the . . O O
role . . O O
of . . O O
MLH3 . . O O
in . . O O
colorectal . . O O
cancer . . O O
tumorigenesis . . O O
remains . . O O
controversial . . O O
. . . O O

We . . O O
investigated . . O O
MLH3 . . O O
' . . O O
s . . O O
role . . O O
in . . O O
endometrial . . O O
tumorigenesis . . O O
through . . O O
analysis . . O O
of . . O O
tumor . . O O
and . . O O
germ . . O O
line . . O O
DNA . . O O
from . . O O
57 . . O O
endometrial . . O O
cancer . . O O
patients . . O O
who . . O O
were . . O O
at . . O O
increased . . O O
risk . . O O
for . . O O
having . . O O
inherited . . O O
cancer . . O O
susceptibility . . O O
. . . O O

Patients . . O O
with . . O O
known . . O O
MSH2 . . O O
or . . O O
MSH6 . . O O
mutations . . B-Mutation B-Mutation
were . . O O
excluded . . O O
as . . O O
well . . O O
as . . O O
those . . O O
who . . O O
had . . O O
MLH1 . . O O
- . . O O
methylated . . O O
tumors . . O O
. . . O O

Sixteen . . O O
different . . O O
variants . . B-Mutation B-Mutation
were . . O O
identified . . O O
by . . O O
single . . O O
- . . O O
strand . . O O
conformational . . O O
variant . . O O
analysis . . O O
. . . O O

Of . . O O
the . . O O
12 . . O O
missense . . B-Mutation B-Mutation
changes . . I-Mutation O
identified . . O O
, . . O O
three . . O O
were . . O O
somatic . . O O
mutations . . B-Mutation B-Mutation
. . . O O

One . . O O
patient . . O O
had . . O O
a . . O O
germ . . O O
line . . O O
missense . . B-Mutation B-Mutation
variant . . I-Mutation I-Mutation
and . . O O
loss . . B-Mutation B-Mutation
of . . I-Mutation I-Mutation
heterozygosity . . I-Mutation I-Mutation
( . . O O
LOH . . B-Mutation B-Mutation
) . . O O
in . . O O
her . . O O
tumor . . O O
specimen . . O O
. . . O O

There . . O O
was . . O O
no . . O O
evidence . . O O
of . . O O
MLH3 . . O O
promoter . . O O
methylation . . O O
based . . O O
on . . O O
combined . . O O
bisulfite . . O O
restriction . . O O
analysis . . O O
. . . O O

The . . O O
identification . . O O
of . . O O
inherited . . O O
missense . . B-Mutation B-Mutation
variants . . I-Mutation I-Mutation
, . . O O
somatic . . O O
missense . . B-Mutation B-Mutation
mutations . . I-Mutation I-Mutation
( . . O O
present . . O O
in . . O O
3 . . O O
of . . O O
57 . . O O
tumors . . O O
) . . O O
, . . O O
and . . O O
LOH . . B-Mutation B-Mutation
in . . O O
the . . O O
tumor . . O O
from . . O O
a . . O O
patient . . O O
with . . O O
a . . O O
germ . . O O
line . . O O
missense . . B-Mutation B-Mutation
change . . I-Mutation O
suggest . . O O
a . . O O
role . . O O
for . . O O
MLH3 . . O O
in . . O O
endometrial . . O O
tumorigenesis . . O O
. . . O O

Mismatch . . O O
repair . . O O
defects . . O O
and . . O O
Lynch . . O O
syndrome . . O O
: . . O O
The . . O O
role . . O O
of . . O O
the . . O O
basic . . O O
scientist . . O O
in . . O O
the . . O O
battle . . O O
against . . O O
cancer . . O O
. . . O O

We . . O O
have . . O O
currently . . O O
entered . . O O
a . . O O
genomic . . O O
era . . O O
of . . O O
cancer . . O O
research . . O O
which . . O O
may . . O O
soon . . O O
lead . . O O
to . . O O
a . . O O
genomic . . O O
era . . O O
of . . O O
cancer . . O O
treatment . . O O
. . . O O

Patient . . O O
DNA . . O O
sequencing . . O O
information . . O O
may . . O O
lead . . O O
to . . O O
a . . O O
personalized . . O O
approach . . O O
to . . O O
managing . . O O
an . . O O
individual . . O O
' . . O O
s . . O O
cancer . . O O
as . . O O
well . . O O
as . . O O
future . . O O
cancer . . O O
risk . . O O
. . . O O

The . . O O
success . . O O
of . . O O
this . . O O
approach . . O O
, . . O O
however . . O O
, . . O O
begins . . O O
not . . O O
necessarily . . O O
in . . O O
the . . O O
clinician . . O O
' . . O O
s . . O O
office . . O O
, . . O O
but . . O O
rather . . O O
at . . O O
the . . O O
laboratory . . O O
bench . . O O
of . . O O
the . . O O
basic . . O O
scientist . . O O
. . . O O

The . . O O
basic . . O O
scientist . . O O
plays . . O O
a . . O O
critical . . O O
role . . O O
since . . O O
the . . O O
DNA . . O O
sequencing . . O O
information . . O O
is . . O O
of . . O O
limited . . O O
use . . O O
unless . . O O
one . . O O
knows . . O O
the . . O O
function . . O O
of . . O O
the . . O O
gene . . O O
that . . O O
is . . O O
altered . . O O
and . . O O
the . . O O
manner . . O O
by . . O O
which . . O O
a . . O O
sequence . . O O
alteration . . O B-Mutation
affects . . O O
that . . O O
function . . O O
. . . O O

The . . O O
role . . O O
of . . O O
basic . . O O
science . . O O
research . . O O
in . . O O
aiding . . O O
the . . O O
clinical . . O O
management . . O O
of . . O O
a . . O O
disease . . O O
is . . O O
perhaps . . O O
best . . O O
exemplified . . O O
by . . O O
considering . . O O
the . . O O
case . . O O
of . . O O
Lynch . . O O
syndrome . . O O
, . . O O
a . . O O
hereditary . . O O
disease . . O O
that . . O O
predisposes . . O O
patients . . O O
to . . O O
colorectal . . O O
and . . O O
other . . O O
cancers . . O O
. . . O O

This . . O O
review . . O O
will . . O O
examine . . O O
how . . O O
the . . O O
diagnosis . . O O
, . . O O
treatment . . O O
and . . O O
even . . O O
prevention . . O O
of . . O O
Lynch . . O O
syndrome . . O O
- . . O O
associated . . O O
cancers . . O O
has . . O O
benefitted . . O O
from . . O O
extensive . . O O
basic . . O O
science . . O O
research . . O O
on . . O O
the . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
whose . . O O
alteration . . O B-Mutation
underlies . . O O
this . . O O
condition . . O O
. . . O O

BRAF . . O O
mutation . . B-Mutation B-Mutation
is . . O O
frequently . . O O
present . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
with . . O O
methylated . . O O
hMLH1 . . O O
, . . O O
but . . O O
not . . O O
in . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
PURPOSE . . O O

The . . O O
BRAF . . O O
gene . . O O
encodes . . O O
a . . O O
serine . . O O
/ . . O O
threonine . . O O
kinase . . O O
and . . O O
plays . . O O
an . . O O
important . . O O
role . . O O
in . . O O
the . . O O
mitogen . . O O
- . . O O
activated . . O O
protein . . O O
kinase . . O O
signaling . . O O
pathway . . O O
. . . O O

BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
with . . O O
microsatellite . . O B-Mutation
instability . . O I-Mutation
( . . O O
MSI . . O B-Mutation
) . . O O
are . . O O
more . . O O
frequently . . O O
detected . . O O
than . . O O
those . . O O
in . . O O
microsatellite . . O O
stable . . O O
cancer . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
sought . . O O
to . . O O
compare . . O O
the . . O O
frequencies . . O O
of . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
with . . O O
MSI . . O B-Mutation
with . . O O
those . . O O
in . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
( . . O O
HNPCC . . O O
) . . O O
. . . O O

# . . O O
# . . O O
EXPERIMENTAL . . O O
DESIGN . . O O

We . . O O
analyzed . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
26 . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
, . . O O
80 . . O O
sporadic . . O O
colorectal . . O O
cancers . . O O
, . . O O
and . . O O
20 . . O O
tumors . . O O
from . . O O
HNPCC . . O O
patients . . O O
by . . O O
DNA . . O O
sequencing . . O O
and . . O O
sequence . . O O
- . . O O
specific . . O O
PCR . . O O
. . . O O

The . . O O
methylation . . O O
status . . O O
of . . O O
the . . O O
hMLH1 . . O O
gene . . O O
was . . O O
measured . . O O
by . . O O
either . . O O
sequencing . . O O
or . . O O
restriction . . O O
enzyme . . O O
digestion . . O O
after . . O O
NaHSO . . O O
( . . O O
3 . . O O
) . . O O
treatment . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

We . . O O
observed . . O O
a . . O O
strong . . O O
correlation . . O O
of . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
with . . O O
hMLH1 . . O O
promoter . . O O
methylation . . O O
. . . O O

BRAF . . O O
mutations . . B-Mutation B-Mutation
were . . O O
present . . O O
in . . O O
13 . . O O
of . . O O
15 . . O O
( . . O O
87 . . O O
% . . O O
) . . O O
of . . O O
the . . O O
colorectal . . O O
cell . . O O
lines . . O O
and . . O O
cancers . . O O
with . . O O
methylated . . O O
hMLH1 . . O O
, . . O O
whereas . . O O
only . . O O
4 . . O O
of . . O O
91 . . O O
( . . O O
4 . . O O
% . . O O
) . . O O
of . . O O
the . . O O
cell . . O O
lines . . O O
and . . O O
cancers . . O O
with . . O O
unmethylated . . O O
hMLH1 . . O O
carried . . O O
the . . O O
mutations . . B-Mutation B-Mutation
( . . O O
P . . O O
< . . O O
0 . . O O
. . . O O
00001 . . O O
) . . O O
. . . O O

Sixteen . . O O
of . . O O
17 . . O O
mutations . . B-Mutation B-Mutation
were . . O O
at . . O O
residue . . O O
599 . . O O
( . . O O
V599E . . B-Mutation B-Mutation
) . . O O
. . . O O

A . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
was . . O O
also . . O O
identified . . O O
at . . O O
residue . . O O
463 . . O O
( . . O O
G463V . . B-Mutation B-Mutation
) . . O O
in . . O O
one . . O O
cell . . O O
line . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
were . . O O
not . . O O
found . . O O
in . . O O
any . . O O
cancers . . O O
or . . O O
cell . . O O
lines . . O O
with . . O O
K . . O O
- . . O O
ras . . O O
mutations . . B-Mutation B-Mutation
. . . O O

In . . O O
20 . . O O
MSI . . O B-Mutation
+ . . O O
cancers . . O O
from . . O O
HNPCC . . O O
patients . . O O
, . . O O
however . . O O
, . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
were . . O O
not . . O O
detectable . . O O
, . . O O
including . . O O
a . . O O
subset . . O O
of . . O O
9 . . O O
tumors . . O O
with . . O O
negative . . O O
hMLH1 . . O O
immunostaining . . O O
and . . O O
methylated . . O O
hMLH1 . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

BRAF . . O O
mutations . . B-Mutation B-Mutation
are . . O O
frequently . . O O
present . . O O
in . . O O
sporadic . . O O
colorectal . . O O
cancer . . O O
with . . O O
methylated . . O O
hMLH1 . . O O
, . . O O
but . . O O
not . . O O
in . . O O
HNPCC . . O O
- . . O O
related . . O O
cancers . . O O
. . . O O

This . . O O
discrepancy . . O O
of . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
between . . O O
sporadic . . O O
MSI . . O B-Mutation
+ . . O O
cancer . . O O
and . . O O
HNPCC . . O O
might . . O O
be . . O O
used . . O O
in . . O O
a . . O O
strategy . . O O
for . . O O
the . . O O
detection . . O O
of . . O O
HNPCC . . O O
families . . O O
. . . O O

Mutation . . B-Mutation B-Mutation
analysis . . O O
of . . O O
p53 . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
BRAF . . O O
genes . . O O
in . . O O
colorectal . . O O
cancer . . O O
progression . . O O
. . . O O

Gene . . O O
mutations . . B-Mutation B-Mutation
in . . O O
APC . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
p53 . . O O
are . . O O
thought . . O O
to . . O O
be . . O O
essential . . O O
events . . O O
for . . O O
colorectal . . O O
cancer . . O O
development . . O O
. . . O O

Recent . . O O
data . . O O
seem . . O O
to . . O O
indicate . . O O
that . . O O
K . . O O
- . . O O
ras . . O O
and . . O O
p53 . . O O
mutations . . B-Mutation B-Mutation
rarely . . O O
co . . O O
- . . O O
exist . . O O
in . . O O
the . . O O
same . . O O
tumor . . O O
, . . O O
indicating . . O O
that . . O O
these . . O O
alterations . . O O
do . . O O
not . . O O
represent . . O O
a . . O O
synergistic . . O O
evolutionary . . O O
pathway . . O O
. . . O O

Moreover . . O O
, . . O O
an . . O O
inverse . . O O
relation . . O O
between . . O O
K . . O O
- . . O O
ras . . O O
gene . . O O
activation . . O O
and . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
has . . O O
been . . O O
demonstrated . . O O
, . . O O
suggesting . . O O
alternative . . O O
pathways . . O O
for . . O O
colorectal . . O O
cancer . . O O
transformation . . O O
. . . O O

To . . O O
reconstruct . . O O
the . . O O
chronological . . O O
modulation . . O O
of . . O O
these . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
during . . O O
cell . . O O
transformation . . O O
and . . O O
colorectal . . O O
cancer . . O O
progression . . O O
, . . O O
mutations . . B-Mutation B-Mutation
of . . O O
p53 . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
BRAF . . O O
genes . . O O
were . . O O
analyzed . . O O
by . . O O
Single . . O B-Mutation
Strand . . O I-Mutation
Conformation . . O I-Mutation
Polymorphism . . O I-Mutation
( . . O O
SSCP . . O O
) . . O O
or . . O O
sequencing . . O O
analysis . . O O
in . . O O
100 . . O O
colorectal . . O O
cancer . . O O
samples . . O O
, . . O O
evenly . . O O
distributed . . O O
among . . O O
different . . O O
Dukes . . O O
' . . O O
stages . . O O
. . . O O

We . . O O
found . . O O
mutations . . B-Mutation B-Mutation
in . . O O
p53 . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
BRAF . . O O
genes . . O O
in . . O O
35 . . O O
% . . O O
, . . O O
30 . . O O
% . . O O
, . . O O
and . . O O
4 . . O O
% . . O O
of . . O O
tumors . . O O
, . . O O
respectively . . O O
, . . O O
and . . O O
observed . . O O
a . . O O
minimal . . O O
or . . O O
no . . O O
co . . O O
- . . O O
presence . . O O
of . . O O
these . . O O
gene . . O O
alterations . . O B-Mutation
. . . O O

Moreover . . O O
, . . O O
the . . O O
frequency . . O O
of . . O O
molecular . . O O
p53 . . O O
mutations . . B-Mutation B-Mutation
increased . . O O
as . . O O
tumor . . O O
stage . . O O
increased . . O O
, . . O O
suggesting . . O O
an . . O O
important . . O O
role . . O O
for . . O O
this . . O O
gene . . O O
in . . O O
the . . O O
progression . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

Conversely . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
or . . O O
BRAF . . O O
genes . . O O
were . . O O
not . . O O
related . . O O
to . . O O
tumor . . O O
stage . . O O
or . . O O
location . . O O
. . . O O

These . . O O
data . . O O
seem . . O O
to . . O O
indicate . . O O
the . . O O
absence . . O O
of . . O O
a . . O O
co . . O O
- . . O O
presence . . O O
of . . O O
the . . O O
genes . . O O
, . . O O
highlighting . . O O
the . . O O
possibility . . O O
of . . O O
multiple . . O O
pathways . . O O
for . . O O
colorectal . . O O
tumor . . O O
progression . . O O
. . . O O

Moreover . . O O
, . . O O
mutations . . B-Mutation B-Mutation
in . . O O
p53 . . O O
, . . O O
K . . O O
- . . O O
ras . . O O
, . . O O
and . . O O
BRAF . . O O
are . . O O
not . . O O
present . . O O
in . . O O
about . . O O
one . . O O
- . . O O
third . . O O
of . . O O
colorectal . . O O
cancers . . O O
and . . O O
therefore . . O O
other . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
need . . O O
to . . O O
be . . O O
investigated . . O O
to . . O O
better . . O O
understand . . O O
molecular . . O O
mechanisms . . O O
at . . O O
the . . O O
basis . . O O
of . . O O
cell . . O O
transformation . . O O
and . . O O
the . . O O
progression . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

[ . . O O
Application . . O O
of . . O O
molecular . . O O
targeted . . O O
agents . . O O
in . . O O
comprehensive . . O O
treatment . . O O
of . . O O
gastrointestinal . . O O
cancer . . O O
] . . O O
. . . O O

Targeted . . O O
agents . . O O
increase . . O O
response . . O O
rates . . O O
and . . O O
improved . . O O
overall . . O O
survival . . O O
in . . O O
treatment . . O O
of . . O O
metastatic . . O O
gastrointestinal . . O O
cancer . . O O
. . . O O

Therefore . . O O
, . . O O
physicians . . O O
pay . . O O
more . . O O
attention . . O O
to . . O O
the . . O O
role . . O O
of . . O O
targeted . . O O
agents . . O O
in . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
gastrointestinal . . O O
cancer . . O O
. . . O O

The . . O O
clinical . . O O
trials . . O O
are . . O O
ongoing . . O O
to . . O O
evaluate . . O O
the . . O O
efficacy . . O O
of . . O O
Trastuzumab . . O O
in . . O O
neoadjuvant . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
gastric . . O O
cancer . . O O
with . . O O
HER . . O O
- . . O O
2 . . O O
gene . . O O
over . . O O
expression . . O O
. . . O O

Many . . O O
studies . . O O
reported . . O O
Cetuximab . . O O
plus . . O O
chemotherapy . . O O
as . . O O
a . . O O
conversion . . O O
treatment . . O O
improve . . O O
R0 . . O O
resection . . O O
rates . . O O
and . . O O
prolonged . . O O
overall . . O O
survival . . O O
of . . O O
the . . O O
patients . . O O
with . . O O
potentially . . O O
resectable . . O O
colorectal . . O O
cancer . . O O
liver . . O O
metastasis . . O O
with . . O O
wild . . O O
type . . O O
KRAS . . O O
gene . . O O
status . . O O
. . . O O

A . . O O
phase . . O O
III . . O O
( . . O O
clinical . . O O
trial . . O O
is . . O O
assessing . . O O
the . . O O
conversion . . O O
efficacy . . O O
of . . O O
Bevacizumab . . O O
in . . O O
unresectable . . O O
disease . . O O
with . . O O
KRAS . . O O
gene . . O O
mutation . . B-Mutation B-Mutation
. . . O O

Current . . O O
evidence . . O O
showed . . O O
that . . O O
neoadjuvant . . O O
therapy . . O O
of . . O O
targeted . . O O
agents . . O O
did . . O O
not . . O O
prolong . . O O
survival . . O O
of . . O O
patients . . O O
with . . O O
resectable . . O O
liver . . O O
metastasis . . O O
. . . O O

However . . O O
, . . O O
this . . O O
is . . O O
controversial . . O O
. . . O O

In . . O O
neoadjuvant . . O O
therapy . . O O
of . . O O
local . . O O
advanced . . O O
rectal . . O O
cancer . . O O
, . . O O
Cetuximab . . O O
did . . O O
not . . O O
improve . . O O
the . . O O
rates . . O O
of . . O O
pathological . . O O
complete . . O O
response . . O O
in . . O O
most . . O O
of . . O O
the . . O O
phase . . O O
II . . O O
( . . O O
trials . . O O
. . . O O

Furthermore . . O O
, . . O O
there . . O O
are . . O O
no . . O O
phase . . O O
III . . O O
( . . O O
trials . . O O
to . . O O
assess . . O O
the . . O O
role . . O O
of . . O O
Bevacizumab . . O O
. . . O O

Compared . . O O
to . . O O
chemotherapy . . O O
alone . . O O
for . . O O
metastatic . . O O
cancer . . O O
, . . O O
it . . O O
is . . O O
more . . O O
important . . O O
to . . O O
evaluate . . O O
the . . O O
interaction . . O O
and . . O O
synergistic . . O O
action . . O O
of . . O O
targeted . . O O
agents . . O O
, . . O O
cytotoxic . . O O
drugs . . O O
, . . O O
surgery . . O O
and . . O O
radiation . . O O
, . . O O
to . . O O
make . . O O
a . . O O
scientific . . O O
multidisciplinary . . O O
model . . O O
in . . O O
comprehensive . . O O
treatment . . O O
of . . O O
local . . O O
advanced . . O O
cancer . . O O
. . . O O

Instability . . O B-Mutation
at . . O O
the . . O O
FRA8I . . O O
common . . O O
fragile . . O O
site . . O O
disrupts . . O O
the . . O O
genomic . . O O
integrity . . O O
of . . O O
the . . O O
KIAA0146 . . O O
, . . O O
CEBPD . . O O
and . . O O
PRKDC . . O O
genes . . O O
in . . O O
colorectal . . O O
cancer . . O O
. . . O O

Specific . . O O
patterns . . O O
of . . O O
genomic . . B-Mutation O
aberrations . . I-Mutation B-Mutation
have . . O O
been . . O O
associated . . O O
with . . O O
different . . O O
types . . O O
of . . O O
malignancies . . O O
. . . O O

In . . O O
colorectal . . O O
cancer . . O O
, . . O O
losses . . B-Mutation O
of . . O O
chromosome . . O O
arm . . O O
8p . . O O
and . . O O
gains . . B-Mutation O
of . . O O
chromosome . . O O
arm . . O O
8q . . O O
are . . O O
among . . O O
the . . O O
most . . O O
common . . O O
chromosomal . . O O
rearrangements . . O B-Mutation
, . . O O
suggesting . . O O
that . . O O
the . . O O
centromeric . . O O
portion . . O O
of . . O O
chromosome . . O O
8 . . O O
is . . O O
particularly . . O O
sensitive . . O O
to . . O O
breakage . . O O
. . . O O

Genomic . . B-Mutation O
alterations . . I-Mutation O
frequently . . O O
occur . . O O
in . . O O
the . . O O
early . . O O
stages . . O O
of . . O O
tumorigenesis . . O O
at . . O O
specific . . O O
genomic . . O O
regions . . O O
known . . O O
as . . O O
common . . O O
fragile . . O O
sites . . O O
( . . O O
cFSs . . O O
) . . O O
. . . O O

CFSs . . O O
represent . . O O
parts . . O O
of . . O O
the . . O O
normal . . O O
chromosome . . O O
structure . . O O
that . . O O
are . . O O
prone . . O O
to . . O O
breakage . . O O
under . . O O
replication . . O O
stress . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
identified . . O O
the . . O O
genomic . . O O
location . . O O
of . . O O
FRA8I . . O O
, . . O O
spanning . . O O
530 . . O O
kb . . O O
at . . O O
8q11 . . O O
. . . O O
21 . . O O
and . . O O
assessed . . O O
the . . O O
composition . . O O
of . . O O
the . . O O
fragile . . O O
DNA . . O O
sequence . . O O
. . . O O

FRA8I . . O O
encompasses . . O O
KIAA0146 . . O O
, . . O O
a . . O O
large . . O O
protein . . O O
- . . O O
coding . . O O
gene . . O O
with . . O O
yet . . O O
unknown . . O O
function . . O O
, . . O O
as . . O O
well . . O O
as . . O O
CEBPD . . O O
and . . O O
part . . O O
of . . O O
PRKDC . . O O
, . . O O
two . . O O
genes . . O O
encoding . . O O
proteins . . O O
involved . . O O
in . . O O
tumorigenesis . . O O
in . . O O
a . . O O
variety . . O O
of . . O O
cancers . . O O
. . . O O

We . . O O
show . . O O
that . . O O
FRA8I . . O O
is . . O O
unstable . . O O
in . . O O
lymphocytes . . O O
and . . O O
epithelial . . O O
cells . . O O
, . . O O
displaying . . O O
similar . . O O
expression . . O O
rates . . O O
. . . O O

We . . O O
examined . . O O
copy . . B-Mutation B-Mutation
number . . I-Mutation I-Mutation
alteration . . I-Mutation I-Mutation
patterns . . O O
within . . O O
FRA8I . . O O
in . . O O
a . . O O
panel . . O O
of . . O O
25 . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
and . . O O
surveyed . . O O
publically . . O O
available . . O O
profiles . . O O
of . . O O
56 . . O O
additional . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

Combining . . O O
these . . O O
data . . O O
shows . . O O
that . . O O
focal . . O O
recombination . . O O
events . . O O
disrupt . . O O
the . . O O
genomic . . O O
integrity . . O O
of . . O O
KIAA0146 . . O O
and . . O O
neighboring . . O O
cFS . . O O
genes . . O O
in . . O O
12 . . O O
. . . O O
3 . . O O
% . . O O
of . . O O
colorectal . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

Moreover . . O O
, . . O O
data . . O O
analysis . . O O
revealed . . O O
evidence . . O O
that . . O O
KIAA0146 . . O O
is . . O O
a . . O O
translocation . . O O
partner . . O O
of . . O O
the . . O O
immunoglobulin . . O O
heavy . . O O
chain . . O O
gene . . O O
in . . O O
recurrent . . O O
t . . B-Mutation O
( . . I-Mutation O
8 . . I-Mutation O
; . . I-Mutation O
14 . . I-Mutation O
) . . I-Mutation O
( . . O O
q11 . . O O
; . . O O
q32 . . O O
) . . O O
translocations . . B-Mutation B-Mutation
in . . O O
a . . O O
subset . . O O
of . . O O
patients . . O O
with . . O O
B . . O O
- . . O O
cell . . O O
precursor . . O O
acute . . O O
lymphoblastic . . O O
leukemia . . O O
. . . O O

Our . . O O
data . . O O
molecularly . . O O
describe . . O O
a . . O O
region . . O O
of . . O O
enhanced . . O O
chromosomal . . B-Mutation O
instability . . I-Mutation B-Mutation
in . . O O
the . . O O
human . . O O
genome . . O O
and . . O O
point . . O O
to . . O O
a . . O O
role . . O O
of . . O O
the . . O O
KIAA0146 . . O O
gene . . O O
in . . O O
tumorigenesis . . O O
. . . O O

Benefits . . O O
of . . O O
colonoscopic . . O O
surveillance . . O O
and . . O O
prophylactic . . O O
colectomy . . O O
in . . O O
patients . . O O
with . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
mutations . . B-Mutation B-Mutation
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Predisposition . . O O
genetic . . O O
testing . . O O
is . . O O
now . . O O
possible . . O O
for . . O O
many . . O O
hereditary . . O O
cancer . . O O
syndromes . . O O
, . . O O
including . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

The . . O O
optimal . . O O
management . . O O
of . . O O
the . . O O
elevated . . O O
risk . . O O
for . . O O
cancer . . O O
in . . O O
carriers . . O O
of . . O O
mutations . . B-Mutation B-Mutation
for . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
is . . O O
unclear . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

To . . O O
assess . . O O
the . . O O
life . . O O
expectancy . . O O
and . . O O
quality . . O O
- . . O O
adjusted . . O O
life . . O O
expectancy . . O O
benefits . . O O
derived . . O O
from . . O O
endoscopic . . O O
surveillance . . O O
and . . O O
prophylactic . . O O
colectomy . . O O
for . . O O
persons . . O O
who . . O O
carry . . O O
a . . O O
mutation . . B-Mutation B-Mutation
associated . . O O
with . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
DESIGN . . O O

Decision . . O O
analysis . . O O
model . . O O
. . . O O

Lifetime . . O O
risk . . O O
for . . O O
colorectal . . O O
cancer . . O O
, . . O O
efficacy . . O O
of . . O O
surveillance . . O O
and . . O O
colectomy . . O O
, . . O O
stage . . O O
- . . O O
specific . . O O
colorectal . . O O
cancer . . O O
mortality . . O O
, . . O O
and . . O O
quality . . O O
of . . O O
life . . O O
were . . O O
included . . O O
in . . O O
the . . O O
model . . O O
. . . O O

# . . O O
# . . O O
SETTING . . O O

Decision . . O O
about . . O O
a . . O O
cancer . . O O
prevention . . O O
strategy . . O O
at . . O O
the . . O O
time . . O O
of . . O O
a . . O O
positive . . O O
result . . O O
on . . O O
genetic . . O O
testing . . O O
. . . O O

# . . O O
# . . O O
PATIENTS . . O O

Carriers . . O O
of . . O O
a . . O O
mutation . . B-Mutation B-Mutation
for . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
who . . O O
were . . O O
25 . . O O
years . . O O
of . . O O
age . . O O
. . . O O

# . . O O
# . . O O
INTERVENTIONS . . O O

Immediate . . O O
prophylactic . . O O
colectomy . . O O
; . . O O
delayed . . O O
colectomy . . O O
on . . O O
the . . O O
basis . . O O
of . . O O
age . . O O
, . . O O
adenoma . . O O
, . . O O
or . . O O
diagnosis . . O O
of . . O O
colorectal . . O O
cancer . . O O
; . . O O
and . . O O
endoscopic . . O O
surveillance . . O O
. . . O O

Prophylactic . . O O
surgical . . O O
options . . O O
were . . O O
proctocolectomy . . O O
with . . O O
ileoanal . . O O
anastomosis . . O O
and . . O O
subtotal . . O O
colectomy . . O O
with . . O O
ileorectal . . O O
anastomosis . . O O
. . . O O

# . . O O
# . . O O
MEASUREMENTS . . O O

Life . . O O
expectancy . . O O
and . . O O
quality . . O O
- . . O O
adjusted . . O O
life . . O O
expectancy . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

All . . O O
risk . . O O
- . . O O
reduction . . O O
strategies . . O O
led . . O O
to . . O O
large . . O O
gains . . O O
in . . O O
life . . O O
expectancy . . O O
for . . O O
carriers . . O O
of . . O O
a . . O O
mutation . . B-Mutation B-Mutation
for . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
, . . O O
with . . O O
benefits . . O O
ranging . . O O
from . . O O
13 . . O O
. . . O O
5 . . O O
years . . O O
for . . O O
surveillance . . O O
to . . O O
15 . . O O
. . . O O
6 . . O O
years . . O O
for . . O O
prophylactic . . O O
proctocolectomy . . O O
at . . O O
25 . . O O
years . . O O
of . . O O
age . . O O
compared . . O O
with . . O O
no . . O O
intervention . . O O
. . . O O

The . . O O
benefits . . O O
of . . O O
colectomy . . O O
compared . . O O
with . . O O
surveillance . . O O
decreased . . O O
with . . O O
increasing . . O O
age . . O O
and . . O O
were . . O O
minimal . . O O
if . . O O
colectomy . . O O
was . . O O
performed . . O O
at . . O O
the . . O O
time . . O O
of . . O O
colorectal . . O O
cancer . . O O
diagnosis . . O O
. . . O O

When . . O O
health . . O O
- . . O O
related . . O O
quality . . O O
of . . O O
life . . O O
was . . O O
considered . . O O
, . . O O
surveillance . . O O
led . . O O
to . . O O
the . . O O
greatest . . O O
quality . . O O
- . . O O
adjusted . . O O
life . . O O
expectancy . . O O
benefit . . O O
( . . O O
3 . . O O
. . . O O
1 . . O O
years . . O O
compared . . O O
with . . O O
proctocolectomy . . O O
and . . O O
0 . . O O
. . . O O
3 . . O O
years . . O O
compared . . O O
with . . O O
subtotal . . O O
colectomy . . O O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Colonoscopic . . O O
surveillance . . O O
is . . O O
an . . O O
effective . . O O
method . . O O
of . . O O
reducing . . O O
risk . . O O
for . . O O
cancer . . O O
in . . O O
carriers . . O O
of . . O O
a . . O O
mutation . . B-Mutation B-Mutation
for . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
. . . O O

The . . O O
individual . . O O
patient . . O O
' . . O O
s . . O O
choice . . O O
between . . O O
prophylactic . . O O
surgery . . O O
and . . O O
surveillance . . O O
is . . O O
a . . O O
complex . . O O
decision . . O O
in . . O O
which . . O O
personal . . O O
preferences . . O O
weigh . . O O
heavily . . O O
. . . O O

Genetic . . O O
analysis . . O O
of . . O O
the . . O O
APC . . O O
gene . . O O
in . . O O
Taiwanese . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
. . . O O

Colorectal . . O O
cancer . . O O
has . . O O
become . . O O
the . . O O
third . . O O
leading . . O O
cause . . O O
of . . O O
death . . O O
from . . O O
cancer . . O O
in . . O O
Taiwan . . O O
. . . O O

Familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
is . . O O
an . . O O
autosomal . . O O
dominant . . O O
inherited . . O O
disease . . O O
characterized . . O O
by . . O O
the . . O O
presence . . O O
of . . O O
multiple . . O O
adenomatous . . O O
polyps . . O O
in . . O O
the . . O O
colon . . O O
and . . O O
rectum . . O O
. . . O O

The . . O O
gene . . O O
responsible . . O O
for . . O O
FAP . . O O
( . . O O
APC . . O O
) . . O O
was . . O O
cloned . . O O
in . . O O
1991 . . O O
. . . O O

Extensive . . O O
analyses . . O O
of . . O O
the . . O O
mutation . . B-Mutation B-Mutation
spectra . . O O
in . . O O
FAP . . O O
kindreds . . O O
have . . O O
been . . O O
performed . . O O
in . . O O
different . . O O
countries . . O O
, . . O O
but . . O O
the . . O O
results . . O O
have . . O O
been . . O O
highly . . O O
variable . . O O
( . . O O
30 . . O O
- . . O O
80 . . O O
% . . O O
) . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
used . . O O
denaturing . . O O
high . . O O
- . . O O
performance . . O O
liquid . . O O
chromatography . . O O
( . . O O
DHPLC . . O O
) . . O O
followed . . O O
by . . O O
automatic . . O O
sequencing . . O O
in . . O O
an . . O O
effort . . O O
to . . O O
establish . . O O
the . . O O
mutation . . B-Mutation B-Mutation
spectrum . . O O
of . . O O
APC . . O O
from . . O O
DNA . . O O
of . . O O
peripheral . . O O
blood . . O O
cells . . O O
. . . O O

Among . . O O
the . . O O
6 . . O O
FAP . . O O
probands . . O O
analyzed . . O O
, . . O O
mutations . . B-Mutation B-Mutation
were . . O O
detected . . O O
in . . O O
3 . . O O
( . . O O
50 . . O O
% . . O O
) . . O O
, . . O O
2 . . O O
of . . O O
which . . O O
were . . O O
novel . . O O
. . . O O

The . . O O
first . . O O
novel . . O O
mutation . . B-Mutation B-Mutation
was . . O O
at . . O O
codon . . O O
2166 . . O O
, . . O O
with . . O O
a . . O O
C . . B-Mutation B-Mutation
to . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
transition . . I-Mutation I-Mutation
, . . O O
resulting . . O O
in . . O O
a . . O O
stop . . O O
codon . . O O
. . . O O

The . . O O
second . . O O
novel . . O O
mutation . . B-Mutation B-Mutation
was . . O O
at . . O O
codon . . O O
1971 . . O O
, . . O O
with . . O O
a . . O O
C . . B-Mutation B-Mutation
to . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
transversion . . I-Mutation I-Mutation
, . . O O
resulting . . O B-Mutation
in . . O O
an . . O O
amino . . O O
acid . . O O
change . . O O
from . . O O
serine . . B-Mutation O
to . . I-Mutation O
cysteine . . I-Mutation O
. . . I-Mutation O

The . . O O
third . . O O
mutation . . B-Mutation B-Mutation
involved . . O O
an . . O O
A . . B-Mutation O
insertion . . I-Mutation B-Mutation
in . . O O
the . . O O
sequence . . O O
of . . O O
- . . O O
AAAAAA . . O O
- . . O O
at . . O O
codons . . O O
1554 . . O O
- . . O O
1556 . . O O
, . . O O
which . . O O
created . . O O
a . . O O
downstream . . O O
stop . . O O
codon . . O O
( . . O O
codon . . O O
1558 . . O O
) . . O O
. . . O O

This . . O O
study . . O O
is . . O O
the . . O O
first . . O O
to . . O O
report . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
in . . O O
Taiwanese . . O O
FAP . . O O
probands . . O O
. . . O O

An . . O O
illustrative . . O O
case . . O O
of . . O O
Muir . . O O
- . . O O
Torre . . O O
syndrome . . O O
: . . O O
contribution . . O O
of . . O O
immunohistochemical . . O O
analysis . . O O
in . . O O
identifying . . O O
indicator . . O O
sebaceous . . O O
lesions . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Muir . . O O
- . . O O
Torre . . O O
syndrome . . O O
( . . O O
MTS . . O O
) . . O O
is . . O O
an . . O O
autosomal . . O O
dominant . . O O
genodermatosis . . O O
characterized . . O O
by . . O O
the . . O O
association . . O O
of . . O O
at . . O O
least . . O O
1 . . O O
cutaneous . . O O
sebaceous . . O O
tumor . . O O
and . . O O
1 . . O O
internal . . O O
malignancy . . O O
, . . O O
often . . O O
arising . . O O
in . . O O
the . . O O
gastrointestinal . . O O
tract . . O O
. . . O O

It . . O O
is . . O O
secondary . . O O
to . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
DNA . . O O
mismatch . . O O
repair . . O O
genes . . O O
, . . O O
mainly . . O O
MLH . . O O
- . . O O
1 . . O O
and . . O O
MSH . . O O
- . . O O
2 . . O O
. . . O O

# . . O O
# . . O O
OBSERVATIONS . . O O

We . . O O
report . . O O
the . . O O
case . . O O
of . . O O
a . . O O
54 . . O O
- . . O O
year . . O O
- . . O O
old . . O O
man . . O O
with . . O O
a . . O O
2 . . O O
- . . O O
year . . O O
history . . O O
of . . O O
skin . . O O
- . . O O
colored . . O O
papules . . O O
clinically . . O O
reminiscent . . O O
of . . O O
large . . O O
sebaceous . . O O
hyperplasias . . O O
on . . O O
the . . O O
nose . . O O
and . . O O
back . . O O
, . . O O
but . . O O
histologically . . O O
diagnosed . . O O
as . . O O
sebaceous . . O O
adenomas . . O O
and . . O O
epitheliomas . . O O
. . . O O

His . . O O
family . . O O
history . . O O
was . . O O
positive . . O O
for . . O O
colon . . O O
cancer . . O O
in . . O O
the . . O O
mother . . O O
and . . O O
2 . . O O
brothers . . O O
. . . O O

A . . O O
colonoscopy . . O O
done . . O O
during . . O O
the . . O O
hospitalization . . O O
revealed . . O O
2 . . O O
sessile . . O O
polyps . . O O
in . . O O
the . . O O
left . . O O
colon . . O O
, . . O O
both . . O O
showing . . O O
a . . O O
low . . O O
- . . O O
grade . . O O
dysplasia . . O O
on . . O O
the . . O O
biopsy . . O O
specimen . . O O
. . . O O

Immunohistochemical . . O O
staining . . O O
performed . . O O
on . . O O
the . . O O
cutaneous . . O O
and . . O O
colic . . O O
biopsy . . O O
specimens . . O O
revealed . . O O
a . . O O
lack . . O O
of . . O O
expression . . O O
of . . O O
MSH . . O O
- . . O O
2 . . O O
and . . O O
MSH . . O O
- . . O O
6 . . O O
. . . O O

Genetic . . O O
testing . . O O
revealed . . O O
microsatellite . . O B-Mutation
instability . . O I-Mutation
in . . O O
the . . O O
colon . . O O
and . . O O
cutaneous . . O O
tumors . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

The . . O O
immunohistochemical . . O O
testing . . O O
for . . O O
MSH . . O O
- . . O O
2 . . O O
, . . O O
MSH . . O O
- . . O O
6 . . O O
, . . O O
and . . O O
MLH . . O O
- . . O O
1 . . O O
is . . O O
useful . . O O
for . . O O
rapid . . O O
identification . . O O
of . . O O
an . . O O
underlying . . O O
mismatch . . O O
repair . . O O
defect . . O O
and . . O O
early . . O O
diagnosis . . O O
of . . O O
MTS . . O O
. . . O O

Increased . . O O
in . . O O
vitro . . O O
tetraploidy . . O O
and . . O O
mandibular . . O O
osteomas . . O O
in . . O O
patients . . O O
with . . O O
and . . O O
without . . O O
colorectal . . O O
diseases . . O O
. . . O O

One . . O O
hundred . . O O
and . . O O
seventy . . O O
- . . O O
six . . O O
individuals . . O O
with . . O O
various . . O O
colorectal . . O O
diseases . . O O
were . . O O
investigated . . O O
simultaneously . . O O
for . . O O
increased . . O O
in . . O O
vitro . . O O
tetraploidy . . O O
in . . O O
dermal . . O O
fibroblast . . O O
cultures . . O O
and . . O O
for . . O O
occult . . O O
mandibular . . O O
osteomas . . O O
. . . O O

In . . O O
only . . O O
10 . . O O
of . . O O
the . . O O
176 . . O O
persons . . O O
were . . O O
both . . O O
presumed . . O O
markers . . O O
of . . O O
colorectal . . O O
genetic . . O O
predisposition . . O O
present . . O O
in . . O O
the . . O O
same . . O O
individual . . O O
. . . O O

No . . O O
evidence . . O O
was . . O O
found . . O O
that . . O O
these . . O O
traits . . O O
are . . O O
causally . . O O
associated . . O O
. . . O O

A . . O O
combination . . O O
of . . O O
the . . O O
two . . O O
presumed . . O O
markers . . O O
showed . . O O
a . . O O
tendency . . O O
towards . . O O
occurrence . . O O
in . . O O
individuals . . O O
with . . O O
a . . O O
positive . . O O
family . . O O
history . . O O
of . . O O
colorectal . . O O
cancer . . O O
among . . O O
first . . O O
- . . O O
degree . . O O
relatives . . O O
. . . O O

Amplified . . O O
Muc1 . . O O
- . . O O
specific . . O O
gene . . O O
expression . . O O
in . . O O
colon . . O O
cancer . . O O
cells . . O O
utilizing . . O O
a . . O O
binary . . O O
system . . O O
in . . O O
adenoviral . . O O
vectors . . O O
. . . O O

Mucin . . O O
- . . O O
1 . . O O
is . . O O
expressed . . O O
in . . O O
a . . O O
variety . . O O
of . . O O
colon . . O O
carcinomas . . O O
and . . O O
Muc . . O O
- . . O O
1 . . O O
/ . . O O
DF3 . . O O
promoters . . O O
have . . O O
been . . O O
utilized . . O O
to . . O O
reduce . . O O
systemic . . O O
toxicity . . O O
through . . O O
specific . . O O
gene . . O O
expression . . O O
. . . O O

To . . O O
overcome . . O O
weak . . O O
expression . . O O
, . . O O
which . . O O
is . . O O
much . . O O
lower . . O O
than . . O O
the . . O O
widely . . O O
used . . O O
cytomegalovirus . . O O
- . . O O
promoter . . O O
( . . O O
CMV . . O O
) . . O O
, . . O O
new . . O O
adenoviral . . O O
vectors . . O O
containing . . O O
a . . O O
binary . . O O
system . . O O
of . . O O
transgene . . O O
amplification . . O O
have . . O O
been . . O O
developed . . O O
. . . O O

The . . O O
Muc . . O O
- . . O O
1 . . O O
/ . . O O
DF3 . . O O
promoter . . O O
was . . O O
used . . O O
to . . O O
control . . O O
the . . O O
expression . . O O
of . . O O
a . . O O
Gal4VP16 . . O O
fusion . . O O
protein . . O O
. . . O O

This . . O O
vector . . O O
also . . O O
contained . . O O
Gal4 . . O O
binding . . O O
sites . . O O
enabling . . O O
the . . O O
fusion . . O O
protein . . O O
to . . O O
act . . O O
as . . O O
a . . O O
transactivator . . O O
, . . O O
inducing . . O O
transgene . . O O
expression . . O O
within . . O O
the . . O O
same . . O O
construct . . O O
. . . O O

Mucin . . O O
- . . O O
1 . . O O
expression . . O O
was . . O O
analyzed . . O O
in . . O O
a . . O O
variety . . O O
of . . O O
colon . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

After . . O O
infection . . O O
with . . O O
recombinant . . O O
adenoviruses . . O O
, . . O O
transgene . . O O
expression . . O O
was . . O O
quantified . . O O
using . . O O
the . . O O
luciferase . . O O
system . . O O
. . . O O

Integration . . O O
of . . O O
the . . O O
Gal4VP16 . . O O
- . . O O
binary . . O O
resulted . . O O
in . . O O
an . . O O
up . . O O
to . . O O
250 . . O O
- . . O O
fold . . O O
increase . . O O
of . . O O
Muc . . O O
- . . O O
1 . . O O
/ . . O O
DF3 . . O O
- . . O O
specific . . O O
gene . . O O
expression . . O O
. . . O O

In . . O O
mucin . . O O
- . . O O
positive . . O O
cell . . O O
lines . . O O
utilizing . . O O
this . . O O
amplified . . O O
Muc . . O O
- . . O O
1 . . O O
/ . . O O
DF3 . . O O
promoter . . O O
, . . O O
expression . . O O
was . . O O
up . . O O
to . . O O
590 . . O O
- . . O O
fold . . O O
higher . . O O
as . . O O
compared . . O O
to . . O O
the . . O O
CMV . . O O
- . . O O
promoter . . O O
. . . O O

Western . . O O
blot . . O O
detected . . O O
the . . O O
presence . . O O
of . . O O
Gal4VP16 . . O O
in . . O O
infected . . O O
muc . . O O
- . . O O
1 . . O O
- . . O O
positive . . O O
but . . O O
not . . O O
- . . O O
negative . . O O
cell . . O O
lines . . O O
. . . O O

These . . O O
new . . O O
adenoviral . . O O
vectors . . O O
combing . . O O
highly . . O O
efficient . . O O
and . . O O
specific . . O O
transgene . . O O
expression . . O O
and . . O O
will . . O O
contribute . . O O
to . . O O
the . . O O
safety . . O O
and . . O O
efficacy . . O O
of . . O O
experimental . . O O
approaches . . O O
in . . O O
cancer . . O O
gene . . O O
therapy . . O O
. . . O O

Genetic . . O O
alterations . . B-Mutation O
of . . O O
microsatellites . . O O
on . . O O
chromosome . . O O
18 . . O O
in . . O O
human . . O O
breast . . O O
carcinoma . . O O
. . . O O

Allelic . . O B-Mutation
alterations . . B-Mutation I-Mutation
of . . O O
chromosome . . O O
18 . . O O
microsatellites . . O O
were . . O O
determined . . O O
using . . O O
normal . . O O
and . . O O
tumor . . O O
DNA . . O O
pairs . . O O
from . . O O
29 . . O O
patients . . O O
with . . O O
infiltrating . . O O
ductal . . O O
carcinoma . . O O
of . . O O
the . . O O
breast . . O O
. . . O O

Loss . . B-Mutation B-Mutation
of . . I-Mutation O
heterozygosity . . I-Mutation B-Mutation
was . . O O
detected . . O O
in . . O O
62 . . O O
% . . O O
( . . O O
18 . . O O
of . . O O
29 . . O O
patients . . O O
) . . O O
of . . O O
the . . O O
tumors . . O O
at . . O O
one . . O O
or . . O O
more . . O O
of . . O O
these . . O O
microsatellites . . O O
. . . O O

Eight . . O O
of . . O O
the . . O O
18 . . O O
patients . . O O
exhibited . . O O
deletions . . B-Mutation B-Mutation
in . . O O
the . . O O
region . . O O
at . . O O
18q21 . . O O
. . . O O
1 . . O O
. . . O O

This . . O O
chromosomal . . O O
band . . O O
is . . O O
known . . O O
to . . O O
contain . . O O
a . . O O
tumor . . O O
suppressor . . O O
gene . . O O
( . . O O
DCC . . O O
) . . O O
whose . . O O
expression . . O O
is . . O O
frequently . . O O
inactivated . . O O
in . . O O
several . . O O
types . . O O
of . . O O
cancer . . O O
. . . O O

Ten . . O O
other . . O O
patients . . O O
had . . O O
deletions . . B-Mutation B-Mutation
in . . O O
regions . . O O
not . . O O
included . . O O
in . . O O
the . . O O
DCC . . O O
locus . . O O
. . . O O

Five . . O O
of . . O O
these . . O O
patients . . O O
revealed . . O O
a . . O O
common . . O O
deletion . . B-Mutation B-Mutation
at . . O O
the . . O O
D18S50 . . O O
locus . . O O
( . . O O
18q23 . . O O
) . . O O
, . . O O
and . . O O
the . . O O
other . . O O
five . . O O
patients . . O O
had . . O O
deletions . . B-Mutation B-Mutation
in . . O O
various . . O O
other . . O O
regions . . O O
of . . O O
the . . O O
chromosome . . O O
. . . O O

No . . O O
apparent . . O O
correlation . . O O
between . . O O
loss . . B-Mutation B-Mutation
of . . I-Mutation I-Mutation
heterozygosity . . I-Mutation I-Mutation
of . . O O
chromosome . . O O
18 . . O O
microsatellites . . O O
and . . O O
the . . O O
clinical . . O O
stage . . O O
was . . O O
found . . O O
in . . O O
this . . O O
series . . O O
. . . O O

The . . O O
results . . O O
indicate . . O O
that . . O O
, . . O O
in . . O O
addition . . O O
to . . O O
the . . O O
DCC . . O O
locus . . O O
, . . O O
the . . O O
18q23 . . O O
region . . O O
is . . O O
likely . . O O
to . . O O
contain . . O O
a . . O O
second . . O O
tumor . . O O
suppressor . . O O
gene . . O O
relevant . . O O
to . . O O
breast . . O O
carcinogenesis . . O O
. . . O O

Four . . O O
percent . . O O
of . . O O
all . . O O
microsatellites . . O O
tested . . O O
in . . O O
these . . O O
patients . . O O
showed . . O O
allelic . . B-Mutation O
differences . . I-Mutation O
in . . O O
the . . O O
sizes . . O O
of . . O O
repeat . . O O
units . . O O
between . . O O
tumor . . O O
and . . O O
the . . O O
corresponding . . O O
constitutional . . O O
DNAs . . O O
. . . O O

The . . O O
pattern . . O O
of . . O O
allele . . B-Mutation O
instability . . I-Mutation B-Mutation
observed . . O O
in . . O O
breast . . O O
carcinoma . . O O
differed . . O O
from . . O O
that . . O O
originally . . O O
reported . . O O
in . . O O
a . . O O
hereditary . . O O
type . . O O
of . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

The . . O O
observation . . O O
suggests . . O O
that . . O O
this . . O O
phenomenon . . O O
is . . O O
not . . O O
a . . O O
mechanism . . O O
specific . . O O
to . . O O
neoplastic . . O O
processes . . O O
in . . O O
breast . . O O
carcinoma . . O O
. . . O O

Possible . . O O
role . . O O
of . . O O
telomerase . . O O
activation . . O O
in . . O O
the . . O O
cancer . . O O
predisposition . . O O
of . . O O
patients . . O O
with . . O O
hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancers . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Hereditary . . O O
nonpolyposis . . O O
colorectal . . O O
cancer . . O O
syndrome . . O O
( . . O O
HNPCC . . O O
syndrome . . O O
; . . O O
also . . O O
called . . O O
Lynch . . O O
syndrome . . O O
) . . O O
is . . O O
one . . O O
of . . O O
the . . O O
most . . O O
common . . O O
cancer . . O O
predisposition . . O O
syndromes . . O O
. . . O O

Most . . O O
cases . . O O
of . . O O
cancer . . O O
associated . . O O
with . . O O
this . . O O
syndrome . . O O
are . . O O
due . . O O
to . . O O
the . . O O
inheritance . . O O
of . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
genes . . O O
that . . O O
encode . . O O
proteins . . O O
required . . O O
for . . O O
DNA . . O O
mismatch . . O O
repair . . O O
; . . O O
defects . . O O
in . . O O
these . . O O
proteins . . O O
allow . . O O
mutations . . B-Mutation B-Mutation
to . . O O
accumulate . . O O
more . . O O
rapidly . . O O
in . . O O
the . . O O
DNA . . O O
and . . O O
influence . . O O
the . . O O
rate . . O O
of . . O O
cancer . . O O
development . . O O
. . . O O

Recent . . O O
studies . . O O
indicate . . O O
that . . O O
the . . O O
reactivation . . O O
of . . O O
the . . O O
activity . . O O
of . . O O
telomerase . . O O
, . . O O
an . . O O
enzyme . . O O
involved . . O O
in . . O O
the . . O O
synthesis . . O O
of . . O O
chromosomal . . O O
ends . . O O
, . . O O
in . . O O
somatic . . O O
cells . . O O
may . . O O
play . . O O
a . . O O
role . . O O
in . . O O
carcinogenesis . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
evaluated . . O O
the . . O O
expression . . O O
of . . O O
telomerase . . O O
in . . O O
normal . . O O
and . . O O
cancerous . . O O
colorectal . . O O
tissue . . O O
specimens . . O O
from . . O O
HNPCC . . O O
and . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

The . . O O
polymerase . . O O
chain . . O O
reaction . . O O
- . . O O
based . . O O
telomeric . . O O
repeat . . O O
amplification . . O O
protocol . . O O
was . . O O
used . . O O
to . . O O
assay . . O O
telomerase . . O O
activity . . O O
in . . O O
colorectal . . O O
tissue . . O O
specimens . . O O
from . . O O
33 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
( . . O O
23 . . O O
normal . . O O
, . . O O
26 . . O O
polyps . . O O
, . . O O
and . . O O
37 . . O O
cancer . . O O
specimens . . O O
) . . O O
and . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
( . . O O
24 . . O O
normal . . O O
, . . O O
0 . . O O
polyps . . O O
, . . O O
and . . O O
28 . . O O
cancer . . O O
specimens . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Thirty . . O O
- . . O O
one . . O O
of . . O O
37 . . O O
carcinoma . . O O
samples . . O O
from . . O O
18 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
and . . O O
27 . . O O
of . . O O
28 . . O O
carcinoma . . O O
samples . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
were . . O O
found . . O O
to . . O O
be . . O O
positive . . O O
for . . O O
telomerase . . O O
activity . . O O
. . . O O

Whereas . . O O
only . . O O
one . . O O
of . . O O
23 . . O O
normal . . O O
mucosa . . O O
samples . . O O
from . . O O
23 . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
was . . O O
found . . O O
to . . O O
have . . O O
( . . O O
weak . . O O
) . . O O
telomerase . . O O
activity . . O O
, . . O O
eight . . O O
of . . O O
24 . . O O
normal . . O O
mucosa . . O O
samples . . O O
from . . O O
24 . . O O
HNPCC . . O O
patients . . O O
were . . O O
positive . . O O
for . . O O
telomerase . . O O
; . . O O
the . . O O
difference . . O O
between . . O O
the . . O O
two . . O O
groups . . O O
was . . O O
statistically . . O O
significant . . O O
( . . O O
two . . O O
- . . O O
sided . . O O
P . . O O
= . . O O
. . . O O
0226 . . O O
) . . O O
. . . O O

# . . O O
# . . O O
IMPLICATION . . O O

This . . O O
study . . O O
generates . . O O
the . . O O
hypothesis . . O O
that . . O O
genetic . . O O
defects . . O B-Mutation
in . . O O
individuals . . O O
with . . O O
HNPCC . . O O
syndrome . . O O
facilitate . . O O
the . . O O
reactivation . . O O
of . . O O
telomerase . . O O
activity . . O O
, . . O O
a . . O O
process . . O O
which . . O O
may . . O O
be . . O O
associated . . O O
with . . O O
their . . O O
predisposition . . O O
to . . O O
develop . . O O
cancer . . O O
. . . O O

Similar . . O O
colorectal . . O O
cancer . . O O
risk . . O O
in . . O O
patients . . O O
with . . O O
monoallelic . . B-Mutation O
and . . I-Mutation O
biallelic . . I-Mutation O
mutations . . I-Mutation B-Mutation
in . . O O
the . . O O
MYH . . O O
gene . . O O
identified . . O O
in . . O O
a . . O O
population . . O O
with . . O O
adenomatous . . O O
polyposis . . O O
. . . O O

A . . O O
large . . O O
proportion . . O O
of . . O O
non . . O O
- . . O O
FAP . . O O
non . . O O
- . . O O
HNPCC . . O O
patients . . O O
with . . O O
multiple . . O O
colorectal . . O O
adenomas . . O O
have . . O O
been . . O O
reported . . O O
to . . O O
carry . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
on . . O O
the . . O O
MYH . . O O
gene . . O O
. . . O O

Although . . O O
the . . O O
number . . O O
of . . O O
adenomas . . O O
appears . . O O
to . . O O
be . . O O
dependent . . O O
on . . O O
the . . O O
number . . O O
of . . O O
mutated . . B-Mutation B-Mutation
MYH . . O O
alleles . . O O
present . . O O
in . . O O
a . . O O
patient . . O O
, . . O O
little . . O O
is . . O O
known . . O O
on . . O O
the . . O O
relation . . O O
of . . O O
this . . O O
number . . O O
with . . O O
cancer . . O O
risk . . O O
. . . O O

Four . . O O
hundred . . O O
fifty . . O O
- . . O O
three . . O O
APC . . O O
- . . O O
negative . . O O
patients . . O O
with . . O O
more . . O O
than . . O O
five . . O O
colorectal . . O O
adenomas . . O O
were . . O O
screened . . O O
for . . O O
mutations . . B-Mutation B-Mutation
on . . O O
the . . O O
entire . . O O
coding . . O O
sequence . . O O
of . . O O
the . . O O
MYH . . O O
gene . . O O
. . . O O

Pathogenic . . O O
mutations . . B-Mutation B-Mutation
were . . O O
initially . . O O
found . . O O
in . . O O
74 . . O O
patients . . O O
without . . O O
extradigestive . . O O
tumors . . O O
( . . O O
22 . . O O
. . . O O
5 . . O O
% . . O O
) . . O O
and . . O O
subsequently . . O O
in . . O O
75 . . O O
at . . O O
- . . O O
risk . . O O
relatives . . O O
. . . O O

Polyposis . . O O
was . . O O
more . . O O
severe . . O O
in . . O O
cases . . O O
with . . O O
biallelic . . B-Mutation O
mutations . . I-Mutation B-Mutation
. . . O O

However . . O O
, . . O O
mutation . . B-Mutation B-Mutation
copy . . O O
number . . O O
was . . O O
correlated . . O O
neither . . O O
with . . O O
the . . O O
age . . O O
at . . O O
diagnosis . . O O
of . . O O
adenomas . . O O
or . . O O
adenocarcinomas . . O O
, . . O O
nor . . O O
with . . O O
the . . O O
presence . . O O
of . . O O
a . . O O
family . . O O
history . . O O
of . . O O
colorectal . . O O
tumors . . O O
. . . O O

Heterozygous . . O O
and . . O O
homozygous . . O O
MYH . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
were . . O O
both . . O O
at . . O O
high . . O O
risk . . O O
for . . O O
synchronous . . O O
cancers . . O O
( . . O O
24 . . O O
% . . O O
in . . O O
colorectum . . O O
and . . O O
16 . . O O
% . . O O
in . . O O
the . . O O
upper . . O O
gastrointestinal . . O O
tract . . O O
) . . O O
, . . O O
but . . O O
did . . O O
not . . O O
demonstrate . . O O
an . . O O
increased . . O O
risk . . O O
for . . O O
extradigestive . . O O
tumors . . O O
. . . O O

MYH . . O O
- . . O O
associated . . O O
polyposis . . O O
is . . O O
a . . O O
frequent . . O O
inherited . . O O
colorectal . . O O
cancer . . O O
predisposition . . O O
with . . O O
a . . O O
strong . . O O
dominance . . O O
component . . O O
. . . O O

From . . O O
age . . O O
25 . . O O
- . . O O
30 . . O O
, . . O O
MYH . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
should . . O O
be . . O O
proposed . . O O
an . . O O
early . . O O
screening . . O O
program . . O O
, . . O O
which . . O O
includes . . O O
endoscopies . . O O
of . . O O
the . . O O
upper . . O O
digestive . . O O
tract . . O O
and . . O O
the . . O O
colorectum . . O O
every . . O O
2 . . O O
years . . O O
. . . O O

Direct . . O O
chromosome . . O O
analysis . . O O
of . . O O
seven . . O O
primary . . O O
colorectal . . O O
carcinomas . . O O
. . . O O

Chromosome . . O O
studies . . O O
were . . O O
performed . . O O
on . . O O
direct . . O O
preparations . . O O
of . . O O
seven . . O O
cases . . O O
of . . O O
primary . . O O
colorectal . . O O
carcinomas . . O O
. . . O O

Two . . O O
cases . . O O
had . . O O
relatively . . O O
simple . . O O
chromosome . . B-Mutation O
changes . . I-Mutation O
: . . O O
48 . . B-Mutation O
, . . I-Mutation O
XY . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
8 . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
21 . . I-Mutation O
/ . . I-Mutation O
51 . . I-Mutation O
, . . O O
XY . . B-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
8 . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
9 . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
10 . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
i . . I-Mutation O
( . . I-Mutation O
17q . . I-Mutation O
) . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
21 . . I-Mutation O
, . . O O
and . . O O
47 . . B-Mutation O
, . . I-Mutation O
der . . I-Mutation O
( . . I-Mutation O
X . . I-Mutation O
) . . I-Mutation O
t . . I-Mutation O
( . . I-Mutation O
X . . I-Mutation O
; . . I-Mutation O
14 . . I-Mutation O
) . . I-Mutation O
( . . I-Mutation O
q11 . . I-Mutation O
; . . I-Mutation O
q11 . . I-Mutation O
) . . I-Mutation O
- . . I-Mutation O
Y . . I-Mutation O
, . . I-Mutation O
t . . I-Mutation O
( . . I-Mutation O
6 . . I-Mutation O
; . . I-Mutation O
18 . . I-Mutation O
) . . I-Mutation O
( . . I-Mutation O
p22 . . I-Mutation O
; . . I-Mutation O
q24 . . I-Mutation O
) . . I-Mutation O
+ . . I-Mutation O
7 . . I-Mutation O
, . . I-Mutation O
+ . . I-Mutation O
8 . . I-Mutation O
, . . I-Mutation O
der . . I-Mutation O
( . . I-Mutation O
19 . . I-Mutation O
) . . I-Mutation O
t . . I-Mutation O
( . . I-Mutation O
19 . . I-Mutation O
; . . I-Mutation O
? . . I-Mutation O
) . . I-Mutation O
( . . I-Mutation O
q13 . . I-Mutation O
; . . I-Mutation O
? . . I-Mutation O
) . . I-Mutation O
. . . O O

The . . O O
five . . O O
others . . O O
had . . O O
complicated . . O O
deletions . . B-Mutation B-Mutation
and . . O O
translocations . . B-Mutation O
; . . O O
1p . . O O
- . . B-Mutation O
was . . O O
noted . . O O
in . . O O
five . . O O
cases . . O O
, . . O O
and . . O O
i . . B-Mutation O
( . . O O
17q . . O O
) . . O O
was . . O O
noted . . O O
in . . O O
three . . O O
cases . . O O
. . . O O

Combined . . O O
use . . O O
of . . O O
molecular . . O O
and . . O O
biomarkers . . O O
for . . O O
presymptomatic . . O O
carrier . . O O
risk . . O O
assessment . . O O
in . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
: . . O O
implications . . O O
for . . O O
screening . . O O
guidelines . . O O
. . . O O

Predictive . . O O
carrier . . O O
testing . . O O
for . . O O
the . . O O
inherited . . O O
disorder . . O O
of . . O O
familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
can . . O O
be . . O O
conducted . . O O
using . . O O
DNA . . O O
markers . . O O
linked . . O O
to . . O O
the . . O O
FAP . . O O
locus . . O O
. . . O O

The . . O O
presence . . O O
of . . O O
characteristic . . O O
hypertrophic . . O O
retinal . . O O
lesions . . O O
has . . O O
been . . O O
advocated . . O O
as . . O O
useful . . O O
biomarkers . . O O
for . . O O
FAP . . O O
. . . O O

We . . O O
have . . O O
compared . . O O
molecular . . O O
linkage . . O O
and . . O O
retinal . . O O
screening . . O O
techniques . . O O
by . . O O
evaluating . . O O
the . . O O
presymptomatic . . O O
carrier . . O O
risk . . O O
of . . O O
40 . . O O
at . . O O
- . . O O
risk . . O O
individuals . . O O
from . . O O
15 . . O O
FAP . . O O
families . . O O
. . . O O

Linkage . . O O
analysis . . O O
was . . O O
informative . . O O
in . . O O
all . . O O
and . . O O
retinal . . O O
lesion . . O O
analysis . . O O
in . . O O
25 . . O O
cases . . O O
. . . O O

For . . O O
informative . . O O
at . . O O
- . . O O
risk . . O O
population . . O O
, . . O O
predictive . . O O
diagnosis . . O O
by . . O O
both . . O O
techniques . . O O
was . . O O
completely . . O O
concordant . . O O
and . . O O
identified . . O O
15 . . O O
members . . O O
at . . O O
" . . O O
high . . O O
" . . O O
and . . O O
10 . . O O
at . . O O
" . . O O
low . . O O
" . . O O
risk . . O O
of . . O O
inheriting . . O O
FAP . . O O
. . . O O

Because . . O O
of . . O O
the . . O O
unique . . O O
advantages . . O O
offered . . O O
by . . O O
each . . O O
technique . . O O
, . . O O
a . . O O
strategy . . O O
integrating . . O O
both . . O O
techniques . . O O
will . . O O
increase . . O O
the . . O O
number . . O O
of . . O O
FAP . . O O
families . . O O
that . . O O
can . . O O
be . . O O
screened . . O O
presymptomatically . . O O
. . . O O

Identification . . O O
of . . O O
individuals . . O O
at . . O O
high . . O O
risk . . O O
of . . O O
polyposis . . O O
will . . O O
improve . . O O
their . . O O
clinical . . O O
surveillance . . O O
and . . O O
further . . O O
reduce . . O O
the . . O O
incidence . . O O
of . . O O
colorectal . . O O
cancer . . O O
in . . O O
FAP . . O O
families . . O O
. . . O O

The . . O O
frequency . . O O
of . . O O
previously . . O O
undetectable . . O O
deletions . . B-Mutation B-Mutation
involving . . O O
3 . . O O
' . . O O
Exons . . O O
of . . O O
the . . O O
PMS2 . . O O
gene . . O O
. . . O O

Lynch . . O O
syndrome . . O O
is . . O O
characterized . . O O
by . . O O
mutations . . B-Mutation B-Mutation
in . . O O
one . . O O
of . . O O
four . . O O
mismatch . . O O
repair . . O O
genes . . O O
, . . O O
MLH1 . . O O
, . . O O
MSH2 . . O O
, . . O O
MSH6 . . O O
, . . O O
or . . O O
PMS2 . . O O
. . . O O

Clinical . . O O
mutation . . B-Mutation B-Mutation
analysis . . O O
of . . O O
these . . O O
genes . . O O
includes . . O O
sequencing . . O O
of . . O O
exonic . . O O
regions . . O O
and . . O O
deletion . . B-Mutation B-Mutation
/ . . O O
duplication . . B-Mutation O
analysis . . O O
. . . O O

However . . O O
, . . O O
detection . . O O
of . . O O
deletions . . B-Mutation B-Mutation
and . . O O
duplications . . B-Mutation O
in . . O O
PMS2 . . O O
has . . O O
previously . . O O
been . . O O
confined . . O O
to . . O O
Exons . . O O
1 . . O O
- . . O O
11 . . O O
due . . O O
to . . O O
gene . . O O
conversion . . O O
between . . O O
PMS2 . . O O
and . . O O
the . . O O
pseudogene . . O O
PMS2CL . . O B-Mutation
in . . O O
the . . O O
remaining . . O O
3 . . O O
' . . O O
exons . . O O
( . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
) . . O O
. . . O O

We . . O O
have . . O O
recently . . O O
described . . O O
an . . O O
MLPA . . O O
- . . O O
based . . O O
method . . O O
that . . O O
permits . . O O
detection . . O O
of . . O O
deletions . . B-Mutation B-Mutation
of . . O O
PMS2 . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
; . . O O
however . . O O
, . . O O
the . . O O
frequency . . O O
of . . O O
such . . O O
deletions . . B-Mutation B-Mutation
has . . O O
not . . O O
yet . . O O
been . . O O
determined . . O O
. . . O O

To . . O O
address . . O O
this . . O O
question . . O O
, . . O O
we . . O O
tested . . O O
for . . O O
3 . . O O
' . . O O
deletions . . B-Mutation B-Mutation
in . . O O
58 . . O O
samples . . O O
that . . O O
were . . O O
reported . . O O
to . . O O
be . . O O
negative . . O O
for . . O O
PMS2 . . O O
mutations . . B-Mutation B-Mutation
using . . O O
previously . . O O
available . . O O
methods . . O O
. . . O O

All . . O O
samples . . O O
were . . O O
from . . O O
individuals . . O O
whose . . O O
tumors . . O O
exhibited . . O O
loss . . O B-Mutation
of . . O O
PMS2 . . O O
immunohistochemical . . O O
staining . . O O
without . . O O
concomitant . . O O
loss . . O B-Mutation
of . . O O
MLH1 . . O O
immunostaining . . O O
. . . O O

We . . O O
identified . . O O
seven . . O O
samples . . O O
in . . O O
this . . O O
cohort . . O O
with . . O O
deletions . . B-Mutation B-Mutation
in . . O O
the . . O O
3 . . O O
' . . O O
region . . O O
of . . O O
PMS2 . . O O
, . . O O
including . . O O
three . . O O
previously . . O O
reported . . O O
samples . . O O
with . . O O
deletions . . B-Mutation B-Mutation
of . . O O
Exons . . O O
13 . . O O
- . . O O
15 . . O O
( . . O O
two . . O O
samples . . O O
) . . O O
and . . O O
Exons . . O O
14 . . O O
- . . O O
15 . . O O
. . . O O

Also . . O O
detected . . O O
were . . O O
deletions . . B-Mutation B-Mutation
of . . O O
Exons . . O O
12 . . O O
- . . O O
15 . . O O
, . . O O
Exon . . O O
13 . . O O
, . . O O
and . . O O
Exon . . O O
14 . . O O
( . . O O
two . . O O
samples . . O O
) . . O O
. . . O O

Breakpoint . . O O
analysis . . O O
of . . O O
the . . O O
intragenic . . O B-Mutation
deletions . . B-Mutation I-Mutation
suggests . . O O
they . . O O
occurred . . O O
through . . O O
Alu . . O O
- . . O O
mediated . . O O
recombination . . O O
. . . O O

Our . . O O
results . . O O
indicate . . O O
that . . O O
 . . O O
12 . . O O
% . . O O
of . . O O
samples . . O O
suspected . . O O
of . . O O
harboring . . O O
a . . O O
PMS2 . . O O
mutation . . B-Mutation B-Mutation
based . . O O
on . . O O
immunohistochemical . . O O
staining . . O O
, . . O O
for . . O O
which . . O O
mutations . . B-Mutation B-Mutation
have . . O O
not . . O O
yet . . O O
been . . O O
identified . . O O
, . . O O
would . . O O
benefit . . O O
from . . O O
testing . . O O
using . . O O
the . . O O
new . . O O
methodology . . O O
. . . O O

Deregulation . . O O
of . . O O
Cdk2 . . O O
causes . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
in . . O O
p53 . . O O
- . . O O
deficient . . O O
tumors . . O O
following . . O O
actin . . O O
damage . . O O
. . . O O

We . . O O
previously . . O O
reported . . O O
that . . O O
actin . . O O
damage . . O O
by . . O O
treatment . . O O
with . . O O
an . . O O
actin . . O O
- . . O O
depolymerizing . . O O
agent . . O O
including . . O O
pectenotoxin . . O O
- . . O O
2 . . O O
induces . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
in . . O O
p53 . . O O
- . . O O
deficient . . O O
human . . O O
tumors . . O O
. . . O O

In . . O O
this . . O O
study . . O O
, . . O O
we . . O O
investigated . . O O
a . . O O
molecular . . O O
mechanism . . O O
underlying . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
of . . O O
p53 . . O O
- . . O O
deficient . . O O
tumor . . O O
cells . . O O
following . . O O
actin . . O O
damage . . O O
. . . O O

We . . O O
found . . O O
that . . O O
actin . . O O
inhibitors . . O O
increased . . O O
the . . O O
protein . . O O
levels . . O O
of . . O O
p53 . . O O
and . . O O
p21 . . O O
and . . O O
thereby . . O O
inactivated . . O O
both . . O O
Cdk2 . . O O
and . . O O
Cdc2 . . O O
kinases . . O O
. . . O O

However . . O O
, . . O O
p53 . . O O
- . . O O
or . . O O
p21 . . O O
- . . O O
knockout . . O O
cells . . O O
fail . . O O
to . . O O
induce . . O O
p21 . . O O
and . . O O
hence . . O O
kept . . O O
both . . O O
Cdk2 . . O O
and . . O O
Cdc2 . . O O
kinases . . O O
active . . O O
even . . O O
after . . O O
treatment . . O O
with . . O O
actin . . O O
inhibitor . . O O
. . . O O

The . . O O
p53 . . O O
- . . O O
or . . O O
p21 . . O O
- . . O O
knockout . . O O
cells . . O O
became . . O O
multinucleate . . O O
and . . O O
polyploidy . . O O
in . . O O
association . . O O
with . . O O
induction . . O O
of . . O O
apoptosis . . O O
. . . O O

Expression . . O O
of . . O O
Bcl . . O O
- . . O O
x . . O O
( . . O O
L . . O O
) . . O O
resulted . . O O
in . . O O
accumulation . . O O
of . . O O
polyploid . . O O
cells . . O O
in . . O O
association . . O O
with . . O O
inhibition . . O O
of . . O O
apoptosis . . O O
. . . O O

However . . O O
, . . O O
expression . . O O
of . . O O
a . . O O
dominant . . B-Mutation O
negative . . I-Mutation O
mutant . . I-Mutation B-Mutation
( . . O O
Cdk2dn . . O O
) . . O O
and . . O O
treatment . . O O
with . . O O
chemical . . O O
inhibitors . . O O
for . . O O
Cdk2 . . O O
suppressed . . O O
not . . O O
only . . O O
accumulation . . O O
of . . O O
multinucleated . . O O
cells . . O O
, . . O O
but . . O O
also . . O O
induction . . O O
of . . O O
Bim . . O O
expression . . O O
and . . O O
apoptosis . . O O
. . . O O

Therefore . . O O
, . . O O
these . . O O
results . . O O
suggest . . O O
that . . O O
Bim . . O O
- . . O O
mediated . . O O
apoptosis . . O O
following . . O O
actin . . O O
damage . . O O
due . . O O
to . . O O
deregulation . . O O
of . . O O
Cdk2 . . O O
and . . O O
the . . O O
cell . . O O
cycle . . O O
by . . O O
the . . O O
absence . . O O
of . . O O
functional . . O O
p53 . . O O
. . . O O

Recurrent . . O O
R . . O O
- . . O O
spondin . . O O
fusions . . B-Mutation O
in . . O O
colon . . O O
cancer . . O O
. . . O O

Identifying . . O O
and . . O O
understanding . . O O
changes . . O O
in . . O O
cancer . . O O
genomes . . O O
is . . O O
essential . . O O
for . . O O
the . . O O
development . . O O
of . . O O
targeted . . O O
therapeutics . . O O
. . . O O

Here . . O O
we . . O O
analyse . . O O
systematically . . O O
more . . O O
than . . O O
70 . . O O
pairs . . O O
of . . O O
primary . . O O
human . . O O
colon . . O O
tumours . . O O
by . . O O
applying . . O O
next . . O O
- . . O O
generation . . O O
sequencing . . O O
to . . O O
characterize . . O O
their . . O O
exomes . . O O
, . . O O
transcriptomes . . O O
and . . O O
copy . . B-Mutation B-Mutation
- . . I-Mutation I-Mutation
number . . I-Mutation I-Mutation
alterations . . I-Mutation I-Mutation
. . . O O

We . . O O
have . . O O
identified . . O O
36 . . O O
, . . O O
303 . . O O
protein . . O O
- . . O O
altering . . O O
somatic . . B-Mutation O
changes . . I-Mutation O
that . . O O
include . . O O
several . . O O
new . . O O
recurrent . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
Wnt . . O O
pathway . . O O
gene . . O O
TCF7L2 . . O O
, . . O O
chromatin . . O O
- . . O O
remodelling . . O O
genes . . O O
such . . O O
as . . O O
TET2 . . O O
and . . O O
TET3 . . O O
and . . O O
receptor . . O O
tyrosine . . O O
kinases . . O O
including . . O O
ERBB3 . . O O
. . . O O

Our . . O O
analysis . . O O
for . . O O
significantly . . O O
mutated . . O B-Mutation
cancer . . O O
genes . . O O
identified . . O O
23 . . O O
candidates . . O O
, . . O O
including . . O O
the . . O O
cell . . O O
cycle . . O O
checkpoint . . O O
kinase . . O O
ATM . . O O
. . . O O

Copy . . O O
- . . O O
number . . O O
and . . O O
RNA . . O O
- . . O O
seq . . O O
data . . O O
analysis . . O O
identified . . O O
amplifications . . O O
and . . O O
corresponding . . O O
overexpression . . O O
of . . O O
IGF2 . . O O
in . . O O
a . . O O
subset . . O O
of . . O O
colon . . O O
tumours . . O O
. . . O O

Furthermore . . O O
, . . O O
using . . O O
RNA . . O O
- . . O O
seq . . O O
data . . O O
we . . O O
identified . . O O
multiple . . O O
fusion . . O O
transcripts . . O O
including . . O O
recurrent . . B-Mutation O
gene . . I-Mutation O
fusions . . I-Mutation O
involving . . O O
R . . O O
- . . O O
spondin . . O O
family . . O O
members . . O O
RSPO2 . . O O
and . . O O
RSPO3 . . O O
that . . O O
together . . O O
occur . . O O
in . . O O
10 . . O O
% . . O O
of . . O O
colon . . O O
tumours . . O O
. . . O O

The . . O O
RSPO . . O O
fusions . . B-Mutation O
were . . O O
mutually . . O O
exclusive . . O O
with . . O O
APC . . O O
mutations . . B-Mutation B-Mutation
, . . O O
indicating . . O O
that . . O O
they . . O O
probably . . O O
have . . O O
a . . O O
role . . O O
in . . O O
the . . O O
activation . . O O
of . . O O
Wnt . . O O
signalling . . O O
and . . O O
tumorigenesis . . O O
. . . O O

Consistent . . O O
with . . O O
this . . O O
we . . O O
show . . O O
that . . O O
the . . O O
RSPO . . O O
fusion . . B-Mutation O
proteins . . O O
were . . O O
capable . . O O
of . . O O
potentiating . . O O
Wnt . . O O
signalling . . O O
. . . O O

The . . O O
R . . O O
- . . O O
spondin . . O O
gene . . B-Mutation O
fusions . . I-Mutation O
and . . O O
several . . O O
other . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
identified . . O O
in . . O O
this . . O O
study . . O O
provide . . O O
new . . O O
potential . . O O
opportunities . . O O
for . . O O
therapeutic . . O O
intervention . . O O
in . . O O
colon . . O O
cancer . . O O
. . . O O

Hereditary . . O O
risk . . O O
of . . O O
women . . O O
' . . O O
s . . O O
cancers . . O O
. . . O O

The . . O O
characterization . . O O
of . . O O
specific . . O O
genes . . O O
responsible . . O O
for . . O O
the . . O O
hereditary . . O O
risk . . O O
of . . O O
common . . O O
cancers . . O O
has . . O O
enabled . . O O
the . . O O
development . . O O
of . . O O
clinical . . O O
tests . . O O
designed . . O O
to . . O O
identify . . O O
at . . O O
- . . O O
risk . . O O
individuals . . O O
and . . O O
to . . O O
significantly . . O O
improve . . O O
the . . O O
clinical . . O O
outcome . . O O
of . . O O
such . . O O
individuals . . O O
. . . O O

Two . . O O
of . . O O
the . . O O
most . . O O
important . . O O
syndromes . . O O
associated . . O O
with . . O O
a . . O O
hereditary . . O O
risk . . O O
of . . O O
cancer . . O O
in . . O O
women . . O O
are . . O O
hereditary . . O O
breast . . O O
and . . O O
ovarian . . O O
cancer . . O O
, . . O O
resulting . . O O
from . . O O
the . . O O
BRCA1 . . O O
and . . O O
BRCA2 . . O O
genes . . O O
, . . O O
and . . O O
hereditary . . O O
non . . O O
- . . O O
polyposis . . O O
colorectal . . O O
cancer . . O O
, . . O O
caused . . O O
primarily . . O O
by . . O O
the . . O O
MLH1 . . O O
and . . O O
MSH2 . . O O
genes . . O O
. . . O O

As . . O O
testing . . O O
for . . O O
the . . O O
hereditary . . O O
risk . . O O
of . . O O
breast . . O O
, . . O O
ovarian . . O O
, . . O O
endometrial . . O O
and . . O O
colorectal . . O O
cancer . . O O
enters . . O O
the . . O O
clinical . . O O
mainstream . . O O
, . . O O
physicians . . O O
responsible . . O O
for . . O O
the . . O O
health . . O O
care . . O O
of . . O O
women . . O O
are . . O O
increasingly . . O O
required . . O O
to . . O O
assess . . O O
and . . O O
provide . . O O
guidance . . O O
to . . O O
healthy . . O O
patients . . O O
with . . O O
a . . O O
strong . . O O
family . . O O
history . . O O
, . . O O
cancer . . O O
survivors . . O O
who . . O O
may . . O O
be . . O O
at . . O O
risk . . O O
of . . O O
a . . O O
second . . O O
cancer . . O O
and . . O O
women . . O O
who . . O O
discover . . O O
that . . O O
a . . O O
family . . O O
member . . O O
carries . . O O
a . . O O
specific . . O O
mutation . . B-Mutation B-Mutation
identified . . O O
through . . O O
genetic . . O O
testing . . O O
. . . O O

Obstetricians . . O O
and . . O O
gynaecologists . . O O
must . . O O
therefore . . O O
become . . O O
familiar . . O O
with . . O O
the . . O O
principles . . O O
of . . O O
assessing . . O O
the . . O O
family . . O O
history . . O O
for . . O O
specific . . O O
hereditary . . O O
cancer . . O O
syndromes . . O O
, . . O O
with . . O O
the . . O O
appropriate . . O O
use . . O O
of . . O O
tests . . O O
to . . O O
confirm . . O O
such . . O O
syndromes . . O O
and . . O O
with . . O O
the . . O O
management . . O O
options . . O O
for . . O O
women . . O O
who . . O O
have . . O O
inherited . . O O
a . . O O
greatly . . O O
increased . . O O
risk . . O O
of . . O O
cancer . . O O
. . . O O

[ . . O O
Rare . . O O
hereditary . . O O
syndromes . . O O
associated . . O O
with . . O O
polyposis . . O O
and . . O O
the . . O O
development . . O O
of . . O O
malignant . . O O
tumors . . O O
] . . O O
. . . O O

# . . O O
# . . O O
UNLABELLED . . O O

Familial . . O O
adenomatous . . O O
polyposis . . O O
( . . O O
FAP . . O O
) . . O O
and . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
syndrome . . O O
are . . O O
genetic . . O O
diseases . . O O
characterized . . O O
by . . O O
gastrointestinal . . O O
polyps . . O O
, . . O O
extraintestinal . . O O
manifestations . . O O
, . . O O
and . . O O
autosomal . . O O
dominant . . O O
inheritance . . O O
. . . O O

The . . O O
carriers . . O O
of . . O O
these . . O O
diseases . . O O
from . . O O
early . . O O
childhood . . O O
are . . O O
at . . O O
risk . . O O
for . . O O
neoplasias . . O O
at . . O O
different . . O O
sites . . O O
, . . O O
which . . O O
are . . O O
symptomatic . . O O
at . . O O
various . . O O
ages . . O O
. . . O O

# . . O O
# . . O O
AIM . . O O

to . . O O
study . . O O
the . . O O
clinical . . O O
organ . . O O
- . . O O
specific . . O O
manifestations . . O O
in . . O O
patients . . O O
with . . O O
FAP . . O O
and . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
, . . O O
genetics . . O O
update . . O O
and . . O O
possibilities . . O O
of . . O O
diagnosis . . O O
, . . O O
monitoring . . O O
, . . O O
and . . O O
treatment . . O O
of . . O O
these . . O O
diseases . . O O
. . . O O

# . . O O
# . . O O
MATERIAL . . O O
AND . . O O
METHODS . . O O

The . . O O
authors . . O O
give . . O O
the . . O O
results . . O O
of . . O O
their . . O O
examination . . O O
and . . O O
follow . . O O
- . . O O
up . . O O
of . . O O
children . . O O
with . . O O
FAP . . O O
and . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
hamartoma . . O O
- . . O O
polypous . . O O
syndrome . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
current . . O O
data . . O O
from . . O O
PubMed . . O O
, . . O O
Medline . . O O
( . . O O
including . . O O
reviews . . O O
, . . O O
original . . O O
articles . . O O
and . . O O
case . . O O
reports . . O O
) . . O O
were . . O O
used . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
main . . O O
clinical . . O O
organ . . O O
- . . O O
specific . . O O
signs . . O O
of . . O O
multiple . . O O
tumors . . O O
in . . O O
FAP . . O O
and . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
syndrome . . O O
are . . O O
shown . . O O
. . . O O

Data . . O O
on . . O O
the . . O O
assessment . . O O
of . . O O
a . . O O
risk . . O O
for . . O O
malignant . . O O
tumors . . O O
at . . O O
various . . O O
sites . . O O
in . . O O
the . . O O
affected . . O O
patients . . O O
and . . O O
their . . O O
family . . O O
members . . O O
at . . O O
different . . O O
ages . . O O
are . . O O
provided . . O O
. . . O O

Each . . O O
of . . O O
these . . O O
syndromes . . O O
has . . O O
a . . O O
dissimilar . . O O
genetic . . O O
foundation . . O O
. . . O O

FAP . . O O
is . . O O
caused . . O O
by . . O O
the . . O O
germline . . O O
mutations . . B-Mutation B-Mutation
in . . O O
the . . O O
APC . . O O
gene . . O O
, . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
syndrome . . O O
is . . O O
by . . O O
the . . O O
STK11 . . O O
gene . . O O
, . . O O
which . . O O
predispose . . O O
individuals . . O O
to . . O O
specifically . . O O
associated . . O O
neoplasias . . O O
and . . O O
require . . O O
different . . O O
follow . . O O
- . . O O
up . . O O
strategies . . O O
. . . O O

Information . . O O
on . . O O
a . . O O
phenotype . . O O
- . . O O
genotype . . O O
correlation . . O O
may . . O O
serve . . O O
as . . O O
a . . O O
reference . . O O
point . . O O
for . . O O
the . . O O
possible . . O O
severity . . O O
and . . O O
various . . O O
manifestations . . O O
of . . O O
a . . O O
disease . . O O
. . . O O

An . . O O
update . . O O
on . . O O
the . . O O
molecular . . O O
pathogenesis . . O O
of . . O O
these . . O O
diseases . . O O
is . . O O
considered . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

Molecular . . O O
genetic . . O O
testing . . O O
of . . O O
the . . O O
genes . . O O
associated . . O O
with . . O O
FAP . . O O
and . . O O
Peutz . . O O
- . . O O
Jeghers . . O O
syndromes . . O O
makes . . O O
it . . O O
possible . . O O
to . . O O
timely . . O O
recognize . . O O
family . . O O
members . . O O
at . . O O
high . . O O
risk . . O O
, . . O O
to . . O O
plan . . O O
therapeutic . . O O
strategy . . O O
and . . O O
to . . O O
affect . . O O
the . . O O
course . . O O
of . . O O
a . . O O
disease . . O O
. . . O O

The . . O O
joint . . O O
participation . . O O
of . . O O
pediatricians . . O O
, . . O O
proctologists . . O O
, . . O O
oncologists . . O O
, . . O O
morphologists . . O O
, . . O O
geneticists . . O O
, . . O O
and . . O O
molecular . . O O
biologists . . O O
is . . O O
essential . . O O
to . . O O
timely . . O O
recognize . . O O
the . . O O
carriers . . O O
of . . O O
the . . O O
syndromes . . O O
and . . O O
a . . O O
better . . O O
prognosis . . O O
in . . O O
these . . O O
patients . . O O
. . . O O

Identification . . O O
of . . O O
candidate . . O O
predisposing . . O O
copy . . B-Mutation B-Mutation
number . . I-Mutation I-Mutation
variants . . I-Mutation I-Mutation
in . . O O
familial . . O O
and . . O O
early . . O O
- . . O O
onset . . O O
colorectal . . O O
cancer . . O O
patients . . O O
. . . O O

In . . O O
the . . O O
majority . . O O
of . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRCs . . O O
) . . O O
under . . O O
clinical . . O O
suspicion . . O O
for . . O O
a . . O O
hereditary . . O O
cause . . O O
, . . O O
the . . O O
disease . . O O
- . . O O
causing . . O O
genetic . . O O
factors . . O O
are . . O O
still . . O O
to . . O O
be . . O O
discovered . . O O
. . . O O

To . . O O
identify . . O O
such . . O O
genetic . . O O
factors . . O O
we . . O O
stringently . . O O
selected . . O O
a . . O O
discovery . . O O
cohort . . O O
of . . O O
41 . . O O
CRC . . O O
index . . O O
patients . . O O
with . . O O
microsatellite . . B-Mutation O
- . . I-Mutation O
stable . . I-Mutation O
tumors . . O O
. . . O O

All . . O O
patients . . O O
were . . O O
below . . O O
40 . . O O
years . . O O
of . . O O
age . . O O
at . . O O
diagnosis . . O O
and . . O O
/ . . O O
or . . O O
exhibited . . O O
an . . O O
overt . . O O
family . . O O
history . . O O
. . . O O

We . . O O
employed . . O O
genome . . O O
- . . O O
wide . . O O
copy . . O O
number . . O O
profiling . . O O
using . . O O
high . . O O
- . . O O
resolution . . O O
SNP . . B-Mutation B-Mutation
arrays . . O O
on . . O O
germline . . O O
DNA . . O O
, . . O O
which . . O O
resulted . . O O
in . . O O
the . . O O
identification . . O O
of . . O O
novel . . O O
copy . . B-Mutation B-Mutation
number . . I-Mutation I-Mutation
variants . . I-Mutation I-Mutation
( . . O O
CNVs . . B-Mutation O
) . . O O
in . . O O
six . . O O
patients . . O O
( . . O O
15 . . O O
% . . O O
) . . O O
encompassing . . O O
, . . O O
among . . O O
others . . O O
, . . O O
the . . O O
cadherin . . O O
gene . . O O
CDH18 . . O O
, . . O O
the . . O O
bone . . O O
morphogenetic . . O O
protein . . O O
antagonist . . O O
family . . O O
gene . . O O
GREM1 . . O O
, . . O O
and . . O O
the . . O O
breakpoint . . O O
cluster . . O O
region . . O O
gene . . O O
BCR . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
two . . O O
genomic . . O O
deletions . . B-Mutation B-Mutation
were . . O O
encountered . . O O
encompassing . . O O
two . . O O
microRNA . . O O
genes . . O O
, . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
491 . . O O
/ . . O O
KIAA1797 . . O O
and . . O O
hsa . . O O
- . . O O
mir . . O O
- . . O O
646 . . O O
/ . . O O
AK309218 . . O O
. . . O O

None . . O O
of . . O O
these . . O O
CNVs . . B-Mutation O
has . . O O
previously . . O O
been . . O O
reported . . O O
in . . O O
relation . . O O
to . . O O
CRC . . O O
predisposition . . O O
in . . O O
humans . . O O
, . . O O
nor . . O O
were . . O O
they . . O O
encountered . . O O
in . . O O
large . . O O
control . . O O
cohorts . . O O
( . . O O
> . . O O
1 . . O O
, . . O O
600 . . O O
unaffected . . O O
individuals . . O O
) . . O O
. . . O O

Since . . O O
several . . O O
of . . O O
these . . O O
newly . . O O
identified . . O O
candidate . . O O
genes . . O O
may . . O O
be . . O O
functionally . . O O
linked . . O O
to . . O O
CRC . . O O
development . . O O
, . . O O
our . . O O
results . . O O
illustrate . . O O
the . . O O
potential . . O O
of . . O O
this . . O O
approach . . O O
for . . O O
the . . O O
identification . . O O
of . . O O
novel . . O O
candidate . . O O
genes . . O O
involved . . O O
in . . O O
CRC . . O O
predisposition . . O O
. . . O O

The . . O O
role . . O O
of . . O O
cytokine . . O O
gene . . O O
polymorphisms . . B-Mutation B-Mutation
in . . O O
colorectal . . O O
cancer . . O O
and . . O O
their . . O O
interaction . . O O
with . . O O
aspirin . . O O
use . . O O
in . . O O
the . . O O
northeast . . O O
of . . O O
Scotland . . O O
. . . O O

The . . O O
reduced . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
associated . . O O
with . . O O
cyclooxygenase . . O O
enzyme . . O O
inhibitors . . O O
, . . O O
such . . O O
as . . O O
aspirin . . O O
and . . O O
other . . O O
nonsteroidal . . O O
anti . . O O
- . . O O
inflammatory . . O O
drugs . . O O
, . . O O
strongly . . O O
suggests . . O O
that . . O O
chronic . . O O
inflammation . . O O
is . . O O
a . . O O
key . . O O
mediator . . O O
in . . O O
the . . O O
development . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

This . . O O
complements . . O O
recent . . O O
molecular . . O O
evidence . . O O
demonstrating . . O O
an . . O O
association . . O O
between . . O O
a . . O O
number . . O O
of . . O O
proinflammatory . . O O
genetic . . O O
polymorphisms . . B-Mutation B-Mutation
and . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

We . . O O
assessed . . O O
polymorphisms . . B-Mutation B-Mutation
in . . O O
the . . O O
IL . . O O
- . . O O
1 . . O O
, . . O O
IL . . O O
- . . O O
10 . . O O
, . . O O
TNF . . O O
- . . O O
A . . O O
, . . O O
and . . O O
TGF . . O O
- . . O O
B . . O O
genes . . O O
in . . O O
a . . O O
population . . O O
- . . O O
based . . O O
case . . O O
- . . O O
control . . O O
study . . O O
of . . O O
colorectal . . O O
cancer . . O O
cases . . O O
( . . O O
n . . O O
= . . O O
264 . . O O
) . . O O
and . . O O
frequency . . O O
- . . O O
matched . . O O
controls . . O O
( . . O O
n . . O O
= . . O O
408 . . O O
) . . O O
in . . O O
the . . O O
Northeast . . O O
of . . O O
Scotland . . O O
and . . O O
analyzed . . O O
their . . O O
interaction . . O O
with . . O O
regular . . O O
aspirin . . O O
use . . O O
. . . O O

There . . O O
was . . O O
no . . O O
evidence . . O O
of . . O O
a . . O O
relation . . O O
between . . O O
any . . O O
of . . O O
the . . O O
individual . . O O
polymorphisms . . B-Mutation B-Mutation
, . . O O
or . . O O
pairs . . O O
of . . O O
polymorphisms . . B-Mutation B-Mutation
, . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
. . . O O

There . . O O
was . . O O
a . . O O
significant . . O O
interaction . . O O
between . . O O
the . . O O
IL . . O O
- . . O O
10 . . O O
- . . O O
592 . . O O
C . . O O
/ . . O O
A . . O O
polymorphism . . B-Mutation B-Mutation
and . . O O
aspirin . . O O
use . . O O
( . . O O
Pinteraction . . O O
= . . O O
0 . . O O
. . . O O
03 . . O O
) . . O O
. . . O O

Carriers . . O O
of . . O O
the . . O O
variant . . B-Mutation B-Mutation
IL . . O O
- . . O O
10 . . O O
- . . O O
592 . . O O
( . . O O
A . . O O
) . . O O
allele . . O O
, . . O O
who . . O O
produce . . O O
less . . O O
of . . O O
the . . O O
anti . . O O
- . . O O
inflammatory . . O O
cytokine . . O O
interleukin . . O O
- . . O O
10 . . O O
, . . O O
had . . O O
a . . O O
statistically . . O O
significant . . O O
50 . . O O
% . . O O
reduced . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
when . . O O
taking . . O O
regular . . O O
aspirin . . O O
( . . O O
odds . . O O
ratio . . O O
, . . O O
0 . . O O
. . . O O
5 . . O O
; . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
, . . O O
0 . . O O
. . . O O
25 . . O O
- . . O O
0 . . O O
. . . O O
97 . . O O
) . . O O
, . . O O
whereas . . O O
risk . . O O
was . . O O
not . . O O
reduced . . O O
in . . O O
carriers . . O O
of . . O O
the . . O O
A . . O O
allele . . O O
who . . O O
did . . O O
not . . O O
use . . O O
aspirin . . O O
, . . O O
or . . O O
among . . O O
aspirin . . O O
users . . O O
with . . O O
the . . O O
CC . . O O
genotype . . O O
. . . O O

It . . O O
is . . O O
possible . . O O
that . . O O
carriers . . O O
of . . O O
the . . O O
mutant . . B-Mutation B-Mutation
IL . . O O
- . . O O
10 . . O O
- . . O O
592 . . O O
allele . . O O
are . . O O
more . . O O
likely . . O O
to . . O O
derive . . O O
anti . . O O
- . . O O
inflammatory . . O O
and . . O O
chemopreventive . . O O
benefits . . O O
from . . O O
aspirin . . O O
in . . O O
the . . O O
presence . . O O
of . . O O
a . . O O
lower . . O O
production . . O O
of . . O O
their . . O O
own . . O O
endogenous . . O O
anti . . O O
- . . O O
inflammatory . . O O
interleukin . . O O
- . . O O
10 . . O O
. . . O O

These . . O O
results . . O O
suggest . . O O
that . . O O
host . . O O
genetics . . O O
may . . O O
play . . O O
a . . O O
role . . O O
in . . O O
predicting . . O O
response . . O O
to . . O O
chemopreventive . . O O
strategies . . O O
. . . O O

Confirmation . . O O
of . . O O
these . . O O
findings . . O O
in . . O O
other . . O O
populations . . O O
is . . O O
required . . O O
. . . O O

Bile . . O O
acid . . O O
regulates . . O O
MUC2 . . O O
transcription . . O O
in . . O O
colon . . O O
cancer . . O O
cells . . O O
via . . O O
positive . . O O
EGFR . . O O
/ . . O O
PKC . . O O
/ . . O O
Ras . . O O
/ . . O O
ERK . . O O
/ . . O O
CREB . . O O
, . . O O
PI3K . . O O
/ . . O O
Akt . . O O
/ . . O O
IkappaB . . O O
/ . . O O
NF . . O O
- . . O O
kappaB . . O O
and . . O O
p38 . . O O
/ . . O O
MSK1 . . O O
/ . . O O
CREB . . O O
pathways . . O O
and . . O O
negative . . O O
JNK . . O O
/ . . O O
c . . O O
- . . O O
Jun . . O O
/ . . O O
AP . . O O
- . . O O
1 . . O O
pathway . . O O
. . . O O

MUC2 . . O O
is . . O O
a . . O O
major . . O O
secretory . . O O
mucin . . O O
normally . . O O
expressed . . O O
by . . O O
goblet . . O O
cells . . O O
of . . O O
the . . O O
intestine . . O O
, . . O O
but . . O O
is . . O O
aberrantly . . O O
expressed . . O O
in . . O O
colonic . . O O
neoplasia . . O O
. . . O O

Bile . . O O
acids . . O O
have . . O O
been . . O O
implicated . . O O
in . . O O
colorectal . . O O
carcinogenesis . . O O
and . . O O
, . . O O
therefore . . O O
, . . O O
we . . O O
sought . . O O
to . . O O
determine . . O O
the . . O O
effects . . O O
of . . O O
bile . . O O
acids . . O O
on . . O O
MUC2 . . O O
expression . . O O
and . . O O
regulation . . O O
in . . O O
colon . . O O
cancer . . O O
cells . . O O
. . . O O

Since . . O O
deoxycholic . . O O
acid . . O O
( . . O O
DCA . . O O
) . . O O
, . . O O
a . . O O
secondary . . O O
bile . . O O
acid . . O O
, . . O O
has . . O O
been . . O O
reported . . O O
to . . O O
be . . O O
a . . O O
potent . . O O
mucin . . O O
secretagogue . . O O
and . . O O
tumor . . O O
promoter . . O O
, . . O O
DCA . . O O
- . . O O
treated . . O O
HM3 . . O O
colon . . O O
cancer . . O O
cells . . O O
were . . O O
analyzed . . O O
using . . O O
promoter . . O O
- . . O O
reporter . . O O
assays . . O O
of . . O O
the . . O O
5 . . O O
' . . O O
flanking . . O O
region . . O O
of . . O O
the . . O O
MUC2 . . O O
gene . . O O
. . . O O

Chemical . . O O
inhibitors . . O O
, . . O O
mutant . . O B-Mutation
reporter . . O O
constructs . . O O
and . . O O
EMSA . . O O
showed . . O O
that . . O O
DCA . . O O
upregulates . . O O
MUC2 . . O O
transcription . . O O
via . . O O
multiple . . O O
pathways . . O O
involving . . O O
activation . . O O
of . . O O
EGFR . . O O
/ . . O O
PKC . . O O
/ . . O O
Ras . . O O
/ . . O O
Raf . . O O
- . . O O
1 . . O O
/ . . O O
MEK1 . . O O
/ . . O O
ERK . . O O
/ . . O O
CREB . . O O
, . . O O
PI3 . . O O
/ . . O O
Akt . . O O
/ . . O O
IkappaB . . O O
/ . . O O
NF . . O O
- . . O O
kappaB . . O O
and . . O O
p38 . . O O
/ . . O O
MSK1 . . O O
/ . . O O
CREB . . O O
while . . O O
DCA . . O O
induced . . O O
MUC2 . . O O
transcription . . O O
is . . O O
inhibited . . O O
by . . O O
JNK . . O O
/ . . O O
c . . O O
- . . O O
Jun . . O O
/ . . O O
AP . . O O
- . . O O
1 . . O O
pathway . . O O
. . . O O

These . . O O
results . . O O
provide . . O O
new . . O O
insight . . O O
into . . O O
the . . O O
complex . . O O
molecular . . O O
mechanisms . . O O
involved . . O O
in . . O O
the . . O O
regulation . . O O
of . . O O
mucin . . O O
gene . . O O
by . . O O
bile . . O O
acids . . O O
in . . O O
colon . . O O
cancer . . O O
cells . . O O
that . . O O
may . . O O
contribute . . O O
to . . O O
further . . O O
elucidation . . O O
of . . O O
colorectal . . O O
carcinogenesis . . O O
. . . O O

Meta . . O O
- . . O O
analyses . . O O
of . . O O
the . . O O
associations . . O O
between . . O O
four . . O O
common . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
genetic . . O O
polymorphisms . . B-Mutation B-Mutation
and . . O O
risk . . O O
of . . O O
colorectal . . O O
tumor . . O O
. . . O O

The . . O O
associations . . O O
between . . O O
four . . O O
common . . O O
genetic . . O O
polymorphisms . . B-Mutation B-Mutation
of . . O O
transforming . . O O
growth . . O O
factor . . O O
- . . O O
 . . O O
1 . . O O
( . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
, . . O O
+ . . B-Mutation B-Mutation
869 . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
+ . . B-Mutation B-Mutation
915 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
and . . O O
- . . B-Mutation B-Mutation
800 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
) . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
tumor . . O O
( . . O O
including . . O O
adenoma . . O O
and . . O O
cancer . . O O
) . . O O
have . . O O
been . . O O
widely . . O O
studied . . O O
. . . O O

To . . O O
date . . O O
, . . O O
no . . O O
conclusions . . O O
could . . O O
be . . O O
available . . O O
because . . O O
of . . O O
controversial . . O O
results . . O O
reported . . O O
. . . O O

Thus . . O O
, . . O O
we . . O O
conducted . . O O
a . . O O
meta . . O O
- . . O O
analysis . . O O
to . . O O
further . . O O
assess . . O O
the . . O O
associations . . O O
. . . O O

We . . O O
searched . . O O
the . . O O
databases . . O O
of . . O O
Medline . . O O
, . . O O
Embase . . O O
, . . O O
and . . O O
Wangfang . . O O
to . . O O
identify . . O O
eligible . . O O
studies . . O O
, . . O O
and . . O O
latest . . O O
update . . O O
was . . O O
on . . O O
January . . O O
1 . . O O
, . . O O
2012 . . O O
. . . O O

Odds . . O O
ratio . . O O
( . . O O
OR . . O O
) . . O O
and . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
( . . O O
95 . . O O
% . . O O
CI . . O O
) . . O O
were . . O O
calculated . . O O
to . . O O
present . . O O
the . . O O
associations . . O O
. . . O O

Our . . O O
meta . . O O
- . . O O
analysis . . O O
indicated . . O O
that . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
, . . O O
+ . . B-Mutation B-Mutation
869 . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
+ . . B-Mutation B-Mutation
915 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
and . . O O
- . . B-Mutation B-Mutation
800 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
were . . O O
not . . O O
associated . . O O
with . . O O
risk . . O O
of . . O O
colorectal . . O O
adenoma . . O O
( . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
89 . . O O
for . . O O
C . . O O
carriers . . O O
vs . . O O
. . . O O
TT . . O O
for . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
, . . O O
1 . . O O
. . . O O
03 . . O O
for . . O O
C . . O O
carriers . . O O
vs . . O O
. . . O O
TT . . O O
for . . O O
+ . . B-Mutation B-Mutation
869 . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
1 . . O O
. . . O O
09 . . O O
for . . O O
C . . O O
carriers . . O O
vs . . O O
. . . O O
GG . . O B-Mutation
for . . O I-Mutation
+ . . B-Mutation I-Mutation
915 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
and . . O O
1 . . O O
. . . O O
19 . . O O
for . . O O
A . . O O
carriers . . O O
vs . . O O
. . . O O
GG . . O B-Mutation
for . . O I-Mutation
800 . . B-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
) . . O O
. . . O O

However . . O O
, . . O O
C . . O O
allele . . O O
of . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
and . . O O
A . . O O
allele . . O B-Mutation
of . . O I-Mutation
- . . B-Mutation I-Mutation
800 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
were . . O O
associated . . O O
with . . O O
increased . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
, . . O O
and . . O O
OR . . O O
( . . O O
95 . . O O
% . . O O
CI . . O O
) . . O O
was . . O O
1 . . O O
. . . O O
23 . . O O
( . . O O
0 . . O O
. . . O O
99 . . O O
- . . O O
1 . . O O
. . . O O
52 . . O O
) . . O O
for . . O O
CC . . O O
vs . . O O
. . . O O
TT . . O O
for . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
and . . O O
6 . . O O
. . . O O
64 . . O O
( . . O O
3 . . O O
. . . O O
46 . . O O
- . . O O
12 . . O O
. . . O O
72 . . O O
) . . O O
for . . O O
A . . O O
carriers . . O O
vs . . O O
. . . O O
GG . . O O
. . . O O

The . . O O
positive . . O O
association . . O O
between . . O O
- . . O O
509 . . O O
C . . O O
allele . . O O
and . . O O
risk . . O O
of . . O O
CRC . . O O
was . . O O
more . . O O
obvious . . O O
when . . O O
subgroup . . O O
analyses . . O O
were . . O O
conducted . . O O
for . . O O
population . . O O
- . . O O
based . . O O
and . . O O
large . . O O
sample . . O O
- . . O O
sized . . O O
studies . . O O
as . . O O
well . . O O
as . . O O
Caucasians . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
we . . O O
did . . O O
not . . O O
observed . . O O
any . . O O
associations . . O O
between . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
+ . . B-Mutation O
869 . . I-Mutation O
T . . I-Mutation B-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
+ . . B-Mutation B-Mutation
915 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
, . . O O
and . . O O
risk . . O O
of . . O O
CRC . . O O
. . . O O

This . . O O
study . . O O
indicated . . O O
that . . O O
C . . O O
allele . . O O
of . . O O
TGF . . O O
- . . O O
 . . O O
1 . . O O
- . . B-Mutation B-Mutation
509 . . I-Mutation I-Mutation
C . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
and . . O O
A . . O O
allele . . O B-Mutation
of . . O I-Mutation
- . . B-Mutation I-Mutation
800 . . I-Mutation I-Mutation
G . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
might . . O O
contribute . . O O
to . . O O
the . . O O
increased . . O O
risk . . O O
of . . O O
CRC . . O O
, . . O O
and . . O O
could . . O O
be . . O O
used . . O O
as . . O O
two . . O O
of . . O O
genetic . . O O
marks . . O O
for . . O O
screening . . O O
individuals . . O O
at . . O O
high . . O O
risk . . O O
of . . O O
CRC . . O O
. . . O O

Because . . O O
of . . O O
modest . . O O
limitation . . O O
, . . O O
large . . O O
sample . . O O
- . . O O
sized . . O O
studies . . O O
were . . O O
required . . O O
to . . O O
confirm . . O O
the . . O O
findings . . O O
. . . O O

Prevention . . O O
of . . O O
colorectal . . O O
cancer . . O O
by . . O O
colonoscopic . . O O
surveillance . . O O
in . . O O
families . . O O
with . . O O
hereditary . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
OBJECTIVE . . O O

In . . O O
recent . . O O
years . . O O
persons . . O O
at . . O O
risk . . O O
for . . O O
colorectal . . O O
cancers . . O O
( . . O O
CRC . . O O
) . . O O
have . . O O
been . . O O
subjected . . O O
to . . O O
follow . . O O
- . . O O
up . . O O
with . . O O
colonoscopy . . O O
in . . O O
many . . O O
centres . . O O
. . . O O

There . . O O
is . . O O
, . . O O
however . . O O
, . . O O
limited . . O O
knowledge . . O O
about . . O O
the . . O O
effect . . O O
of . . O O
such . . O O
interventions . . O O
. . . O O

The . . O O
objective . . O O
of . . O O
this . . O O
study . . O O
was . . O O
to . . O O
report . . O O
the . . O O
results . . O O
of . . O O
our . . O O
observations . . O O
during . . O O
the . . O O
past . . O O
15 . . O O
years . . O O
. . . O O

# . . O O
# . . O O
MATERIAL . . O O
AND . . O O
METHODS . . O O

Healthy . . O O
persons . . O O
were . . O O
included . . O O
in . . O O
the . . O O
study . . O O
according . . O O
to . . O O
their . . O O
family . . O O
history . . O O
of . . O O
CRCs . . O O
, . . O O
and . . O O
prospectively . . O O
followed . . O O
with . . O O
colonoscopies . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Altogether . . O O
, . . O O
1133 . . O O
individuals . . O O
were . . O O
included . . O O
and . . O O
observed . . O O
for . . O O
a . . O O
total . . O O
of . . O O
3474 . . O O
follow . . O O
- . . O O
up . . O O
years . . O O
from . . O O
the . . O O
first . . O O
to . . O O
the . . O O
last . . O O
colonoscopy . . O O
initiated . . O O
by . . O O
our . . O O
activity . . O O
. . . O O

Mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
mutations . . B-Mutation B-Mutation
were . . O O
detected . . O O
in . . O O
6 . . O O
. . . O O
5 . . O O
% . . O O
of . . O O
cases . . O O
. . . O O

A . . O O
total . . O O
of . . O O
1383 . . O O
polyps . . O O
were . . O O
removed . . O O
, . . O O
72 . . O O
% . . O O
were . . O O
less . . O O
than . . O O
5 . . O O
mm . . O O
in . . O O
diameter . . O O
. . . O O

Findings . . O O
were . . O O
scored . . O O
as . . O O
hyperplastic . . O O
polyps . . O O
( . . O O
n . . O O
= . . O O
887 . . O O
) . . O O
, . . O O
adenomas . . O O
with . . O O
mild . . O O
to . . O O
moderate . . O O
dysplasia . . O O
( . . O O
n . . O O
= . . O O
460 . . O O
) . . O O
, . . O O
adenomas . . O O
with . . O O
high . . O O
- . . O O
grade . . O O
dysplasia . . O O
( . . O O
n . . O O
= . . O O
30 . . O O
) . . O O
and . . O O
cancers . . O O
( . . O O
n . . O O
= . . O O
6 . . O O
) . . O O
. . . O O

Two . . O O
cancers . . O O
were . . O O
observed . . O O
after . . O O
the . . O O
first . . O O
colonoscopy . . O O
, . . O O
compared . . O O
with . . O O
2 . . O O
. . . O O
6 . . O O
expected . . O O
by . . O O
chance . . O O
and . . O O
more . . O O
than . . O O
20 . . O O
expected . . O O
under . . O O
the . . O O
hypothesis . . O O
of . . O O
predominant . . O O
inherited . . O O
diseases . . O O
in . . O O
the . . O O
families . . O O
. . . O O

Observed . . O O
annual . . O O
incidence . . O O
rates . . O O
for . . O O
adenomas . . O O
were . . O O
similar . . O O
in . . O O
all . . O O
groups . . O O
, . . O O
while . . O O
in . . O O
the . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
there . . O O
was . . O O
a . . O O
higher . . O O
frequency . . O O
of . . O O
progression . . O O
to . . O O
severe . . O O
dysplasia . . O O
or . . O O
infiltrating . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

A . . O O
simple . . O O
explanation . . O O
for . . O O
the . . O O
combined . . O O
findings . . O O
may . . O O
be . . O O
that . . O O
all . . O O
selected . . O O
families . . O O
had . . O O
a . . O O
similar . . O O
tendency . . O O
to . . O O
produce . . O O
adenomas . . O O
, . . O O
while . . O O
mutation . . B-Mutation B-Mutation
carriers . . O O
more . . O O
frequently . . O O
demonstrated . . O O
dysplasia . . O O
/ . . O O
cancer . . O O
in . . O O
the . . O O
adenomas . . O O
. . . O O

The . . O O
low . . O O
annual . . O O
incidence . . O O
rates . . O O
for . . O O
CRC . . O O
indicated . . O O
that . . O O
the . . O O
removal . . O O
of . . O O
adenomas . . O O
may . . O O
have . . O O
prevented . . O O
cancers . . O O
. . . O O

Editorial . . O O
: . . O O
sessile . . O O
serrated . . O O
adenomas . . O O
and . . O O
their . . O O
pit . . O O
patterns . . O O
: . . O O
we . . O O
must . . O O
first . . O O
see . . O O
the . . O O
forest . . O O
through . . O O
the . . O O
trees . . O O
. . . O O

Serrated . . O O
lesions . . O O
of . . O O
the . . O O
colorectum . . O O
include . . O O
hyperplastic . . O O
polyps . . O O
, . . O O
which . . O O
are . . O O
non . . O O
- . . O O
neoplastic . . O O
, . . O O
and . . O O
sessile . . O O
serrated . . O O
adenomas . . O O
( . . O O
SSAs . . O O
, . . O O
also . . O O
known . . O O
as . . O O
sessile . . O O
serrated . . O O
polyps . . O O
) . . O O
and . . O O
traditional . . O O
serrated . . O O
adenomas . . O O
, . . O O
which . . O O
are . . O O
premalignant . . O O
. . . O O

It . . O O
is . . O O
believed . . O O
that . . O O
up . . O O
to . . O O
30 . . O O
% . . O O
of . . O O
colon . . O O
cancers . . O O
and . . O O
many . . O O
post . . O O
- . . O O
colonoscopy . . O O
cancers . . O O
arise . . O O
from . . O O
serrated . . O O
neoplasms . . O O
. . . O O

Post . . O O
- . . O O
colonoscopy . . O O
cancers . . O O
have . . O O
been . . O O
found . . O O
to . . O O
have . . O O
a . . O O
molecular . . O O
signature . . O O
similar . . O O
to . . O O
SSAs . . O O
, . . O O
including . . O O
CpG . . O O
island . . O O
methylation . . O O
, . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
, . . O O
and . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
. . . O O

A . . O O
novel . . O O
pit . . O O
pattern . . O O
, . . O O
Type . . O O
II . . O O
- . . O O
O . . O O
, . . O O
has . . O O
been . . O O
demonstrated . . O O
to . . O O
have . . O O
a . . O O
high . . O O
specificity . . O O
for . . O O
SSAs . . O O
. . . O O

Unfortunately . . O O
, . . O O
the . . O O
sensitivity . . O O
is . . O O
too . . O O
low . . O O
to . . O O
utilize . . O O
a . . O O
Type . . O O
II . . O O
- . . O O
O . . O O
pit . . O O
pattern . . O O
to . . O O
determine . . O O
which . . O O
serrated . . O O
lesion . . O O
is . . O O
neoplastic . . O O
and . . O O
needs . . O O
resection . . O O
. . . O O

Moreover . . O O
, . . O O
there . . O O
is . . O O
significant . . O O
endoscopist . . O O
- . . O O
related . . O O
variability . . O O
in . . O O
the . . O O
detection . . O O
of . . O O
serrated . . O O
lesions . . O O
of . . O O
the . . O O
colon . . O O
. . . O O

Efforts . . O O
to . . O O
improve . . O O
the . . O O
detection . . O O
of . . O O
serrated . . O O
neoplasms . . O O
are . . O O
warranted . . O O
. . . O O

Hydrophobic . . O O
bile . . O O
acid . . O O
- . . O O
induced . . O O
micronuclei . . O O
formation . . O O
, . . O O
mitotic . . O O
perturbations . . O O
, . . O O
and . . O O
decreases . . O O
in . . O O
spindle . . O O
checkpoint . . O O
proteins . . O O
: . . O O
relevance . . O O
to . . O O
genomic . . O O
instability . . O B-Mutation
in . . O O
colon . . O O
carcinogenesis . . O O
. . . O O

We . . O O
show . . O O
, . . O O
for . . O O
the . . O O
first . . O O
time . . O O
, . . O O
that . . O O
hydrophobic . . O O
bile . . O O
acids . . O O
cause . . O O
aberrations . . O O
of . . O O
the . . O O
mitotic . . O O
machinery . . O O
of . . O O
colon . . O O
cells . . O O
that . . O O
can . . O O
give . . O O
rise . . O O
to . . O O
aneuploidy . . O B-Mutation
, . . O O
the . . O O
chromosomal . . O O
perturbations . . O O
common . . O O
in . . O O
colon . . O O
tumors . . O O
. . . O O

First . . O O
, . . O O
we . . O O
show . . O O
that . . O O
DOC . . O O
induces . . O O
a . . O O
statistically . . O O
significant . . O O
fourfold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
micronuclei . . O O
in . . O O
NCM . . O O
- . . O O
460 . . O O
cells . . O O
( . . O O
a . . O O
noncancerous . . O O
colon . . O O
cell . . O O
line . . O O
) . . O O
and . . O O
a . . O O
threefold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
micronuclei . . O O
in . . O O
binucleated . . O O
HT . . O O
- . . O O
29 . . O O
colon . . O O
cancer . . O O
cells . . O O
using . . O O
the . . O O
cytokinesis . . O O
block . . O O
micronucleus . . O O
assay . . O O
. . . O O

Second . . O O
, . . O O
we . . O O
observed . . O O
mitotic . . B-Mutation O
aberrations . . I-Mutation B-Mutation
after . . O O
DOC . . O O
treatment . . O O
, . . O O
including . . O O
improper . . B-Mutation O
alignment . . I-Mutation O
of . . O O
chromosomes . . O O
at . . O O
the . . O O
metaphase . . O O
plate . . O O
, . . O O
lagging . . O O
chromosomes . . O O
during . . O O
anaphase . . O O
, . . O O
anaphase . . O O
/ . . O O
telophase . . O O
chromatin . . O O
bridges . . O O
, . . O O
multipolar . . O O
divisions . . O O
, . . O O
and . . O O
formation . . O O
of . . O O
polynucleated . . O O
cells . . O O
. . . O O

It . . O O
was . . O O
determined . . O O
that . . O O
there . . O O
was . . O O
a . . O O
statistically . . O O
significant . . O O
threefold . . O O
increase . . O O
in . . O O
the . . O O
number . . O O
of . . O O
aberrant . . O O
metaphases . . O O
after . . O O
short . . O O
- . . O O
term . . O O
and . . O O
long . . O O
- . . O O
term . . O O
exposure . . O O
of . . O O
HT . . O O
- . . O O
29 . . O O
and . . O O
HCT . . O O
- . . O O
116 . . O O
cells . . O O
, . . O O
respectively . . O O
. . . O O

Third . . O O
, . . O O
we . . O O
showed . . O O
with . . O O
Western . . O O
blots . . O O
and . . O O
immunohistochemistry . . O O
that . . O O
a . . O O
likely . . O O
basis . . O O
for . . O O
these . . O O
mitosis . . O O
- . . O O
related . . O O
perturbations . . O O
included . . O O
decreased . . O O
expression . . O O
of . . O O
the . . O O
spindle . . O O
checkpoint . . O O
proteins . . O O
, . . O O
Mad2 . . O O
, . . O O
BubR1 . . O O
, . . O O
and . . O O
securin . . O O
. . . O O

Fourth . . O O
, . . O O
results . . O O
of . . O O
DOC . . O O
treatment . . O O
on . . O O
nocodazole . . O O
- . . O O
challenged . . O O
cells . . O O
further . . O O
indicated . . O O
deficiencies . . O O
in . . O O
activation . . O O
of . . O O
the . . O O
spindle . . O O
assembly . . O O
checkpoint . . O O
. . . O O

This . . O O
study . . O O
provides . . O O
mechanisms . . O O
by . . O O
which . . O O
hydrophobic . . O O
bile . . O O
acids . . O O
can . . O O
induce . . O O
genomic . . O O
instability . . O B-Mutation
in . . O O
colon . . O O
epithelial . . O O
cells . . O O
. . . O O

Polymorphisms . . B-Mutation B-Mutation
in . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
genes . . O O
as . . O O
prognostic . . O O
markers . . O O
for . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

Currently . . O O
, . . O O
the . . O O
TNM . . O O
classification . . O O
of . . O O
malignant . . O O
tumours . . O O
based . . O O
on . . O O
clinicopathological . . O O
staging . . O O
remains . . O O
the . . O O
standard . . O O
for . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
prognostication . . O O
. . . O O

Recently . . O O
, . . O O
we . . O O
identified . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
as . . O O
a . . O O
consistently . . O O
overrepresented . . O O
category . . O O
in . . O O
the . . O O
published . . O O
gene . . O O
expression . . O O
profiling . . O O
( . . O O
GEP . . O O
) . . O O
studies . . O O
on . . O O
CRC . . O O
prognosis . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

We . . O O
evaluated . . O O
associations . . O O
of . . O O
putative . . O O
regulatory . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
( . . O O
SNPs . . B-Mutation B-Mutation
) . . O O
in . . O O
genes . . O O
from . . O O
the . . O O
oxidative . . O O
phosphorylation . . O O
chain . . O O
with . . O O
survival . . O O
and . . O O
disease . . O O
prognosis . . O O
in . . O O
613 . . O O
CRC . . O O
patients . . O O
from . . O O
Northern . . O O
Germany . . O O
( . . O O
PopGen . . O O
cohort . . O O
) . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Two . . O O
SNPs . . B-Mutation B-Mutation
in . . O O
the . . O O
3 . . O O
' . . O O
untranslated . . O O
region . . O O
of . . O O
UQCRB . . O O
( . . O O
complex . . O O
III . . O O
) . . O O
, . . O O
rs7836698 . . B-Mutation B-Mutation
and . . O O
rs10504961 . . B-Mutation O
, . . O O
were . . O O
associated . . O O
with . . O O
overall . . O O
survival . . O O
( . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
52 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
32 . . O O
- . . O O
0 . . O O
. . . O O
85 . . O O
and . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
64 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
42 . . O O
- . . O O
0 . . O O
. . . O O
99 . . O O
, . . O O
for . . O O
TT . . O O
carriers . . O O
) . . O O
. . . O O

These . . O O
associations . . O O
were . . O O
restricted . . O O
to . . O O
the . . O O
group . . O O
of . . O O
patients . . O O
with . . O O
cancer . . O O
located . . O O
in . . O O
the . . O O
colon . . O O
( . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
42 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
22 . . O O
- . . O O
0 . . O O
. . . O O
82 . . O O
and . . O O
HR . . O O
= . . O O
0 . . O O
. . . O O
46 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
0 . . O O
. . . O O
25 . . O O
- . . O O
0 . . O O
. . . O O
83 . . O O
) . . O O
. . . O O

Multivariate . . O O
analysis . . O O
indicated . . O O
that . . O O
both . . O O
markers . . O O
might . . O O
act . . O O
as . . O O
independent . . O O
prognostic . . O O
markers . . O O
. . . O O

Additionally . . O O
, . . O O
the . . O O
TT . . O O
carriers . . O O
were . . O O
~ . . O O
2 . . O O
times . . O O
more . . O O
likely . . O O
to . . O O
develop . . O O
tumours . . O O
in . . O O
the . . O O
colon . . O O
than . . O O
in . . O O
the . . O O
rectum . . O O
. . . O O

Two . . O O
SNPs . . B-Mutation B-Mutation
in . . O O
COX6B1 . . O O
( . . O O
complex . . O O
IV . . O O
) . . O O
were . . O O
associated . . O O
with . . O O
lymph . . O O
node . . O O
metastasis . . O O
in . . O O
a . . O O
dominant . . O O
model . . O O
( . . O O
rs6510502 . . B-Mutation O
, . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
75 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
20 . . O O
- . . O O
2 . . O O
. . . O O
57 . . O O
; . . O O
rs10420252 . . B-Mutation O
, . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
68 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
11 . . O O
- . . O O
2 . . O O
. . . O O
53 . . O O
) . . O O
; . . O O
rs6510502 . . B-Mutation B-Mutation
was . . O O
associated . . O O
also . . O O
with . . O O
distant . . O O
metastasis . . O O
( . . O O
OR . . O O
= . . O O
1 . . O O
. . . O O
67 . . O O
, . . O O
95 . . O O
% . . O O
CI . . O O
1 . . O O
. . . O O
09 . . O O
- . . O O
2 . . O O
. . . O O
56 . . O O
in . . O O
a . . O O
dominant . . O O
model . . O O
) . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

This . . O O
is . . O O
the . . O O
first . . O O
report . . O O
suggesting . . O O
that . . O O
markers . . O O
in . . O O
genes . . O O
from . . O O
the . . O O
mitochondrial . . O O
oxidative . . O O
chain . . O O
might . . O O
be . . O O
prognostic . . O O
factors . . O O
for . . O O
CRC . . O O
. . . O O

Additional . . O O
studies . . O O
replicating . . O O
the . . O O
presented . . O O
findings . . O O
are . . O O
needed . . O O
. . . O O

A . . O O
mutant . . B-Mutation B-Mutation
allele . . O O
of . . O O
MRE11 . . O O
found . . O O
in . . O O
mismatch . . O O
repair . . O O
- . . O O
deficient . . O O
tumor . . O O
cells . . O O
suppresses . . O O
the . . O O
cellular . . O O
response . . O O
to . . O O
DNA . . O O
replication . . O O
fork . . O O
stress . . O O
in . . O O
a . . O O
dominant . . O O
negative . . O O
manner . . O O
. . . O O

The . . O O
interaction . . O O
of . . O O
ataxia . . O O
- . . O O
telangiectasia . . O O
mutated . . O B-Mutation
( . . O O
ATM . . O O
) . . O O
and . . O O
the . . O O
Mre11 . . O O
/ . . O O
Rad50 . . O O
/ . . O O
Nbs1 . . O O
( . . O O
MRN . . O O
) . . O O
complex . . O O
is . . O O
critical . . O O
for . . O O
the . . O O
response . . O O
of . . O O
cells . . O O
to . . O O
DNA . . O O
double . . O O
- . . O O
strand . . O O
breaks . . O O
; . . O O
however . . O O
, . . O O
little . . O O
is . . O O
known . . O O
of . . O O
the . . O O
role . . O O
of . . O O
these . . O O
proteins . . O O
in . . O O
response . . O O
to . . O O
DNA . . O O
replication . . O O
stress . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
report . . O O
a . . O O
mutant . . B-Mutation B-Mutation
allele . . O O
of . . O O
MRE11 . . O O
found . . O O
in . . O O
a . . O O
colon . . O O
cancer . . O O
cell . . O O
line . . O O
that . . O O
sensitizes . . O O
cells . . O O
to . . O O
agents . . O O
causing . . O O
replication . . O O
fork . . O O
stress . . O O
. . . O O

The . . O O
mutant . . B-Mutation B-Mutation
Mre11 . . O O
weakly . . O O
interacts . . O O
with . . O O
Rad50 . . O O
relative . . O O
to . . O O
wild . . O O
type . . O O
and . . O O
shows . . O O
little . . O O
affinity . . O O
for . . O O
Nbs1 . . O O
. . . O O

The . . O O
mutant . . B-Mutation B-Mutation
protein . . O O
lacks . . O O
3 . . O O
' . . O O
- . . O O
5 . . O O
' . . O O
exonuclease . . O O
activity . . O O
as . . O O
a . . O O
result . . O O
of . . O O
loss . . O B-Mutation
of . . O O
part . . O O
of . . O O
the . . O O
conserved . . O O
nuclease . . O O
domain . . O O
; . . O O
however . . O O
, . . O O
it . . O O
retains . . O O
binding . . O O
affinity . . O O
for . . O O
single . . O O
- . . O O
stranded . . O O
DNA . . O O
( . . O O
ssDNA . . O O
) . . O O
, . . O O
double . . O O
- . . O O
stranded . . O O
DNA . . O O
with . . O O
a . . O O
3 . . O O
' . . O O
single . . O O
- . . O O
strand . . O O
overhang . . O O
, . . O O
and . . O O
fork . . O O
- . . O O
like . . O O
structures . . O O
containing . . O O
ssDNA . . O O
regions . . O O
. . . O O

In . . O O
cells . . O O
, . . O O
the . . O O
mutant . . B-Mutation B-Mutation
protein . . O O
shows . . O O
a . . O O
time . . O O
- . . O O
and . . O O
dose . . O O
- . . O O
dependent . . O O
accumulation . . O O
in . . O O
chromatin . . O O
after . . O O
thymidine . . O O
treatment . . O O
that . . O O
corresponds . . O O
with . . O O
increased . . O O
recruitment . . O O
and . . O O
hyperphosphorylation . . O O
of . . O O
replication . . O O
protein . . O O
A . . O O
. . . O O

ATM . . O O
autophosphorylation . . O O
, . . O O
Mre11 . . O O
foci . . O O
, . . O O
and . . O O
thymidine . . O O
- . . O O
induced . . O O
homologous . . O O
recombination . . O O
are . . O O
suppressed . . O O
in . . O O
cells . . O O
expressing . . O O
the . . O O
mutant . . B-Mutation B-Mutation
allele . . O O
. . . O O

Together . . O O
, . . O O
our . . O O
results . . O O
suggest . . O O
that . . O O
the . . O O
mutant . . B-Mutation B-Mutation
Mre11 . . O O
suppresses . . O O
the . . O O
cellular . . O O
response . . O O
to . . O O
replication . . O O
stress . . O O
by . . O O
binding . . O O
to . . O O
ssDNA . . O O
regions . . O O
at . . O O
disrupted . . O O
forks . . O O
and . . O O
impeding . . O O
replication . . O O
restart . . O O
in . . O O
a . . O O
dominant . . O O
negative . . O O
manner . . O O
. . . O O

Antibody . . O O
to . . O O
ras . . O O
proteins . . O O
in . . O O
patients . . O O
with . . O O
colon . . O O
cancer . . O O
. . . O O

The . . O O
current . . O O
study . . O O
examined . . O O
sera . . O O
from . . O O
160 . . O O
colon . . O O
cancer . . O O
patients . . O O
and . . O O
60 . . O O
normal . . O O
individuals . . O O
to . . O O
determine . . O O
whether . . O O
antibody . . O O
to . . O O
mutated . . B-Mutation B-Mutation
p21 . . O O
ras . . O O
protein . . O O
was . . O O
present . . O O
. . . O O

Studies . . O O
focused . . O O
on . . O O
the . . O O
aspartic . . B-Mutation O
acid . . I-Mutation O
substitution . . I-Mutation B-Mutation
at . . O O
amino . . O O
acid . . O O
position . . O O
12 . . O O
( . . O O
denoted . . O O
D12 . . B-Mutation O
) . . O O
, . . O O
one . . O O
of . . O O
the . . O O
most . . O O
common . . O O
mutations . . B-Mutation B-Mutation
in . . O O
colon . . O O
adenocarcinoma . . O O
. . . O O

IgA . . O O
antibodies . . O O
directed . . O O
against . . O O
mutated . . B-Mutation B-Mutation
p21 . . O O
ras . . O O
- . . O O
D12 . . B-Mutation O
protein . . O O
were . . O O
detected . . O O
in . . O O
51 . . O O
( . . O O
32 . . O O
% . . O O
) . . O O
of . . O O
160 . . O O
colon . . O O
cancer . . O O
patients . . O O
, . . O O
but . . O O
only . . O O
in . . O O
1 . . O O
( . . O O
2 . . O O
. . . O O
5 . . O O
% . . O O
) . . O O
of . . O O
40 . . O O
normal . . O O
individuals . . O O
. . . O O

The . . O O
greater . . O O
incidence . . O O
of . . O O
antibody . . O O
in . . O O
cancer . . O O
patients . . O O
provides . . O O
presumptive . . O O
evidence . . O O
that . . O O
immunization . . O O
to . . O O
the . . O O
ras . . O O
proteins . . O O
occurred . . O O
as . . O O
a . . O O
result . . O O
of . . O O
the . . O O
malignancy . . O O
. . . O O

Examination . . O O
of . . O O
sera . . O O
for . . O O
antibody . . O O
reactivity . . O O
to . . O O
wild . . O O
- . . O O
type . . O O
p21 . . O O
ras . . O O
protein . . O O
( . . O O
denoted . . O O
p21 . . O O
ras . . O O
- . . O O
G12 . . O O
) . . O O
as . . O O
well . . O O
as . . O O
p21 . . O O
ras . . O O
proteins . . O O
bearing . . O O
the . . O O
D12 . . B-Mutation O
, . . O O
V12 . . B-Mutation O
, . . O O
S12 . . B-Mutation O
, . . O O
or . . O O
L61 . . B-Mutation O
mutations . . I-Mutation B-Mutation
showed . . O O
that . . O O
antibody . . O O
detected . . O O
was . . O O
largely . . O O
to . . O O
normal . . O O
segments . . O O
of . . O O
the . . O O
p21 . . O O
ras . . O O
protein . . O O
. . . O O

Epitope . . O O
mapping . . O O
, . . O O
using . . O O
peptide . . O O
neutralization . . O O
assays . . O O
with . . O O
mutated . . B-Mutation B-Mutation
or . . O O
normal . . O O
ras . . O O
peptides . . O O
as . . O O
competitors . . O O
, . . O O
demonstrated . . O O
that . . O O
in . . O O
10 . . O O
( . . O O
67 . . O O
% . . O O
) . . O O
of . . O O
15 . . O O
sera . . O O
examined . . O O
the . . O O
antibody . . O O
reactivity . . O O
to . . O O
p21 . . O O
ras . . O O
- . . O O
G12 . . O O
protein . . O O
was . . O O
neutralized . . O O
by . . O O
peptides . . O O
near . . O O
the . . O O
carboxyl . . O O
terminus . . O O
of . . O O
p21 . . O O
ras . . O O
protein . . O O
, . . O O
but . . O O
not . . O O
by . . O O
peptides . . O O
spanning . . O O
the . . O O
specific . . O O
point . . O O
mutation . . B-Mutation B-Mutation
region . . O O
. . . O O

Antibody . . O O
reactivities . . O O
correlated . . O O
with . . O O
peripheral . . O O
blood . . O O
lymphocyte . . O O
count . . O O
, . . O O
but . . O O
did . . O O
not . . O O
correlate . . O O
with . . O O
patient . . O O
age . . O O
, . . O O
sex . . O O
, . . O O
histology . . O O
, . . O O
stage . . O O
, . . O O
tumor . . O O
locus . . O O
, . . O O
lymph . . O O
node . . O O
metastasis . . O O
, . . O O
or . . O O
serum . . O O
carcinoembryonic . . O O
antigen . . O O
. . . O O

Cells . . O O
with . . O O
pathogenic . . O O
biallelic . . B-Mutation O
mutations . . I-Mutation B-Mutation
in . . O O
the . . O O
human . . O O
MUTYH . . O O
gene . . O O
are . . O O
defective . . O O
in . . O O
DNA . . O O
damage . . O O
binding . . O O
and . . O O
repair . . O O
. . . O O

Inherited . . O O
biallelic . . B-Mutation B-Mutation
mutations . . I-Mutation I-Mutation
in . . O O
the . . O O
human . . O O
MUTYH . . O O
gene . . O O
are . . O O
responsible . . O O
for . . O O
the . . O O
recessive . . O O
syndrome . . O O
- . . O O
- . . O O
adenomatous . . O O
colorectal . . O O
polyposis . . O O
( . . O O
MUTYH . . O O
associated . . O O
polyposis . . O O
, . . O O
MAP . . O O
) . . O O
- . . O O
- . . O O
which . . O O
significantly . . O O
increases . . O O
the . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

Defective . . O O
MUTYH . . O O
activity . . O O
causes . . O O
G . . B-Mutation O
: . . I-Mutation O
C . . I-Mutation B-Mutation
to . . I-Mutation I-Mutation
T . . I-Mutation I-Mutation
: . . I-Mutation O
A . . I-Mutation O
transversions . . I-Mutation B-Mutation
in . . O O
tumour . . O O
APC . . O O
and . . O O
other . . O O
genes . . O O
thereby . . O O
altering . . O O
genomic . . O O
integrity . . O O
. . . O O

We . . O O
report . . O O
that . . O O
of . . O O
the . . O O
four . . O O
established . . O O
cell . . O O
lines . . O O
, . . O O
derived . . O O
from . . O O
patients . . O O
with . . O O
the . . O O
MAP . . O O
phenotype . . O O
and . . O O
containing . . O O
biallelic . . O O
MUTYH . . O O
mutations . . B-Mutation B-Mutation
, . . O O
three . . O O
contain . . O O
altered . . O O
expressions . . O O
of . . O O
MUTYH . . O O
protein . . O O
( . . O O
MUTYH . . O O
Y165C . . B-Mutation B-Mutation
( . . I-Mutation O
- . . I-Mutation O
/ . . I-Mutation O
- . . I-Mutation O
) . . I-Mutation O
, . . O O
MUTYH . . O O
1103delC . . B-Mutation O
/ . . O O
G382D . . B-Mutation O
and . . O O
MUTYH . . O O
Y165C . . B-Mutation B-Mutation
/ . . O O
G382D . . B-Mutation B-Mutation
but . . O O
not . . O O
MUTYH . . O O
G382D . . B-Mutation B-Mutation
( . . I-Mutation O
- . . I-Mutation O
/ . . I-Mutation O
- . . I-Mutation O
) . . I-Mutation O
) . . O O
, . . O O
but . . O O
that . . O O
all . . O O
four . . O O
cell . . O O
lines . . O O
have . . O O
wild . . O O
type . . O O
levels . . O O
of . . O O
MUTYH . . O O
mRNA . . O O
. . . O O

Mutant . . B-Mutation O
MUTYH . . O O
proteins . . O O
in . . O O
these . . O O
four . . O O
cell . . O O
lines . . O O
possess . . O O
significantly . . O O
lowered . . O O
binding . . O O
and . . O O
cleavage . . O O
activities . . O O
with . . O O
heteroduplex . . O O
oligonucleotides . . O O
containing . . O O
A . . B-Mutation O
. . . I-Mutation O
8 . . I-Mutation O
- . . I-Mutation O
oxoG . . I-Mutation O
and . . O O
8 . . B-Mutation O
- . . I-Mutation O
oxoA . . I-Mutation O
. . . I-Mutation O
G . . I-Mutation O
mispairs . . O O
. . . O O

Transfection . . O O
of . . O O
mitochondrial . . O O
or . . O O
nuclear . . O O
MUTYH . . O O
cDNAs . . O O
partially . . O O
correct . . O O
altered . . O O
MUTYH . . O O
expression . . O O
and . . O O
activity . . O O
in . . O O
these . . O O
defective . . O O
cell . . O O
lines . . O O
. . . O O

Finally . . O O
, . . O O
we . . O O
surprisingly . . O O
find . . O O
that . . O O
defective . . O O
MUTYH . . O O
may . . O O
not . . O O
alter . . O O
cell . . O O
survival . . O O
after . . O O
hydrogen . . O O
peroxide . . O O
and . . O O
menadione . . O O
treatments . . O O
. . . O O

The . . O O
Y165C . . B-Mutation O
and . . O O
1103delC . . B-Mutation O
mutations . . I-Mutation B-Mutation
significantly . . O O
reduce . . O O
MUTYH . . O O
protein . . O O
stability . . O O
and . . O O
thus . . O O
repair . . O O
activity . . O O
, . . O O
whereas . . O O
the . . O O
G382D . . B-Mutation O
mutation . . I-Mutation B-Mutation
produces . . O O
dysfunctional . . O O
protein . . O O
only . . O O
suggesting . . O O
different . . O O
functional . . O O
molecular . . O O
mechanisms . . O O
by . . O O
which . . O O
the . . O O
MAP . . O O
phenotype . . O O
may . . O O
contribute . . O O
to . . O O
the . . O O
development . . O O
of . . O O
CRC . . O O
. . . O O

GPX . . O O
Pro198Leu . . B-Mutation B-Mutation
and . . O O
OGG1 . . O O
Ser326Cys . . B-Mutation B-Mutation
polymorphisms . . B-Mutation B-Mutation
and . . O O
risk . . O O
of . . O O
development . . O O
of . . O O
colorectal . . O O
adenomas . . O O
and . . O O
colorectal . . O O
cancer . . O O
. . . O O

Little . . O O
is . . O O
known . . O O
about . . O O
genetic . . O O
risk . . O O
factors . . O O
for . . O O
colorectal . . O O
cancer . . O O
. . . O O

We . . O O
assessed . . O O
the . . O O
association . . O O
between . . O O
polymorphisms . . B-Mutation B-Mutation
in . . O O
two . . O O
genes . . O O
involved . . O O
in . . O O
DNA . . O O
repair . . O O
of . . O O
oxidative . . O O
stress . . O O
, . . O O
GPX . . O O
and . . O O
OGG1 . . O O
, . . O O
and . . O O
risk . . O O
of . . O O
colorectal . . O O
carcinoma . . O O
or . . O O
adenomas . . O O
. . . O O

We . . O O
studied . . O O
166 . . O O
cases . . O O
with . . O O
adenocarcinoma . . O O
, . . O O
974 . . O O
with . . O O
adenomas . . O O
and . . O O
397 . . O O
controls . . O O
recruited . . O O
from . . O O
the . . O O
Norwegian . . O O
cohort . . O O
NORCCAP . . O O
. . . O O

No . . O O
associations . . O O
were . . O O
found . . O O
between . . O O
the . . O O
polymorphism . . B-Mutation B-Mutation
GPX . . O O
Pro198Leu . . B-Mutation B-Mutation
and . . O O
risk . . O O
of . . O O
colorectal . . O O
adenomas . . O O
or . . O O
carcinomas . . O O
. . . O O

Carriers . . O O
of . . O O
the . . O O
variant . . O B-Mutation
allele . . O O
OGG1 . . O O
Ser326Cys . . B-Mutation B-Mutation
polymorphism . . B-Mutation B-Mutation
had . . O O
a . . O O
lowered . . O O
risk . . O O
of . . O O
colorectal . . O O
cancer . . O O
, . . O O
OR . . O O
= . . O O
0 . . O O
. . . O O
56 . . O O
( . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
0 . . O O
. . . O O
33 . . O O
- . . O O
0 . . O O
. . . O O
95 . . O O
) . . O O
, . . O O
while . . O O
no . . O O
association . . O O
were . . O O
found . . O O
with . . O O
risk . . O O
of . . O O
adenomas . . O O
. . . O O

This . . O O
indicates . . O O
that . . O O
a . . O O
low . . O O
repair . . O O
capacity . . O O
of . . O O
oxidative . . O O
DNA . . O O
damage . . O O
may . . O O
not . . O O
be . . O O
a . . O O
risk . . O O
factor . . O O
for . . O O
development . . O O
of . . O O
colorectal . . O O
adenomas . . O O
or . . O O
carcinoma . . O O
. . . O O

[ . . O O
Peculiarities . . O O
of . . O O
regulation . . O O
of . . O O
tumour . . O O
cell . . O O
apoptosis . . O O
] . . O O
. . . O O

Studies . . O O
of . . O O
expression . . O O
of . . O O
BCL . . O O
- . . O O
2 . . O O
gene . . O O
family . . O O
revealed . . O O
abnormal . . O O
regulation . . O O
of . . O O
biosynthesis . . O O
of . . O O
apoptosis . . O O
- . . O O
related . . O O
proteins . . O O
in . . O O
tumour . . O O
cells . . O O
involved . . O O
in . . O O
the . . O O
development . . O O
and . . O O
progress . . O O
of . . O O
neoplastic . . O O
diseases . . O O
. . . O O

Expression . . O O
of . . O O
BCL . . O O
- . . O O
2 . . O O
proteins . . O O
in . . O O
highly . . O O
differentiated . . O O
gastric . . O O
and . . O O
colonic . . O O
tumours . . O O
was . . O O
roughly . . O O
1 . . O O
. . . O O
2 . . O O
times . . O O
lower . . O O
than . . O O
in . . O O
the . . O O
normal . . O O
cells . . O O
. . . O O

A . . O O
3 . . O O
. . . O O
5 . . O O
- . . O O
fold . . O O
rise . . O O
in . . O O
BCL . . O O
- . . O O
2 . . O O
expression . . O O
was . . O O
documented . . O O
in . . O O
a . . O O
group . . O O
of . . O O
moderately . . O O
differentiated . . O O
adenocarcinomas . . O O
and . . O O
undifferentiated . . O O
tumours . . O O
. . . O O

The . . O O
most . . O O
striking . . O O
( . . O O
9 . . O O
- . . O O
fold . . O O
) . . O O
difference . . O O
between . . O O
BCL . . O O
expression . . O O
in . . O O
untransformed . . O O
and . . O O
atypical . . O O
cells . . O O
was . . O O
recorded . . O O
in . . O O
moderately . . O O
differentiated . . O O
metastatic . . O O
colonic . . O O
adenocarcinoma . . O O
. . . O O

Immunohistochemical . . O O
studies . . O O
of . . O O
BAX . . O O
expression . . O O
in . . O O
untransformed . . O O
and . . O O
atypical . . O O
gastric . . O O
and . . O O
colonic . . O O
cells . . O O
demonstrated . . O O
activation . . O O
of . . O O
apoptosis . . O O
- . . O O
inducing . . O O
mechanisms . . O O
in . . O O
the . . O O
pathologically . . O O
changed . . O O
tissue . . O O
. . . O O

Investigations . . O O
with . . O O
the . . O O
use . . O O
of . . O O
SSCP . . O B-Mutation
showed . . O O
that . . O O
20 . . O O
% . . O O
of . . O O
the . . O O
patients . . O O
had . . O O
BAX . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
affecting . . O O
codons . . O O
38 . . O O
to . . O O
41 . . O O
of . . O O
exone . . O O
3 . . O O
. . . O O

This . . O O
region . . O O
was . . O O
found . . O O
to . . O O
contain . . O O
octadeoxyguanosine . . O O
G8 . . O O
sequence . . O O
. . . O O

The . . O O
mutations . . B-Mutation B-Mutation
were . . O O
caused . . O O
by . . O O
deletion . . B-Mutation B-Mutation
of . . O O
G7 . . O O
or . . O O
insertion . . B-Mutation B-Mutation
of . . O O
G9 . . O O
. . . O O

[ . . O O
Immunochemical . . O O
evidence . . O O
of . . O O
a . . O O
mutated . . B-Mutation B-Mutation
p53 . . O O
protein . . O O
expressed . . O O
in . . O O
human . . O O
colorectal . . O O
adenocarcinoma . . O O
] . . O O
. . . O O

Evidence . . O O
is . . O O
accumulating . . O O
that . . O O
the . . O O
p53 . . O O
anti . . O O
- . . O O
oncogene . . O O
is . . O O
a . . O O
key . . O O
gene . . O O
in . . O O
the . . O O
genesis . . O O
of . . O O
carcinoma . . O O
in . . O O
human . . O O
colon . . O O
and . . O O
rectum . . O O
. . . O O

Although . . O O
mutations . . B-Mutation B-Mutation
of . . O O
the . . O O
p53 . . O O
gene . . O O
have . . O O
been . . O O
shown . . O O
to . . O O
be . . O O
frequent . . O O
, . . O O
the . . O O
protein . . O O
was . . O O
present . . O O
in . . O O
only . . O O
approximately . . O O
50 . . O O
percent . . O O
of . . O O
specimens . . O O
examined . . O O
. . . O O

However . . O O
only . . O O
one . . O O
monoclonal . . O O
antibody . . O O
recognizing . . O O
an . . O O
epitope . . O O
present . . O O
on . . O O
wild . . O O
- . . O O
type . . O O
p53 . . O O
had . . O O
been . . O O
used . . O O
. . . O O

We . . O O
studied . . O O
the . . O O
p53 . . O O
expression . . O O
in . . O O
a . . O O
series . . O O
of . . O O
16 . . O O
colorectal . . O O
carcinoma . . O O
specimens . . O O
using . . O O
3 . . O O
different . . O O
monoclonal . . O O
antibodies . . O O
( . . O O
pAb . . O O
421 . . O O
, . . O O
1801 . . O O
, . . O O
240 . . O O
) . . O O
. . . O O

Specific . . O O
immunofluorescent . . O O
staining . . O O
was . . O O
quantified . . O O
by . . O O
dual . . O O
parameter . . O O
( . . O O
DNA . . O O
/ . . O O
p53 . . O O
) . . O O
flow . . O O
cytometry . . O O
. . . O O

Two . . O O
different . . O O
types . . O O
of . . O O
preparations . . O O
were . . O O
compared . . O O
in . . O O
order . . O O
to . . O O
verify . . O O
the . . O O
conservation . . O O
of . . O O
the . . O O
antigen . . O O
. . . O O

Nuclear . . O O
suspensions . . O O
prepared . . O O
from . . O O
frozen . . O O
tumor . . O O
fragments . . O O
were . . O O
shown . . O O
to . . O O
produce . . O O
results . . O O
equivalent . . O O
to . . O O
those . . O O
of . . O O
whole . . O O
cell . . O O
preparations . . O O
originating . . O O
from . . O O
fresh . . O O
surgical . . O O
specimens . . O O
. . . O O

The . . O O
p53 . . O O
protein . . O O
was . . O O
detected . . O O
in . . O O
9 . . O O
of . . O O
the . . O O
16 . . O O
cancers . . O O
with . . O O
pAb . . O O
421 . . O O
and . . O O
240 . . O O
monoclonal . . O O
antibodies . . O O
( . . O O
8 . . O O
of . . O O
which . . O O
were . . O O
also . . O O
positive . . O O
for . . O O
pAb . . O O
1801 . . O O
antibody . . O O
) . . O O
. . . O O

Four . . O O
additional . . O O
tumors . . O O
were . . O O
considered . . O O
positive . . O O
for . . O O
pAb . . O O
240 . . O O
antibody . . O O
alone . . O O
. . . O O

Overall . . O O
, . . O O
13 . . O O
/ . . O O
16 . . O O
cancer . . O O
specimens . . O O
were . . O O
shown . . O O
to . . O O
present . . O O
immunoreactivity . . O O
for . . O O
pAb . . O O
240 . . O O
antibody . . O O
. . . O O

Topography . . O O
of . . O O
staining . . O O
was . . O O
investigated . . O O
by . . O O
immunohistochemistry . . O O
with . . O O
peroxidase . . O O
methods . . O O
. . . O O

Eight . . O O
cases . . O O
were . . O O
informative . . O O
, . . O O
6 . . O O
of . . O O
which . . O O
presented . . O O
nuclear . . O O
staining . . O O
compatible . . O O
with . . O O
the . . O O
cytometry . . O O
results . . O O
. . . O O

There . . O O
was . . O O
one . . O O
discordant . . O O
case . . O O
i . . O O
. . . O O
e . . O O
. . . O O
pAb . . O O
240 . . O O
antibody . . O O
being . . O O
positive . . O O
on . . O O
cytometry . . O O
and . . O O
entirely . . O O
negative . . O O
on . . O O
immunohistochemistry . . O O
. . . O O

This . . O O
small . . O O
series . . O O
allowed . . O O
us . . O O
to . . O O
show . . O O
that . . O O
81 . . O O
percent . . O O
of . . O O
tumor . . O O
samples . . O O
stained . . O O
with . . O O
monoclonal . . O O
antibody . . O O
pAb . . O O
240 . . O O
, . . O O
considered . . O O
to . . O O
be . . O O
specific . . O O
to . . O O
mutated . . B-Mutation B-Mutation
protein . . O O
, . . O O
and . . O O
that . . O O
some . . O O
tumors . . O O
express . . O O
a . . O O
p53 . . O O
protein . . O O
which . . O O
is . . O O
not . . O O
detected . . O O
with . . O O
terminal . . O O
sequence . . O O
- . . O O
specific . . O O
antibodies . . O O
. . . O O

Self . . O O
administered . . O O
screening . . O O
for . . O O
hereditary . . O O
cancers . . O O
in . . O O
conjunction . . O O
with . . O O
mammography . . O O
and . . O O
ultrasound . . O O
. . . O O

We . . O O
evaluated . . O O
the . . O O
feasibility . . O O
of . . O O
an . . O O
automated . . O O
tablet . . O O
computer . . O O
application . . O O
providing . . O O
a . . O O
family . . O O
and . . O O
personal . . O O
history . . O O
based . . O O
cancer . . O O
risk . . O O
assessment . . O O
for . . O O
hereditary . . O O
breast . . O O
, . . O O
ovarian . . O O
, . . O O
endometrial . . O O
and . . O O
colorectal . . O O
cancers . . O O
. . . O O

1 . . O O
, . . O O
002 . . O O
women . . O O
presenting . . O O
for . . O O
screening . . O O
mammography . . O O
and . . O O
1 . . O O
, . . O O
000 . . O O
presenting . . O O
for . . O O
ultrasound . . O O
were . . O O
offered . . O O
screening . . O O
. . . O O

The . . O O
application . . O O
calculated . . O O
the . . O O
risk . . O O
of . . O O
BRCA . . O O
mutations . . B-Mutation B-Mutation
using . . O O
BRCAPRO . . O O
, . . O O
Myriad . . O O
and . . O O
Tyrer . . O O
- . . O O
Cuzick . . O O
risk . . O O
assessment . . O O
models . . O O
. . . O O

Lifetime . . O O
risk . . O O
of . . O O
breast . . O O
and . . O O
ovarian . . O O
cancer . . O O
was . . O O
assessed . . O O
with . . O O
the . . O O
BRCAPRO . . O O
, . . O O
Claus . . O O
and . . O O
Tyrer . . O O
- . . O O
Cuzick . . O O
models . . O O
. . . O O

Colorectal . . O O
and . . O O
endometrial . . O O
cancer . . O O
risk . . O O
was . . O O
calculated . . O O
via . . O O
the . . O O
MMRpro . . O O
model . . O O
. . . O O

Patients . . O O
were . . O O
identified . . O O
as . . O O
high . . O O
- . . O O
risk . . O O
based . . O O
on . . O O
thresholds . . O O
10 . . O O
% . . O O
or . . O O
greater . . O O
risk . . O O
for . . O O
carrying . . O O
genetic . . B-Mutation O
mutations . . I-Mutation B-Mutation
or . . O O
20 . . O O
% . . O O
or . . O O
greater . . O O
lifetime . . O O
risk . . O O
of . . O O
breast . . O O
or . . O O
ovarian . . O O
cancer . . O O
. . . O O

The . . O O
percent . . O O
of . . O O
women . . O O
found . . O O
to . . O O
be . . O O
high . . O O
- . . O O
risk . . O O
by . . O O
a . . O O
single . . O O
risk . . O O
assessment . . O O
tool . . O O
ranged . . O O
from . . O O
0 . . O O
. . . O O
5 . . O O
to . . O O
5 . . O O
. . . O O
3 . . O O
% . . O O
. . . O O

Combining . . O O
assessment . . O O
tools . . O O
found . . O O
9 . . O O
. . . O O
3 . . O O
% . . O O
of . . O O
women . . O O
to . . O O
be . . O O
high . . O O
- . . O O
risk . . O O
. . . O O

The . . O O
risk . . O O
assessments . . O O
performed . . O O
similarly . . O O
for . . O O
the . . O O
mammography . . O O
and . . O O
ultrasound . . O O
cohorts . . O O
with . . O O
yields . . O O
( . . O O
combining . . O O
assessment . . O O
tools . . O O
) . . O O
of . . O O
9 . . O O
. . . O O
2 . . O O
and . . O O
9 . . O O
. . . O O
4 . . O O
% . . O O
respectively . . O O
. . . O O

The . . O O
average . . O O
ages . . O O
of . . O O
all . . O O
the . . O O
high . . O O
- . . O O
risk . . O O
women . . O O
were . . O O
45 . . O O
. . . O O
8 . . O O
and . . O O
39 . . O O
. . . O O
6 . . O O
years . . O O
for . . O O
the . . O O
mammography . . O O
and . . O O
ultrasound . . O O
cohorts . . O O
respectively . . O O
. . . O O

Difficulties . . O O
encountered . . O O
included . . O O
a . . O O
need . . O O
for . . O O
software . . O O
upgrade . . O O
, . . O O
wireless . . O O
network . . O O
unreliability . . O O
and . . O O
hardware . . O O
theft . . O O
. . . O O

Automated . . O O
family . . O O
history . . O O
screening . . O O
can . . O O
identify . . O O
women . . O O
probably . . O O
at . . O O
high . . O O
- . . O O
risk . . O O
for . . O O
hereditary . . O O
cancers . . O O
efficiently . . O O
. . . O O

The . . O O
number . . O O
of . . O O
women . . O O
identified . . O O
is . . O O
increased . . O O
by . . O O
employing . . O O
multiple . . O O
risk . . O O
assessment . . O O
models . . O O
simultaneously . . O O
. . . O O

Surveying . . O O
women . . O O
in . . O O
conjunction . . O O
with . . O O
ultrasound . . O O
identified . . O O
women . . O O
at . . O O
increased . . O O
risk . . O O
as . . O O
effectively . . O O
and . . O O
at . . O O
a . . O O
younger . . O O
age . . O O
than . . O O
with . . O O
screening . . O O
mammography . . O O
. . . O O

Large . . O O
- . . O O
scale . . O O
evaluation . . O O
of . . O O
genetic . . O O
variants . . B-Mutation B-Mutation
in . . O O
candidate . . O O
genes . . O O
for . . O O
colorectal . . O O
cancer . . O O
risk . . O O
in . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
and . . O O
the . . O O
Health . . O O
Professionals . . O O
' . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
. . . O O

Advances . . O O
in . . O O
genomics . . O O
offer . . O O
new . . O O
strategies . . O O
for . . O O
assessing . . O O
the . . O O
association . . O O
of . . O O
common . . O O
genetic . . O O
variations . . B-Mutation B-Mutation
at . . O O
multiple . . O O
loci . . O O
and . . O O
risk . . O O
of . . O O
many . . O O
diseases . . O O
, . . O O
including . . O O
colorectal . . O O
cancer . . O O
. . . O O

Low . . O O
- . . O O
penetrance . . O O
alleles . . O O
of . . O O
genes . . O O
in . . O O
many . . O O
biological . . O O
pathways . . O O
, . . O O
such . . O O
as . . O O
DNA . . O O
repair . . O O
, . . O O
metabolism . . O O
, . . O O
inflammation . . O O
, . . O O
cell . . O O
cycle . . O O
, . . O O
apoptosis . . O O
, . . O O
and . . O O
Wnt . . O O
signaling . . O O
, . . O O
may . . O O
influence . . O O
the . . O O
risk . . O O
of . . O O
nonfamilial . . O O
colorectal . . O O
cancer . . O O
. . . O O

To . . O O
identify . . O O
susceptibility . . O O
genes . . O O
for . . O O
colorectal . . O O
cancer . . O O
, . . O O
we . . O O
designed . . O O
a . . O O
large . . O O
- . . O O
scale . . O O
case . . O O
- . . O O
control . . O O
association . . O O
study . . O O
nested . . O O
within . . O O
the . . O O
Nurses . . O O
' . . O O
Health . . O O
Study . . O O
( . . O O
190 . . O O
cases . . O O
and . . O O
190 . . O O
controls . . O O
) . . O O
and . . O O
the . . O O
Health . . O O
Professionals . . O O
' . . O O
Follow . . O O
- . . O O
up . . O O
Study . . O O
( . . O O
168 . . O O
cases . . O O
and . . O O
168 . . O O
controls . . O O
) . . O O
. . . O O

We . . O O
used . . O O
a . . O O
custom . . O O
GoldenGate . . O O
( . . O O
Illumina . . O O
) . . O O
oligonucleotide . . O O
pool . . O O
assay . . O O
including . . O O
1 . . O O
, . . O O
536 . . O O
single . . B-Mutation B-Mutation
nucleotide . . I-Mutation I-Mutation
polymorphisms . . I-Mutation I-Mutation
( . . O O
SNP . . B-Mutation B-Mutation
) . . O O
selected . . O O
in . . O O
candidate . . O O
genes . . O O
from . . O O
cancer . . O O
- . . O O
related . . O O
pathways . . O O
, . . O O
which . . O O
have . . O O
been . . O O
sequenced . . O O
and . . O O
genotyped . . O O
in . . O O
the . . O O
SNP500Cancer . . B-Mutation O
project . . O O
; . . O O
1 . . O O
, . . O O
412 . . O O
of . . O O
the . . O O
1 . . O O
, . . O O
536 . . O O
( . . O O
92 . . O O
% . . O O
) . . O O
of . . O O
the . . O O
SNPs . . B-Mutation B-Mutation
were . . O O
genotyped . . O O
successfully . . O O
within . . O O
388 . . O O
genes . . O O
. . . O O

SNPs . . B-Mutation B-Mutation
in . . O O
high . . O O
linkage . . O O
disequilibrium . . O O
( . . O O
r . . O O
( . . O O
2 . . O O
) . . O O
> . . O O
/ . . O O
= . . O O
0 . . O O
. . . O O
90 . . O O
) . . O O
with . . O O
another . . O O
assayed . . O O
SNP . . B-Mutation B-Mutation
were . . O O
excluded . . O O
from . . O O
further . . O O
analyses . . O O
. . . O O

As . . O O
expected . . O O
by . . O O
chance . . O O
( . . O O
and . . O O
not . . O O
significant . . O O
compared . . O O
with . . O O
a . . O O
corrected . . O O
Bonferroni . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
00004 . . O O
) . . O O
, . . O O
in . . O O
the . . O O
additive . . O O
model . . O O
, . . O O
11 . . O O
of . . O O
1 . . O O
, . . O O
253 . . O O
( . . O O
0 . . O O
. . . O O
9 . . O O
% . . O O
) . . O O
SNPs . . B-Mutation B-Mutation
had . . O O
a . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
< . . O O
0 . . O O
. . . O O
01 . . O O
and . . O O
38 . . O O
of . . O O
1 . . O O
, . . O O
253 . . O O
( . . O O
3 . . O O
. . . O O
0 . . O O
% . . O O
) . . O O
SNPs . . B-Mutation B-Mutation
had . . O O
a . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
> . . O O
/ . . O O
= . . O O
0 . . O O
. . . O O
01 . . O O
and . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
< . . O O
0 . . O O
. . . O O
05 . . O O
. . . O O

Of . . O O
note . . O O
, . . O O
the . . O O
MGMT . . O O
Lys . . B-Mutation B-Mutation
( . . I-Mutation O
178 . . I-Mutation O
) . . I-Mutation O
Arg . . I-Mutation O
( . . O O
rs2308237 . . B-Mutation B-Mutation
) . . O O
SNP . . B-Mutation B-Mutation
, . . O O
in . . O O
linkage . . O O
disequilibrium . . O O
with . . O O
the . . O O
previously . . O O
reported . . O O
MGMT . . O O
Ile . . B-Mutation O
( . . I-Mutation O
143 . . I-Mutation O
) . . I-Mutation O
Val . . I-Mutation O
SNP . . B-Mutation B-Mutation
, . . O O
had . . O O
an . . O O
inverse . . O O
association . . O O
with . . O O
colorectal . . O O
cancer . . O O
risk . . O O
( . . O O
MGMT . . O O
Lys . . B-Mutation B-Mutation
( . . I-Mutation O
178 . . I-Mutation O
) . . I-Mutation O
Arg . . I-Mutation O
: . . O O
odds . . O O
ratio . . O O
, . . O O
0 . . O O
. . . O O
52 . . O O
; . . O O
95 . . O O
% . . O O
confidence . . O O
interval . . O O
, . . O O
0 . . O O
. . . O O
35 . . O O
- . . O O
0 . . O O
. . . O O
78 . . O O
; . . O O
unadjusted . . O O
P . . O O
( . . O O
trend . . O O
) . . O O
= . . O O
0 . . O O
. . . O O
0003 . . O O
for . . O O
the . . O O
additive . . O O
model . . O O
; . . O O
gene . . O O
- . . O O
based . . O O
test . . O O
global . . O O
P . . O O
= . . O O
0 . . O O
. . . O O
00003 . . O O
) . . O O
. . . O O

The . . O O
SNP500Cancer . . B-Mutation O
database . . O O
and . . O O
the . . O O
Illumina . . O O
GoldenGate . . O O
Assay . . O O
allowed . . O O
us . . O O
to . . O O
test . . O O
a . . O O
larger . . O O
number . . O O
of . . O O
SNPs . . B-Mutation B-Mutation
than . . O O
previously . . O O
possible . . O O
. . . O O

We . . O O
identified . . O O
several . . O O
SNPs . . B-Mutation B-Mutation
worthy . . O O
of . . O O
investigation . . O O
in . . O O
larger . . O O
studies . . O O
. . . O O

Phase . . O O
I . . O O
pharmacokinetic . . O O
and . . O O
pharmacodynamic . . O O
study . . O O
of . . O O
cetuximab . . O O
, . . O O
irinotecan . . O O
and . . O O
sorafenib . . O O
in . . O O
advanced . . O O
colorectal . . O O
cancer . . O O
. . . O O

Background . . O O
This . . O O
phase . . O O
Ib . . O O
study . . O O
was . . O O
designed . . O O
to . . O O
determine . . O O
the . . O O
maximum . . O O
tolerated . . O O
doses . . O O
( . . O O
MTD . . O O
) . . O O
and . . O O
dose . . O O
limiting . . O O
toxicities . . O O
( . . O O
DLTs . . O O
) . . O O
of . . O O
irinotecan . . O O
and . . O O
cetuximab . . O O
with . . O O
sorafenib . . O O
. . . O O

Secondary . . O O
objectives . . O O
included . . O O
characterizing . . O O
the . . O O
pharmacokinetics . . O O
and . . O O
pharmacodynamics . . O O
and . . O O
evaluating . . O O
preliminary . . O O
antitumor . . O O
activity . . O O
in . . O O
patients . . O O
with . . O O
advanced . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
. . . O O

Methods . . O O
Patients . . O O
with . . O O
metastatic . . O O
, . . O O
pretreated . . O O
CRC . . O O
were . . O O
treated . . O O
at . . O O
five . . O O
dose . . O O
levels . . O O
. . . O O

Results . . O O
Eighteen . . O O
patients . . O O
were . . O O
recruited . . O O
with . . O O
median . . O O
age . . O O
56 . . O O
. . . O O
5 . . O O
years . . O O
. . . O O

In . . O O
the . . O O
first . . O O
five . . O O
patients . . O O
treated . . O O
, . . O O
2 . . O O
irinotecan . . O O
related . . O O
DLTs . . O O
were . . O O
observed . . O O
. . . O O

With . . O O
reduced . . O O
dose . . O O
intensity . . O O
irinotecan . . O O
, . . O O
there . . O O
were . . O O
no . . O O
further . . O O
DLTs . . O O
. . . O O

The . . O O
most . . O O
common . . O O
toxicities . . O O
were . . O O
diarrhea . . O O
, . . O O
nausea . . O O
/ . . O O
vomiting . . O O
, . . O O
fatigue . . O O
, . . O O
anorexia . . O O
and . . O O
rash . . O O
. . . O O

DLTs . . O O
included . . O O
neutropenia . . O O
and . . O O
thrombocytopenia . . O O
. . . O O

Two . . O O
patients . . O O
had . . O O
partial . . O O
responses . . O O
( . . O O
one . . O O
with . . O O
a . . O O
KRAS . . O O
mutation . . B-Mutation B-Mutation
) . . O O
and . . O O
8 . . O O
had . . O O
stable . . O O
disease . . O O
( . . O O
8 . . O O
- . . O O
36 . . O O
weeks . . O O
) . . O O
. . . O O

The . . O O
median . . O O
progression . . O O
free . . O O
survival . . O O
( . . O O
PFS . . O O
) . . O O
and . . O O
overall . . O O
survival . . O O
( . . O O
OS . . O O
) . . O O
were . . O O
2 . . O O
. . . O O
5 . . O O
and . . O O
4 . . O O
. . . O O
7 . . O O
months . . O O
respectively . . O O
. . . O O

Pharmacokinetic . . O O
analyses . . O O
suggest . . O O
sorafenib . . O O
and . . O O
metabolite . . O O
exposure . . O O
correlate . . O O
with . . O O
OS . . O O
and . . O O
DLTs . . O O
. . . O O

Conclusions . . O O
The . . O O
recommended . . O O
phase . . O O
II . . O O
dose . . O O
( . . O O
RP2D . . O O
) . . O O
is . . O O
irinotecan . . O O
100 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
days . . O O
1 . . O O
, . . O O
8 . . O O
; . . O O
cetuximab . . O O
400 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
days . . O O
1 . . O O
and . . O O
250 . . O O
mg . . O O
/ . . O O
m . . O O
( . . O O
2 . . O O
) . . O O
i . . O O
. . . O O
v . . O O
. . . O O
weekly . . O O
; . . O O
and . . O O
sorafenib . . O O
400 . . O O
mg . . O O
orally . . O O
twice . . O O
daily . . O O
in . . O O
advanced . . O O
, . . O O
pretreated . . O O
CRC . . O O
. . . O O

The . . O O
combination . . O O
resulted . . O O
in . . O O
a . . O O
modest . . O O
response . . O O
rate . . O O
. . . O O

Allelic . . O O
status . . O O
of . . O O
chromosomes . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
[ . . O O
corrected . . O O
] . . O O
3p . . O O
and . . O O
their . . O O
clinical . . O O
usefulness . . O O
in . . O O
colorectal . . O O
cancer . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

To . . O O
determine . . O O
whether . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
chromosomes . . O O
is . . O O
clinically . . O O
useful . . O O
in . . O O
colorectal . . O O
cancer . . O O
, . . O O
the . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
at . . O O
chromosomes . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
and . . O O
3p . . O O
and . . O O
their . . O O
relationships . . O O
with . . O O
the . . O O
clinicopathological . . O O
features . . O O
in . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
patients . . O O
, . . O O
who . . O O
had . . O O
undergone . . O O
curative . . O O
surgery . . O O
without . . O O
adjuvant . . O O
chemotherapy . . O O
, . . O O
were . . O O
examined . . O O
. . . O O

# . . O O
# . . O O
MATERIALS . . O O
AND . . O O
METHODS . . O O

The . . O O
allelic . . O O
status . . O O
at . . O O
17p . . O O
, . . O O
18q . . O O
, . . O O
22q . . O O
and . . O O
3p . . O O
was . . O O
analyzed . . O O
by . . O O
PCR . . O O
- . . O O
SSCP . . O O
( . . O O
polymerase . . O O
chain . . O O
reaction . . O O
single . . O O
- . . O O
strand . . O O
conformation . . O O
polymorphism . . O O
) . . O O
in . . O O
139 . . O O
CRC . . O O
from . . O O
patients . . O O
who . . O O
had . . O O
undergone . . O O
curative . . O O
surgery . . O O
between . . O O
October . . O O
1994 . . O O
and . . O O
June . . O O
1996 . . O O
. . . O O

The . . O O
relationships . . O O
between . . O O
these . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
and . . O O
the . . O O
clinicopathological . . O O
features . . O O
were . . O O
investigated . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

The . . O O
lymph . . O O
node . . O O
status . . O O
was . . O O
significantly . . O O
associated . . O O
with . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
17p . . O O
, . . O O
18q . . O O
and . . O O
22q . . O O
. . . O O

The . . O O
tumor . . O O
site . . O O
and . . O O
tumor . . O O
differentiation . . O O
were . . O O
significantly . . O O
associated . . O O
with . . O O
the . . O O
allelic . . O O
status . . O O
of . . O O
18q . . O O
. . . O O

When . . O O
patients . . O O
with . . O O
more . . O O
than . . O O
two . . O O
allelic . . B-Mutation O
losses . . I-Mutation O
were . . O O
defined . . O O
as . . O O
the . . O O
high . . O O
allelic . . B-Mutation O
loss . . I-Mutation B-Mutation
group . . O O
and . . O O
those . . O O
with . . O O
no . . O O
, . . O O
or . . O O
only . . O O
one . . O O
allelic . . B-Mutation O
loss . . I-Mutation B-Mutation
were . . O O
defined . . O O
as . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation B-Mutation
group . . O O
, . . O O
it . . O O
was . . O O
found . . O O
that . . O O
the . . O O
lymph . . O O
node . . O O
involvement . . O O
was . . O O
significantly . . O O
higher . . O O
in . . O O
the . . O O
high . . O O
than . . O O
in . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation B-Mutation
group . . O O
. . . O O

Only . . O O
three . . O O
out . . O O
of . . O O
25 . . O O
patients . . O O
in . . O O
the . . O O
low . . O O
allelic . . B-Mutation O
loss . . I-Mutation B-Mutation
group . . O O
had . . O O
lymph . . O O
node . . O O
metastasis . . O O
, . . O O
and . . O O
15 . . O O
patients . . O O
in . . O O
this . . O O
group . . O O
without . . O O
lymphatic . . O O
invasion . . O O
had . . O O
no . . O O
lymph . . O O
node . . O O
metastasis . . O O
. . . O O

There . . O O
was . . O O
no . . O O
relationship . . O O
between . . O O
the . . O O
allelic . . O O
status . . O O
and . . O O
survival . . O O
at . . O O
any . . O O
stage . . O O
. . . O O

# . . O O
# . . O O
CONCLUSION . . O O

The . . O O
allelic . . O O
status . . O O
was . . O O
significantly . . O O
associated . . O O
with . . O O
lymph . . O O
node . . O O
metastasis . . O O
. . . O O

A . . O O
combination . . O O
of . . O O
allelic . . O O
status . . O O
and . . O O
lymphatic . . O O
invasion . . O O
assessment . . O O
can . . O O
predict . . O O
the . . O O
lymph . . O O
node . . O O
status . . O O
before . . O O
radical . . O O
surgery . . O O
. . . O O

Transcriptional . . O O
regulation . . O O
of . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
expression . . O O
by . . O O
nitric . . O O
oxide . . O O
in . . O O
colon . . O O
cancer . . O O
cell . . O O
lines . . O O
. . . O O

To . . O O
determine . . O O
the . . O O
effect . . O O
of . . O O
nitric . . O O
oxide . . O O
( . . O O
NO . . O O
) . . O O
on . . O O
the . . O O
cyclooxygenase . . O O
- . . O O
2 . . O O
( . . O O
COX . . O O
- . . O O
2 . . O O
) . . O O
regulation . . O O
in . . O O
colon . . O O
cancer . . O O
cell . . O O
lines . . O O
we . . O O
used . . O O
the . . O O
physiological . . O O
NO . . O O
donor . . O O
GSNO . . O O
. . . O O

The . . O O
proximal . . O O
6 . . O O
. . . O O
6 . . O O
kb . . O O
of . . O O
the . . O O
COX . . O O
- . . O O
2 . . O O
promoter . . O O
was . . O O
cloned . . O O
into . . O O
the . . O O
pGL3 . . O O
basic . . O O
vector . . O O
and . . O O
the . . O O
sequential . . O O
deletion . . B-Mutation B-Mutation
of . . O O
the . . O O
6 . . O O
. . . O O
6 . . O O
kb . . O O
COX . . O O
- . . O O
2 . . O O
promoter . . O O
generated . . O O
promoter . . O O
constructs . . O O
of . . O O
4 . . O O
, . . O O
2 . . O O
. . . O O
6 . . O O
, . . O O
1 . . O O
. . . O O
9 . . O O
and . . O O
0 . . O O
. . . O O
9 . . O O
kb . . O O
. . . O O

These . . O O
constructs . . O O
clearly . . O O
show . . O O
that . . O O
the . . O O
main . . O O
regulatory . . O O
region . . O O
lies . . O O
within . . O O
0 . . O O
. . . O O
9 . . O O
kb . . O O
of . . O O
the . . O O
transcription . . O O
start . . O O
site . . O O
. . . O O

Therefore . . O O
, . . O O
constructs . . O O
of . . O O
the . . O O
main . . O O
transcription . . O O
binding . . O O
sites . . O O
within . . O O
this . . O O
region . . O O
namely . . O O
CRE . . O O
, . . O O
NF . . O O
- . . O O
IL6 . . O O
and . . O O
NF . . O O
- . . O O
kappaB . . O O
and . . O O
mutations . . B-Mutation B-Mutation
of . . O O
these . . O O
sites . . O O
were . . O O
used . . O O
to . . O O
monitor . . O O
the . . O O
transcriptional . . O O
activation . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
. . . O O

This . . O O
study . . O O
was . . O O
performed . . O O
on . . O O
the . . O O
colon . . O O
cancer . . O O
cell . . O O
lines . . O O
HCA7 . . O O
and . . O O
HCT116 . . O O
which . . O O
have . . O O
a . . O O
differential . . O O
expression . . O O
of . . O O
COX . . O O
- . . O O
2 . . O O
. . . O O

There . . O O
was . . O O
no . . O O
evidence . . O O
that . . O O
the . . O O
luciferase . . O O
activity . . O O
is . . O O
negatively . . O O
affected . . O O
by . . O O
NO . . O O
as . . O O
was . . O O
previously . . O O
reported . . O O
. . . O O

The . . O O
CRE . . O O
and . . O O
NF . . O O
- . . O O
IL6 . . O O
binding . . O O
sites . . O O
within . . O O
this . . O O
region . . O O
were . . O O
responsible . . O O
for . . O O
the . . O O
constitutive . . O O
and . . O O
physiological . . O O
NO . . O O
- . . O O
induced . . O O
COX . . O O
- . . O O
2 . . O O
transcriptional . . O O
activity . . O O
in . . O O
the . . O O
HCA7 . . O O
and . . O O
HCT116 . . O O
cells . . O O
. . . O O

While . . O O
NF . . O O
- . . O O
kappaB . . O O
involvement . . O O
was . . O O
only . . O O
observed . . O O
in . . O O
the . . O O
HCT116 . . O O
cells . . O O
, . . O O
the . . O O
cell . . O O
lines . . O O
displayed . . O O
increased . . O O
NF . . O O
- . . O O
kappaB . . O O
transcriptional . . O O
activity . . O O
after . . O O
exposure . . O O
to . . O O
NO . . O O
. . . O O

Childhood . . O O
brain . . O O
tumours . . O O
due . . O O
to . . O O
germline . . O O
bi . . O O
- . . O O
allelic . . O O
mismatch . . O O
repair . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Childhood . . O O
brain . . O O
tumours . . O O
may . . O O
be . . O O
due . . O O
to . . O O
germline . . O O
bi . . O O
- . . O O
allelic . . O O
mismatch . . O O
repair . . O O
( . . O O
MMR . . O O
) . . O O
gene . . O O
mutations . . B-Mutation B-Mutation
in . . O O
MLH1 . . O O
, . . O O
MSH2 . . O O
, . . O O
MSH6 . . O O
or . . O O
PMS2 . . O O
. . . O O

These . . O O
mutations . . B-Mutation B-Mutation
can . . O O
also . . O O
lead . . O O
to . . O O
colorectal . . O O
neoplasia . . O O
and . . O O
haematological . . O O
malignancies . . O O
. . . O O

Here . . O O
, . . O O
we . . O O
review . . O O
this . . O O
syndrome . . O O
and . . O O
present . . O O
siblings . . O O
with . . O O
early . . O O
- . . O O
onset . . O O
rectal . . O O
adenoma . . O O
and . . O O
papillary . . O O
glioneural . . O O
brain . . O O
tumour . . O O
, . . O O
respectively . . O O
, . . O O
due . . O O
to . . O O
novel . . O O
germline . . O O
bi . . O O
- . . O O
allelic . . O O
PMS2 . . O O
mutations . . B-Mutation B-Mutation
. . . O O

Identification . . O O
of . . O O
MMR . . O O
protein . . O O
defects . . O B-Mutation
can . . O O
lead . . O O
to . . O O
early . . O O
diagnosis . . O O
of . . O O
this . . O O
condition . . O O
. . . O O

In . . O O
addition . . O O
, . . O O
assays . . O O
for . . O O
these . . O O
defects . . O O
may . . O O
help . . O O
to . . O O
classify . . O O
brain . . O O
tumours . . O O
for . . O O
research . . O O
protocols . . O O
aimed . . O O
at . . O O
targeted . . O O
therapies . . O O
. . . O O

Colorectal . . O O
carcinoma . . O O
. . . O O

DNA . . B-Mutation O
ploidy . . I-Mutation O
pattern . . I-Mutation O
and . . O O
prognosis . . O O
with . . O O
reference . . O O
to . . O O
tumor . . O O
DNA . . B-Mutation O
heterogeneity . . I-Mutation O
. . . O O

Nuclear . . O O
DNA . . O O
content . . O O
was . . O O
measured . . O O
in . . O O
72 . . O O
colorectal . . O O
carcinomas . . O O
using . . O O
single . . O O
- . . O O
cell . . O O
microspectrophotometry . . O O
on . . O O
Feulgen . . O O
- . . O O
stained . . O O
smears . . O O
. . . O O

Four . . O O
samples . . O O
were . . O O
analyzed . . O O
from . . O O
each . . O O
tumor . . O O
. . . O O

Patients . . O O
were . . O O
followed . . O O
for . . O O
41 . . O O
- . . O O
65 . . O O
months . . O O
( . . O O
average . . O O
, . . O O
53 . . O O
) . . O O
. . . O O

DNA . . B-Mutation O
heterogeneity . . I-Mutation O
( . . O O
both . . O O
aneuploid . . B-Mutation O
and . . O O
nonaneuploid . . B-Mutation O
patterns . . O O
) . . O O
was . . O O
present . . O O
in . . O O
44 . . O O
% . . O O
of . . O O
the . . O O
cases . . O O
. . . O O

Sixty . . O O
- . . O O
eight . . O O
percent . . O O
of . . O O
the . . O O
tumors . . O O
showed . . O O
an . . O O
aneuploid . . B-Mutation O
DNA . . O O
pattern . . O O
in . . O O
at . . O O
least . . O O
one . . O O
of . . O O
the . . O O
samples . . O O
. . . O O

Patients . . O O
with . . O O
nonaneuploid . . B-Mutation O
tumors . . O O
tended . . O O
to . . O O
have . . O O
a . . O O
survival . . O O
advantage . . O O
over . . O O
patients . . O O
with . . O O
homogeneously . . O O
aneuploid . . B-Mutation O
tumors . . O O
and . . O O
demonstrated . . O O
a . . O O
significantly . . O O
longer . . O O
disease . . O O
- . . O O
free . . O O
survival . . O O
. . . O O

The . . O O
DNA . . B-Mutation O
ploidy . . I-Mutation O
pattern . . O O
is . . O O
of . . O O
potential . . O O
value . . O O
in . . O O
conjunction . . O O
with . . O O
histopathologic . . O O
prognostic . . O O
parameters . . O O
in . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

Since . . O O
colorectal . . O O
tumors . . O O
exhibit . . O O
pronounced . . O O
DNA . . B-Mutation O
heterogeneity . . I-Mutation O
, . . O O
multiple . . O O
samples . . O O
are . . O O
required . . O O
from . . O O
each . . O O
tumor . . O O
to . . O O
permit . . O O
a . . O O
proper . . O O
evaluation . . O O
of . . O O
its . . O O
DNA . . O O
pattern . . O O
. . . O O

The . . O O
DNA . . B-Mutation O
heterogeneity . . I-Mutation O
may . . O O
represent . . O O
tumor . . O O
progression . . O O
and . . O O
can . . O O
partly . . O O
explain . . O O
the . . O O
conflicting . . O O
results . . O O
reported . . O O
concerning . . O O
DNA . . O O
pattern . . O O
and . . O O
prognosis . . O O
in . . O O
colorectal . . O O
carcinoma . . O O
. . . O O

BRAF . . O O
mutation . . B-Mutation B-Mutation
status . . O O
and . . O O
survival . . O O
after . . O O
colorectal . . O O
cancer . . O O
diagnosis . . O O
according . . O O
to . . O O
patient . . O O
and . . O O
tumor . . O O
characteristics . . O O
. . . O O

# . . O O
# . . O O
BACKGROUND . . O O

BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
colorectal . . O O
cancer . . O O
( . . O O
CRC . . O O
) . . O O
are . . O O
disproportionately . . O O
observed . . O O
in . . O O
tumors . . O O
exhibiting . . O O
microsatellite . . B-Mutation B-Mutation
instability . . I-Mutation I-Mutation
( . . O O
MSI . . B-Mutation B-Mutation
) . . O O
and . . O O
are . . O O
associated . . O O
with . . O O
other . . O O
prognostic . . O O
factors . . O O
. . . O O

The . . O O
independent . . O O
association . . O O
between . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
status . . O O
and . . O O
CRC . . O O
survival . . O O
, . . O O
however . . O O
, . . O O
remains . . O O
unclear . . O O
. . . O O

# . . O O
# . . O O
METHODS . . O O

We . . O O
evaluated . . O O
the . . O O
association . . O O
between . . O O
the . . O O
BRAF . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
1799T . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
( . . O O
p . . B-Mutation O
. . . I-Mutation O
V600E . . I-Mutation B-Mutation
) . . O O
mutation . . B-Mutation B-Mutation
and . . O O
survival . . O O
in . . O O
individuals . . O O
with . . O O
incident . . O O
invasive . . O O
CRC . . O O
diagnosed . . O O
between . . O O
1997 . . O O
and . . O O
2007 . . O O
in . . O O
Western . . O O
Washington . . O O
State . . O O
. . . O O

Tumor . . O O
specimens . . O O
were . . O O
tested . . O O
for . . O O
this . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
and . . O O
MSI . . B-Mutation B-Mutation
status . . O O
. . . O O

We . . O O
used . . O O
Cox . . O O
regression . . O O
to . . O O
estimate . . O O
HRs . . O O
and . . O O
95 . . O O
% . . O O
confidence . . O O
intervals . . O O
( . . O O
CI . . O O
) . . O O
for . . O O
the . . O O
association . . O O
between . . O O
BRAF . . O O
mutation . . B-Mutation B-Mutation
status . . O O
and . . O O
disease . . O O
- . . O O
specific . . O O
and . . O O
overall . . O O
survival . . O O
. . . O O

Stratified . . O O
analyses . . O O
were . . O O
conducted . . O O
by . . O O
age . . O O
, . . O O
sex . . O O
, . . O O
tumor . . O O
site . . O O
, . . O O
stage . . O O
, . . O O
and . . O O
MSI . . B-Mutation B-Mutation
status . . O O
. . . O O

# . . O O
# . . O O
RESULTS . . O O

Among . . O O
1 . . O O
, . . O O
980 . . O O
cases . . O O
tested . . O O
, . . O O
12 . . O O
% . . O O
were . . O O
BRAF . . O O
c . . B-Mutation B-Mutation
. . . I-Mutation I-Mutation
1799T . . I-Mutation I-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
( . . O O
p . . B-Mutation O
. . . I-Mutation O
V600E . . I-Mutation B-Mutation
) . . O O
mutation . . B-Mutation B-Mutation
- . . O O
positive . . O O
( . . O O
n . . O O
= . . O O
247 . . O O
) . . O O
. . . O O

BRAF . . O O
- . . O O
mutated . . B-Mutation B-Mutation
CRC . . O O
was . . O O
associated . . O O
with . . O O
poorer . . O O
disease . . O O
- . . O O
specific . . O O
survival . . O O
adjusting . . O O
for . . O O
age . . O O
, . . O O
sex . . O O
, . . O O
time . . O O
from . . O O
diagnosis . . O O
to . . O O
enrollment . . O O
, . . O O
stage . . O O
, . . O O
and . . O O
MSI . . B-Mutation B-Mutation
status . . O O
( . . O O
HR . . O O
, . . O O
1 . . O O
. . . O O
43 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
1 . . O O
. . . O O
05 . . O O
- . . O O
1 . . O O
. . . O O
95 . . O O
) . . O O
. . . O O

This . . O O
association . . O O
was . . O O
limited . . O O
to . . O O
cases . . O O
diagnosed . . O O
at . . O O
ages . . O O
< . . O O
50 . . O O
( . . O O
HR . . O O
, . . O O
3 . . O O
. . . O O
06 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
1 . . O O
. . . O O
70 . . O O
- . . O O
5 . . O O
. . . O O
52 . . O O
) . . O O
and . . O O
was . . O O
not . . O O
evident . . O O
in . . O O
cases . . O O
with . . O O
MSI . . B-Mutation B-Mutation
- . . O O
high . . O O
tumors . . O O
( . . O O
HR . . O O
, . . O O
0 . . O O
. . . O O
94 . . O O
; . . O O
95 . . O O
% . . O O
CI . . O O
, . . O O
0 . . O O
. . . O O
44 . . O O
- . . O O
2 . . O O
. . . O O
03 . . O O
) . . O O
. . . O O

Associations . . O O
with . . O O
overall . . O O
survival . . O O
were . . O O
similar . . O O
. . . O O

# . . O O
# . . O O
CONCLUSIONS . . O O

Our . . O O
results . . O O
show . . O O
that . . O O
the . . O O
prevalence . . O O
of . . O O
BRAF . . O O
mutations . . B-Mutation B-Mutation
in . . O O
CRC . . O O
differs . . O O
by . . O O
patient . . O O
and . . O O
tumor . . O O
characteristics . . O O
and . . O O
suggest . . O O
that . . O O
the . . O O
association . . O O
between . . O O
BRAF . . O O
status . . O O
and . . O O
CRC . . O O
survival . . O O
may . . O O
differ . . O O
by . . O O
some . . O O
of . . O O
these . . O O
factors . . O O
. . . O O

# . . O O
# . . O O
IMPACT . . O O

The . . O O
presence . . O O
of . . O O
a . . O O
BRAF . . O O
c . . B-Mutation O
. . . I-Mutation O
1799T . . I-Mutation B-Mutation
> . . I-Mutation I-Mutation
A . . I-Mutation I-Mutation
( . . O O
p . . B-Mutation O
. . . I-Mutation O
V600E . . I-Mutation B-Mutation
) . . O O
mutation . . B-Mutation B-Mutation
is . . O O
associated . . O O
with . . O O
significantly . . O O
poorer . . O O
prognosis . . O O
after . . O O
CRC . . O O
diagnosis . . O O
among . . O O
subgroups . . O O
of . . O O
patients . . O O
. . . O O

Expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
, . . O O
an . . O O
autophagy . . O O
- . . O O
related . . O O
protein . . O O
, . . O O
in . . O O
gastric . . O O
and . . O O
colorectal . . O O
cancers . . O O
. . . O O

Autophagy . . O O
plays . . O O
important . . O O
roles . . O O
in . . O O
both . . O O
cell . . O O
death . . O O
and . . O O
cell . . O O
survival . . O O
. . . O O

Beclin . . O O
- . . O O
1 . . O O
, . . O O
a . . O O
key . . O O
regulator . . O O
of . . O O
autophagy . . O O
formation . . O O
, . . O O
has . . O O
been . . O O
considered . . O O
as . . O O
a . . O O
haploinsufficient . . B-Mutation O
tumor . . O O
suppressor . . O O
. . . O O

Loss . . O B-Mutation
of . . O O
expression . . O O
or . . O O
point . . O O
mutation . . B-Mutation B-Mutation
could . . O O
serve . . O O
as . . O O
a . . O O
mechanism . . O O
of . . O O
loss . . O B-Mutation
of . . O O
beclin . . O O
- . . O O
1 . . O O
tumor . . O O
suppressor . . O O
function . . O O
in . . O O
cancers . . O O
. . . O O

However . . O O
, . . O O
our . . O O
recent . . O O
study . . O O
revealed . . O O
that . . O O
point . . O O
mutation . . B-Mutation B-Mutation
of . . O O
the . . O O
beclin . . O O
- . . O O
1 . . O O
gene . . O O
is . . O O
a . . O O
rare . . O O
event . . O O
in . . O O
common . . O O
human . . O O
cancers . . O O
. . . O O

In . . O O
this . . O O
study . . O O
we . . O O
investigated . . O O
beclin . . O O
- . . O O
1 . . O O
protein . . O O
expression . . O O
in . . O O
103 . . O O
colorectal . . O O
and . . O O
60 . . O O
gastric . . O O
carcinoma . . O O
tissues . . O O
by . . O O
immunohistochemistry . . O O
using . . O O
a . . O O
tissue . . O O
microarray . . O O
approach . . O O
. . . O O

In . . O O
the . . O O
cancers . . O O
, . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
was . . O O
detected . . O O
in . . O O
95 . . O O
% . . O O
of . . O O
the . . O O
colorectal . . O O
carcinomas . . O O
and . . O O
83 . . O O
% . . O O
of . . O O
the . . O O
gastric . . O O
carcinomas . . O O
. . . O O

In . . O O
contrast . . O O
, . . O O
normal . . O O
mucosal . . O O
cells . . O O
of . . O O
both . . O O
stomach . . O O
and . . O O
colon . . O O
showed . . O O
no . . O O
or . . O O
very . . O O
weak . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
. . . O O

There . . O O
was . . O O
no . . O O
significant . . O O
association . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
with . . O O
clinocopathologic . . O O
characteristics . . O O
, . . O O
including . . O O
invasion . . O O
, . . O O
metastasis . . O O
and . . O O
stage . . O O
. . . O O

The . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
of . . O O
colorectal . . O O
and . . O O
gastric . . O O
cancers . . O O
in . . O O
the . . O O
present . . O O
study . . O O
is . . O O
quite . . O O
in . . O O
contrast . . O O
to . . O O
that . . O O
of . . O O
the . . O O
breast . . O O
cancers . . O O
in . . O O
the . . O O
previous . . O O
study . . O O
, . . O O
which . . O O
showed . . O O
a . . O O
decreased . . O O
beclin . . O O
- . . O O
1 . . O O
expression . . O O
in . . O O
breast . . O O
cancer . . O O
cells . . O O
compared . . O O
to . . O O
normal . . O O
breast . . O O
cells . . O O
. . . O O

Our . . O O
data . . O O
indicate . . O O
that . . O O
beclin . . O O
- . . O O
1 . . O O
inactivation . . O O
by . . O O
loss . . O B-Mutation
of . . O O
expression . . O O
may . . O O
not . . O O
occur . . O O
in . . O O
colorectal . . O O
and . . O O
gastric . . O O
cancers . . O O
. . . O O

Rather . . O O
, . . O O
increased . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
in . . O O
the . . O O
malignant . . O O
colorectal . . O O
and . . O O
gastric . . O O
epithelial . . O O
cells . . O O
compared . . O O
to . . O O
their . . O O
normal . . O O
mucosal . . O O
epithelial . . O O
cells . . O O
suggests . . O O
that . . O O
neo . . O O
- . . O O
expression . . O O
of . . O O
beclin . . O O
- . . O O
1 . . O O
may . . O O
play . . O O
a . . O O
role . . O O
in . . O O
both . . O O
colorectal . . O O
and . . O O
gastric . . O O
tumorigenesis . . O O
. . . O O
